Fused pyrazine derivatives as A2A / A2B inhibitors
By contacting the adenosine receptor with fused pyrazine derivatives, the problem of regulating the activity of adenosine receptors in the prior art is solved, providing effective solutions for the treatment of a variety of diseases, demonstrating its in terms of regulating immune responses and suppressing inflammation effect.
Patent Information
- Application Number
- CN201980057732.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-05
- Filing Date
- 2019-07-03
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-07-03
AI Technical Summary
The prior art is difficult to effectively regulate the activity of adenosine receptors, especially the A2A and A2B subtypes, leading to challenges in the treatment of cancer, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases.
The fused pyrazine derivatives are developed as a selective ligand for adenosine receptors, which are used to treat diseases associated with adenosine receptors by contacting them to regulate their activity.
Fused pyrazine derivatives can effectively regulate the activity of adenosine receptors, provide potential therapeutic options for the above-mentioned diseases, demonstrating their role in regulating immune responses and suppressing inflammation.
Smart Images

Figure CN113166153B_ABST
Abstract
Description
Technical Field
[0001] The present invention provides fused pyrazine derivatives that modulate the activity of adenosine receptors, such as subtypes A2A and A2B, and are useful in treating diseases associated with the activity of adenosine receptors, including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Background Art
[0002] Adenosine is an extracellular signaling molecule that regulates immune responses by many immune cell types. Adenosine is considered to be a physiological regulator of coronary vascular tone (Sachdeva, S. and Gupta, M. Saudi Pharmaceutical Journal, 2013, 21, 245-253). However, it was not until 1970 that Sattin and Rall demonstrated that adenosine regulates cellular function by occupying specific receptors on the cell surface (Sattin, A. and Rall, TW, 1970. Mol. Pharmacol. 6, 13-23; Hasko', G. et al., 2007, Pharmacol. Ther. 113, 264-275).
[0003] Adenosine plays a vital role in various other physiological functions. When connected to three phosphate groups, it participates in the synthesis of nucleic acids; it forms ATP, a component of the cell energy system. Adenosine can be produced by the enzymatic decomposition of extracellular ATP, or it can also be released from damaged neurons and glial cells by passing through the damaged plasma membrane (Tautenhahn, M. et al. Neuropharmacology, 2012, 62, 1756-1766). Adenosine produces various pharmacological effects in both the peripheral and central nervous systems by acting on specific receptors located on the cell membrane (Matsumoto, T. et al. Pharmacol. Res., 2012, 65, 81-90). Alternative pathways for the production of extracellular adenosine have been described. These pathways include the production of adenosine from nicotinamide dinucleotide (NAD) rather than ATP through the synergistic action of CD38, CD203a and CD73. The CD73-independent production of adenosine can also occur through other phosphates such as alkaline phosphatase or prostate-specific phosphatase.
[0004] There are four known adenosine receptor subtypes in humans, including A1, A2A, A2B, and A3 receptors. A1 and A2A are high-affinity receptors, while A2B and A3 are low-affinity receptors. Adenosine and its agonists can act through one or more of these receptors and regulate the activity of adenylate cyclase, an enzyme responsible for increasing cyclic AMP (cAMP). Different receptors have different stimulatory and inhibitory effects on this enzyme. Increased intracellular cAMP concentrations can suppress the activity of immune and inflammatory cells (Livingston, M. et al., Inflamm. Res., 2004, 53, 171-178).
[0005] A2A adenosine receptors can signal in the periphery and CNS, with agonists being explored as anti-inflammatory drugs and antagonists being explored for neurodegenerative diseases (Carlsson, J. et al., J. Med. Chem., 2010, 53, 3748-3755). In most cell types, the A2A subtype suppresses intracellular calcium levels, while A2B enhances them. The A2A receptor generally appears to suppress inflammatory responses from immune cells (Borrmann, T. et al., J. Med. Chem., 2009, 52(13), 3994-4006).
[0006] The A2B receptor is highly expressed in the gastrointestinal tract, bladder, lungs, and on obese cells (Antonioli, L. et al., Nature Reviews Cancer, 2013, 13, 842-857). Although the A2B receptor is structurally closely related to the A2A receptor and can activate adenylate cyclase, it is functionally distinct. It has been hypothesized that this subtype can utilize signal transduction systems other than adenylate cyclase (Livingston, M. et al., Inflamm. Res., 2004, 53, 171-178). Of all adenosine receptors, the A2B adenosine receptor is a low-affinity receptor that is thought to remain silent under physiological conditions and to be activated by increased extracellular adenosine levels (Ryzhov, S. et al., Neoplasia, 2008, 10, 987-995). Activation of the A2B adenosine receptor can stimulate adenylate cyclase and phospholipase C through activation of Gs and Gq proteins, respectively. Coupling to mitogen-activated protein kinases has also been described (Borrmann, T. et al., J. Med. Chem., 2009, 52(13), 3994-4006).
[0007] In the immune system, the participation of adenosine signaling can be a key regulatory mechanism for protecting tissues from excessive immune responses. Adenosine can negatively regulate immune responses through many immune cell types, including T cells, natural killer cells, macrophages, dendritic cells, obese cells, and myeloid-derived suppressor cells (Allard, B. et al. Current Opinion in Pharmacology, 2016, 29, 7-16).
[0008] In tumors, this pathway is hijacked by the tumor microenvironment and undermines the anti-tumor ability of the immune system, thereby promoting cancer progression. In the tumor microenvironment, adenosine is mainly produced from extracellular ATP through CD39 and CD73. A variety of cell types can produce adenosine by expressing CD39 and CD73. This is the case for tumor cells, T effector cells, T regulatory cells, tumor-associated macrophages, myeloid-derived suppressor cells (MDSC), endothelial cells, cancer-associated fibroblasts (CAFs), and mesenchymal stromal / stem cells (MSCs). Hypoxia, inflammation, and other immunosuppressive signaling in the tumor microenvironment can induce the expression of CD39, CD73, and subsequent adenosine production. Therefore, adenosine levels in solid tumors are abnormally high compared to normal physiological conditions.
[0009] A2A is primarily expressed on lymphoid-derived cells, including T effector cells, T regulatory cells, and natural killer cells. Blocking the A2A receptor prevents downstream immunosuppressive signals that temporarily inactivate T cells. The A2B receptor is primarily expressed on monocyte-derived cells, including dendritic cells, tumor-associated macrophages, myeloid-derived suppressor cells (MDSCs), and mesenchymal stromal / stem cells (MSCs). In preclinical models, blocking the A2B receptor inhibits tumor growth, blocks metastasis, and increases tumor antigen presentation.
[0010] Regarding the safety profile of ADORA2A / ADORA2B (A2A / A2B) blockade, both A2A and A2B receptor knockout mice are viable, show no growth abnormalities, and are fertile (Allard, B. et al. Current Opinion in Pharmacology, 2016, 29, 7-16). A2A KO mice only display increased levels of proinflammatory cytokines upon LPS challenge and have no evidence of inflammation at baseline (Antonioli, L. et al., Nature Reviews Cancer, 2013, 13, 842-857). A2B KO mice exhibit normal platelet, red blood cell, and white blood cell counts, but baseline inflammation is increased (TNF-α, IL-6) in untreated A2B KO mice (Antonioli, L. et al., Nature Reviews Cancer, 2013, 13, 842-857). Excessive production of TNF-α and IL-6 has been detected following LPS treatment. A2B KO mice also exhibit increased vascular adhesion molecules that mediate inflammation and leukocyte adhesion / rolling; enhanced adipocyte activation; increased susceptibility to IgE-mediated allergic reactions and increased vascular leakage and neutrophil influx under hypoxia (Antonioli, L. et al., Nature Reviews Cancer, 2013, 13, 842-857).
[0011] In summary, there is a need in the art to develop new adenosine receptor selective ligands (such as for subtypes A2A and A2B) for treating diseases such as cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. The present application addresses this need and others. Summary of the Invention
[0012] The present invention particularly relates to compounds of formula (I):
[0013]
[0014] or a pharmaceutically acceptable salt thereof, wherein the constituent members are defined herein.
[0015] The present invention further provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0016] The present invention further provides a method for inhibiting the activity of an adenosine receptor, said method comprising contacting said receptor with a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0017] The present invention further provides a method for treating a disease or condition associated with abnormal expression of adenosine receptors, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0018] The present invention further provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.
[0019] The present invention further provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the preparation of a medicament for use in any of the methods described herein. DETAILED DESCRIPTION
[0020] Compound
[0021] The present application provides, inter alia, compounds of formula (I):
[0022]
[0023] or a pharmaceutically acceptable salt thereof, wherein:
[0024] R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C(O)R b1 、C(O)NR c1 R d1 、C(O)OR a1 、C(=NR e1 )R b1 、C(=NR e1 )NR c1 R d1 、S(O)2R b1 and S(O)2NR c1 R d1 , where R 1 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Each haloalkyl group is optionally replaced by 1, 2, 3 or 4 independently selected R 1A Substituent substitution;
[0025] Each R a1 、R b1 、R c1 and R d1 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl, where Ra1 、R b1 、R c1 and R d1 The C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is optionally substituted with 1, 2, 3 or 4 independently selected R 1A Substituent substitution;
[0026] Each R e1 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0027] Each R 1A Independently selected from OH, CN, halogen, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Halogenated alkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, amino, C 1-3 Alkylamino and di(C 1-3 alkyl)amino;
[0028] X 3 Is N or CR 3 ;
[0029] R 3 Selected from H, D, halogen, OH, CN, NO2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, cyano-C 1-3 Alkyl, HO-C 1-3 Alkyl, C 1-3 Alkoxy-C 1-3 Alkyl, C 3-5 Cycloalkyl, amino, C 1-3 Alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkylsulfonyl, carbamoyl, C 1-3 Alkylcarbamoyl, di(C1-3 alkyl)carbamoyl, carboxyl, C 1-3 Alkylcarbonyl, C 1-4 Alkoxycarbonyl, C 1-3 Alkylcarbonylamino, C 1-3 Alkoxycarbonylamino, C 1-3 Alkylcarbonyloxy, aminocarbonyloxy, C 1-3 Alkylaminocarbonyloxy, di(C 1-3 alkyl)aminocarbonyloxy, C 1-3 Alkylsulfonylamino, aminosulfonyl, C 1-3 Alkylaminosulfonyl, di(C 1-3 alkyl)aminosulfonyl, aminosulfonylamino, C 1-3 Alkylaminosulfonylamino, di(C 1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-3 Alkylaminocarbonylamino and di(C 1-3 alkyl)aminocarbonylamino;
[0030] Cy 1 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein Cy 1 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, 4, 5 or 6 independently selected R 7 Substituent substitution;
[0031] Each R 7 Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a7 SR a7 NHOR a7 、C(O)R b7 、C(O)NR c7 R d7、C(O)NR c7 (OR a7 )、C(O)OR a7 、OC(O)R b7 、OC(O)NR c7 R d7 、NR c7 R d7 、NR c7 NR c7 R d7 、NR c7 C(O)R b7 、NR c7 C(O)OR a7 、NR c7 C(O)NR c7 R d7 、C(=NR e7 )R b7 、C(=NOH)R b7 、C(=NCN)R b7 、C(=NR e7 )NR c7 R d7 、NR c7 C(=NR e7 )NR c7 R d7 、NR c7 C(=NOH)NR c7 R d7 、NR c7 C(=NCN)NR c7 R d7 、NR c7 C(=NR e7 )R b7 、NR c7 S(O)NR c7 R d7 、NR c7 S(O)R b7 、NR c7 S(O)2R b7 、NR c7 S(O)(=NR e7 )R b7 、NR c7 S(O)2NR c7 R d7 、S(O)R b7 、S(O)NR c7 R d7 、S(O)2R b7 、S(O)2NR c7 R d7 、OS(O)(=NR e7)R b7 、OS(O)2R b7 、SF5、P(O)R f7 R g7 、OP(O)(OR h7 )(OR i7 )、P(O)(OR h7 )(OR i7 ) and BR j7 R k7 , where R 7 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 7A Substituent substitution;
[0032] Each R a7 、R b7 、R c7 and R d7 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a7 、R b7 、R c7 and R d7 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 7A Substituent substitution;
[0033] Alternatively, any R attached to the same N atom c7 and R d7 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3 or 4 independently selected R 7A Substituent substitution;
[0034] Each R e7 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0035] Each R f7 and R g7 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0036] Each R h7 and R i7 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0037] Each R j7 and R k7 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0038] or any R connected to the same B atom j7 and R k7 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0039] Each R 7A Independently selected from OH, NO2, CN, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, cyano-C 1-6 Alkyl, HO-C 1-6 Alkyl, C 1-6 Alkoxy-C 1-6 Alkyl, C 3-5 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, amino, C 1-6 Alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkylsulfonyl, carbamoyl, C 1-6 Alkylcarbamoyl, di(C 1-6 alkyl)carbamoyl, carboxyl, C 1-6 Alkylcarbonyl, C 1-4 Alkoxycarbonyl, C 1-6 Alkylcarbonylamino, C 1-6 Alkoxycarbonylamino, C 1-6 Alkylcarbonyloxy, aminocarbonyloxy, C 1-6 Alkylaminocarbonyloxy, di(C 1-6 alkyl)aminocarbonyloxy, C1-6 Alkylsulfonylamino, aminosulfonyl, C 1-6 Alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 Alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 Alkylaminocarbonylamino and di(C 1-6 alkyl)aminocarbonylamino;
[0040] R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a2 SR a2 NHOR a2 、C(O)R b2 、C(O)NR c2 R d2 、C(O)NR c2 (OR a2 )、C(O)OR a2 、OC(O)R b2 、OC(O)NR c2 R d2 NR c2 R d2 NR c2 NR c2 R d2 NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 、C(=NR e2 )R b2 、C(=NOH)R b2 、C(=NCN)R b2 、C(=NR e2)NR c2 R d2 NR c2 C(=NR e2 )NR c2 R d2 NR c2 C(=NOH)NR c2 R d2 NR c2 C(=NCN)NR c2 R d2 NR c2 C(=NR e2 )R b2 NR c2 S(O)NR c2 R d2 NR c2 S(O)R b2 NR c2 S(O)2R b2 NR c2 S(O)(=NR e2 )R b2 NR c2 S(O)2NR c2 R d2 、S(O)R b2 、S(O)NR c2 R d2 、S(O)2R b2 、S(O)2NR c2 R d2 、OS(O)(=NR e2 )R b2 、OS(O)2R b2 、SF5、P(O)R f2 R g2 、OP(O)(OR h2 )(OR i2 )、P(O)(OR h2 )(OR i2 ) and BR j2 R k2 , where R 2 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 2A Substituent substitution;
[0041] R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)NR c4 (OR a4 )、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、C(=NR e4 )R b4 、C(=NOH)R b4 、C(=NCN)R b4 、C(=NR e4 )NR c4 R d4 NR c4 C(=NR e4 )NR c4 R d4 NR c4C(=NOH)NR c4 R d4 NR c4 C(=NCN)NR c4 R d4 NR c4 C(=NR e4 )R b4 NR c4 S(O)NR c4 R d4 NR c4 S(O)R b4 NR c4 S(O)2R b4 NR c4 S(O)(=NR e4 )R b4 NR c4 S(O)2NR c4 R d4 、S(O)R b4 、S(O)NR c4 R d4 、S(O)2R b4 、S(O)2NR c4 R d4 、OS(O)(=NR e4 )R b4 、OS(O)2R b4 、SF5、P(O)R f4 R g4 、OP(O)(OR h4 )(OR i4 )、P(O)(OR h4 )(OR i4 ) and BR j4 R k4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 4A Substituent substitution;
[0042] The conditions are:
[0043] (a) When R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3, 4, 5 or 6 independently selected R 2A When the substituent is substituted,
[0044] Then R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)NR c4 (OR a4 )、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、C(=NR e4 )R b4 、C(=NOH)R b4 、C(=NCN)Rb4 、C(=NR e4 )NR c4 R d4 NR c4 C(=NR e4 )NR c4 R d4 NR c4 C(=NOH)NR c4 R d4 NR c4 C(=NCN)NR c4 R d4 NR c4 C(=NR e4 )R b4 NR c4 S(O)NR c4 R d4 NR c4 S(O)R b4 NR c4 S(O)2R b4 NR c4 S(O)(=NR e4 )R b4 NR c4 S(O)2NR c4 R d4 、S(O)R b4 、S(O)NR c4 R d4 、S(O)2R b4 、S(O)2NR c4 R d4 、OS(O)(=NR e4 )R b4 、OS(O)2R b4 、SF5、P(O)R f4 R g4 、OP(O)(OR h4 )(OR i4 )、P(O)(OR h4 )(OR i4 ) and BR j4 R k4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 4A Substituent substitution;
[0045] Or, alternatively,
[0046] (b) When R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a2 SR a2 NHOR a2 、C(O)R b2 、C(O)NR c2 R d2 、C(O)NR c2 (OR a2 )、C(O)OR a2 、OC(O)R b2 、OC(O)NR c2 R d2 NR c2 R d2 NR c2 NR c2 R d2 NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 、C(=NR e2 )R b2 、C(=NOH)R b2 、C(=NCN)R b2 、C(=NR e2 )NR c2 R d2 NR c2 C(=NR e2 )NR c2 R d2 NRc2 C(=NOH)NR c2 R d2 NR c2 C(=NCN)NR c2 R d2 NR c2 C(=NR e2 )R b2 NR c2 S(O)NR c2 R d2 NR c2 S(O)R b2 NR c2 S(O)2R b2 NR c2 S(O)(=NR e2 )R b2 NR c2 S(O)2NR c2 R d2 、S(O)R b2 、S(O)NR c2 R d2 、S(O)2R b2 、S(O)2NR c2 R d2 、OS(O)(=NR e2 )R b2 、OS(O)2R b2 、SF5、P(O)R f2 R g2 、OP(O)(OR h2 )(OR i2 )、P(O)(OR h2 )(OR i2 ) and BR j2 R k2 , where R 2 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 2A When the substituent is substituted,
[0047] Then R 4 Selected from D, halogen, C 1-6 Alkyl, C1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)NR c4 (OR a4 )、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、C(=NR e4 )R b4 、C(=NOH)R b4 、C(=NCN)R b4 、C(=NR e4 )NR c4 R d4 NR c4 C(=NR e4 )NR c4 R d4 NR c4 C(=NOH)NR c4 R d4 NR c4 C(=NCN)NR c4 R d4 NR c4 C(=NR e4 )R b4 NR c4 S(O)NR c4 R d4 NR c4S(O)R b4 NR c4 S(O)2R b4 NR c4 S(O)(=NR e4 )R b4 NR c4 S(O)2NR c4 R d4 、S(O)R b4 、S(O)NR c4 R d4 、S(O)2R b4 、S(O)2NR c4 R d4 、OS(O)(=NR e4 )R b4 、OS(O)2R b4 、SF5、P(O)R f4 R g4 、OP(O)(OR h4 )(OR i4 )、P(O)(OR h4 )(OR i4 ) and BR j4 R k4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 4A Substituent substitution;
[0048] Each R a2 、R b2 、R c2 and R d2 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a2 、R b2 、R c2 and R d2 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 2A Substituent substitution;
[0049] Alternatively, any R attached to the same N atom c2 and R d2 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3, 4, 5 or 6 independently selected R 2A Substituent substitution;
[0050] Each R e2 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0051] Each R f2 and R g2 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0052] Each R h2 and R i2 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0053] Each R j2 and R k2 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0054] or any R connected to the same B atom j2 and R k2 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0055] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a21 SR a21 NHORa21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)NR c21 (OR a21 )、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 、NR c21 R d21 、NR c21 NR c21 R d21 、NR c21 C(O)R b21 、NR c21 C(O)OR a21 、NR c21 C(O)NR c21 R d21 、C(=NR e21 )R b21 、C(=NOH)R b21 、C(=NCN)R b21 、C(=NR e21 )NR c21 R d21 、NR c21 C(=NR e21 )NR c21 R d21 、NR c21 C(=NOH)NR c21 R d21 、NR c21 C(=NCN)NR c21 R d21 、NR c21 C(=NR e21 )R b21 、NR c21 S(O)NR c21 R d21 、NR c21 S(O)R b21 、NR c21 S(O)2R b21 、NR c21 S(O)(=NR e21 )R b21 、NR c21 S(O)2NR c21 R d21 、S(O)R b21 、S(O)NR c21 R d21 、S(O)2Rb21 、S(O)2NR c21 R d21 、OS(O)(=NR e21 )R b21 、OS(O)2R b21 、SF5、P(O)R f21 R g21 、OP(O)(OR h21 )(OR i21 )、P(O)(OR h21 )(OR i21 ) and BR j21 R k21 , where R 2A The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 2B Substituent substitution;
[0056] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a21 、R b21 、R c21 and R d21 The C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 2B Substituent substitution;
[0057] Alternatively, any R attached to the same N atom c21 and R d21 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3 or 4 independently selected R 2B Substituent substitution;
[0058] Each R e21 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0059] Each R f21 and R g21 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0060] Each R h21 and R i21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0061] Each R j21 and R k21 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0062] or any R connected to the same B atom j21 and R k21 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0063] Each R 2B Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a22 SR a22 NHOR a22 、C(O)R b22 、C(O)NR c22 R d22 、C(O)NR c22 (OR a22 )、C(O)OR a22 、OC(O)R b22 、OC(O)NR c22 R d22、NR c22 R d22 、NR c22 NR c22 R d22 、NR c22 C(O)R b22 、NR c22 C(O)OR a22 、NR c22 C(O)NR c22 R d22 、C(=NR e22 )R b22 、C(=NOH)R b22 、C(=NCN)R b22 、C(=NR e22 )NR c22 R d22 、NR c22 C(=NR e22 )NR c22 R d22 、NR c22 C(=NOH)NR c22 R d22 、NR c22 C(=NCN)NR c22 R d22 、NR c22 C(=NR e22 )R b22 、NR c22 S(O)NR c22 R d22 、NR c22 S(O)R b22 、NR c22 S(O)2R b22 、NR c22 S(O)(=NR e22 )R b22 、NR c22 S(O)2NR c22 R d22 、S(O)R b22 、S(O)NR c22 R d22 、S(O)2R b22 、S(O)2NR c22 R d22 、OS(O)(=NR e22 )R b22 、OS(O)2R b22 、SF5、P(O)R f22 R g22 、OP(O)(OR h22 )(OR i22)、P(O)(OR h22 )(OR i22 ) and BR j22 R k22 , where R 2B The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 2C Substituent substitution;
[0064] Each R a22 、R b22 、R c22 and R d22 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a22 、R b22 、R c22 and R d22 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 2C Substituent substitution;
[0065] Alternatively, any R attached to the same N atom c22 and R d22 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group, wherein said 4-, 5-, 6-, or 7-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 2C Substituent substitution;
[0066] Each R e22 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0067] Each R f22 and R g22 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0068] Each R h22 and R i22 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0069] Each R j22 and R k22 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0070] or any R connected to the same B atom j22 and R k22 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0071] Each R 2C Independently selected from OH, NO2, CN, halogen, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Haloalkyl, cyano-C 1-3 Alkyl, HO-C 1-3 Alkyl, C 1-3 Alkoxy-C 1-3 Alkyl, C 3-5 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, amino, C 1-3 Alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkylsulfonyl, carbamoyl, C 1-3 Alkylcarbamoyl, di(C 1-3 alkyl)carbamoyl, carboxyl, C 1-3 Alkylcarbonyl, C 1-4 Alkoxycarbonyl, C 1-3 Alkylcarbonylamino, C 1-3 Alkoxycarbonylamino, C 1-3 Alkylcarbonyloxy, aminocarbonyloxy, C 1-3 Alkylaminocarbonyloxy, di(C 1-3 alkyl)aminocarbonyloxy, C 1-3 Alkylsulfonylamino, aminosulfonyl, C 1-3 Alkylaminosulfonyl, di(C 1-3 alkyl)aminosulfonyl, aminosulfonylamino, C 1-3 Alkylaminosulfonylamino, di(C1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-3 Alkylaminocarbonylamino and di(C 1-3 alkyl)aminocarbonylamino;
[0072] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0073] Alternatively, any R attached to the same N atom c4 and R d4 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3, 4, 5 or 6 independently selected R 4A Substituent substitution;
[0074] Each R e4 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0075] Each R f4 and R g4 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0076] Each R h4 and R i4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0077] Each R j4 and R k4 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0078] or any R connected to the same B atom j4 and R k4 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6Substitution of haloalkyl groups;
[0079] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)NR c41 (OR a41 )、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、C(=NR e41 )R b41 、C(=NOH)R b41 、C(=NCN)R b41 、C(=NR e41 )NR c41 R d41 NR c41 C(=NR e41 )NR c41 R d41 NR c41 C(=NOH)NR c41 R d41 NR c41 C(=NCN)NRc41 R d41 NR c41 C(=NR e41 )R b41 NR c41 S(O)NR c41 R d41 NR c41 S(O)R b41 NR c41 S(O)2R b41 NR c41 S(O)(=NR e41 )R b41 NR c41 S(O)2NR c41 R d41 、S(O)R b41 、S(O)NR c41 R d41 、S(O)2R b41 、S(O)2NR c41 R d41 、OS(O)(=NR e41 )R b41 、OS(O)2R b41 、SF5、P(O)R f41 R g41 、OP(O)(OR h41 )(OR i41 )、P(O)(OR h41 )(OR i41 ) and BR j41 R k41 , where R 4A The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4B Substituent substitution;
[0080] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a41 、R b41 、R c41 and R d41 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4B Substituent substitution;
[0081] Alternatively, any R attached to the same N atom c41 and R d41 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3, 4, 5 or 6 independently selected R 4B Substituent substitution;
[0082] Each R e41 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0083] Each R f41 and R g41 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0084] Each R h41 and R i41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0085] Each R j41 and R k41 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0086] or any R connected to the same B atom j41 and R k41 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0087] Each R 4B Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a42 SR a42 NHOR a42 、C(O)R b42 、C(O)NR c42 R d42 、C(O)NR c42 (OR a42 )、C(O)OR a42 、OC(O)R b42 、OC(O)NR c42 R d42 NR c42 R d42 NR c42 NR c42 R d42 NR c42 C(O)R b42 NR c42 C(O)OR a42 NR c42 C(O)NR c42 R d42 、C(=NR e42 )R b42 、C(=NO H)R b42 、C(=NCN)R b42 、C(=NR e42 )NR c42 R d42 NR c42 C(=NR e42 )NR c42 R d42 NR c42 C(=NOH)NR c42 R d42 NR c42 C(=NCN)NR c42 R d42 NR c42 C(=NR e42 )R b42 NR c42 S(O)NR c42 R d42 NR c42 S(O)R b42 NRc42 S(O)2R b42 NR c42 S(O)(=NR e42 )R b42 NR c42 S(O)2NR c42 R d42 、S(O)R b42 、S(O)NR c42 R d42 、S(O)2R b42 、S(O)2NR c42 R d42 、OS(O)(=NR e42 )R b42 、OS(O)2R b42 、SF5、P(O)R f42 R g42 、OP(O)(OR h42 )(OR i42 )、P(O)(OR h42 )(OR i42 ) and BR j42 R k42 , where R 4B The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4C Substituent substitution;
[0088] Each R a42 、R b42 、R c42 and R d42 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a42 、R b42 、R c42 and R d42 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4C Substituent substitution;
[0089] Alternatively, any R attached to the same N atom c42 and R d42 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group, wherein said 4-, 5-, 6-, or 7-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4C Substituent substitution;
[0090] Each R e42 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0091] Each R f42 and R g42 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0092] Each R h42 and R i42 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0093] Each R j42 and R k42 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0094] or any R connected to the same B atom j42 and R k42 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0095] Each R 4C Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, ORa43 、SR a43 、NHOR a43 、C(O)R b43 、C(O)NR c43 R d43 、C(O)NR c43 (OR a43 )、C(O)OR a43 、OC(O)R b43 、OC(O)NR c43 R d43 、NR c43 R d43 、NR c43 NR c43 R d43 、NR c43 C(O)R b43 、NR c43 C(O)OR a43 、NR c43 C(O)NR c43 R d43 、C(=NR e43 )R b43 、C(=NOH)R b43 、C(=NCN)R b43 、C(=NR e43 )NR c43 R d43 、NR c43 C(=NR e43 )NR c43 R d43 、NR c43 C(=NOH)NR c43 R d43 、NR c43 C(=NCN)NR c43 R d43 、NR c43 C(=NR e43 )R b43 、NR c43 S(O)NR c43 R d43 、NR c43 S(O)R b43 、NR c43 S(O)2R b43 、NR c43 S(O)(=NR e43 )R b43 、NR c43 S(O)2NR c43 R d43 、S(O)R b43 、S(O)NRc43 R d43 、S(O)2R b43 、S(O)2NR c43 R d43 、OS(O)(=NR e43 )R b43 、OS(O)2R b43 、SF5、P(O)R f43 R g43 、OP(O)(OR h43 )(OR i43 )、P(O)(OR h43 )(OR i43 ) and BR j43 R k43 , where R 4C The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4D Substituent substitution;
[0096] Each R a43 、R b43 、R c43 and R d43 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a43 、R b43 、R c43 and R d43 The C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4D Substituent substitution;
[0097] Alternatively, any R attached to the same N atom c43 and R d43 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group, wherein said 4-, 5-, 6-, or 7-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4D Substituent substitution;
[0098] Each R e43 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0099] Each R f43 and R g43 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0100] Each R h43 and R i43Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-;
[0101] Each R j43 and R k43 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0102] or any R connected to the same B atom j43 and R k43 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 Substitution of haloalkyl groups;
[0103] Each R 4D Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-7 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 Alkyl-, C 3-7 Cycloalkyl-C 1-6 Alkyl-, (5-7 membered heteroaryl)-C 1-6 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a44 SR a44 NHOR a44 、C(O)R b44 、C(O)NR c44 R d44 、C(O)NR c44 (OR a44 )、C(O)OR a44 、OC(O)R b44 、OC(O)NR c44R d44 、NR c44 R d44 、NR c44 NR c44 R d44 、NR c44 C(O)R b44 、NR c44 C(O)OR a44 、NR c44 C(O)NR c44 R d44 、C(=NR e44 )R b44 、C(=NOH)R b44 、C(=NCN)R b44 、C(=NR e44 )NR c44 R d44 、NR c44 C(=NR e44 )NR c44 R d44 、NR c44 C(=NOH)NR c44 R d44 、NR c44 C(=NCN)NR c44 R d44 、NR c44 C(=NR e44 )R b44 、NR c44 S(O)NR c44 R d44 、NR c44 S(O)R b44 、NR c44 S(O)2R b44 、NR c44 S(O)(=NR e44 )R b44 、NR c44 S(O)2NR c44 R d44 、S(O)R b44 、S(O)NR c44 R d44 、S(O)2R b44 、S(O)2NR c44 R d44 、OS(O)(=NR e44 )R b44 、OS(O)2R b44 、SF5、P(O)R f44 R g44 、OP(O)(OR h44 )(ORi44 )、P(O)(OR h44 )(OR i44 ) and BR j44 R k44 , where R 4D The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-7 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 Alkyl-, C 3-7 Cycloalkyl-C 1-6 Alkyl-, (5-7 membered heteroaryl)-C 1-6 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4E Substituent substitution;
[0104] Each R a44 、R b44 、R c44 and R d44 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-7 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 Alkyl-, C 3-7 Cycloalkyl-C 1-6 Alkyl-, (5-7 membered heteroaryl)-C 1-6 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a44 、R b44 、R c44 and R d44 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-7 membered heteroaryl, 4-10 membered heterocycloalkyl, phenyl-C 1-6 Alkyl-, C 3-7 Cycloalkyl-C 1-6 Alkyl-, (5-7 membered heteroaryl)-C 1-6 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4E Substituent substitution;
[0105] Alternatively, any R attached to the same N atom c44 and R d44 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group, wherein said 4-, 5-, 6-, or 7-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4E Substituent substitution;
[0106] Each R e44 Independently selected from H, OH, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0107] Each R f44 and R g44 Independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-7 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 Alkyl-, C 3-7 Cycloalkyl-C 1-6 Alkyl-, (5-7 membered heteroaryl)-C 1-6 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
[0108] Each R h44 and R i44 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-7 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-6 Alkyl-, C 3-7 Cycloalkyl-C 1-6 Alkyl-, (5-7 membered heteroaryl)-C 1-6 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-6 alkyl-;
[0109] Each R j44 and R k44 Independently selected from OH, C 1-6 Alkoxy and C 1-6 haloalkoxy;
[0110] or any R connected to the same B atom j44 and R k44 Together with the B atoms to which they are attached, they form a 5- or 6-membered heterocycloalkyl group, which is optionally substituted by 1, 2, 3 or 4 independently selected C 1-6 Alkyl and C 1-6 The substituent of the haloalkyl group is substituted; and
[0111] Each R 4E Independently selected from OH, NO2, CN, halogen, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Haloalkyl, cyano-C 1-3 Alkyl, HO-C 1-3 Alkyl, C 1-3 Alkoxy-C 1-3 Alkyl, C 3-5 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, amino, C 1-3 Alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkylsulfonyl, carbamoyl, C 1-3 Alkylcarbamoyl, di(C 1-3 alkyl)carbamoyl, carboxyl, C 1-3 Alkylcarbonyl, C 1-4 Alkoxycarbonyl, C 1-3 Alkylcarbonylamino, C 1-3 Alkoxycarbonylamino, C 1-3 Alkylcarbonyloxy, aminocarbonyloxy, C 1-3 Alkylaminocarbonyloxy, di(C 1-3 alkyl)aminocarbonyloxy, C 1-3 Alkylsulfonylamino, aminosulfonyl, C 1-3 Alkylaminosulfonyl, di(C 1-3 alkyl)aminosulfonyl, aminosulfonylamino, C 1-3 Alkylaminosulfonylamino, di(C 1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-3 Alkylaminocarbonylamino and di(C 1-3 alkyl)aminocarbonylamino.
[0112] In some embodiments, the substituents are "alkyl," "alkenyl," "alkynyl," "aryl," "cycloalkyl," "heterocycloalkyl," or "heteroaryl" or "-C 1-6 1, 2, 3, 4, 5, 6, 7 or 8 hydrogen atoms attached to a carbon atom of any of the alkyl-, "alkylene", "alkenylene" and "alkynylene" linking groups are each optionally replaced with a deuterium atom.
[0113] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof provided herein is a compound of formula (II):
[0114]
[0115] or a pharmaceutically acceptable salt thereof.
[0116] In some embodiments of Formulas (I) and (II), R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Haloalkyl, where R 1 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Each haloalkyl group is optionally replaced by 1, 2, 3 or 4 independently selected R 1A Substituent substitution.
[0117] In some embodiments of Formulas (I) and (II), R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Halogenated alkyl.
[0118] In some embodiments of Formulas (I) and (II), R 1 Is H or C 1-3 alkyl.
[0119] In some embodiments of Formulas (I) and (II), R 1 It’s H.
[0120] In some embodiments of Formulas (I) and (II), R 3 Selected from H, D, halogen, OH, CN, NO2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6Haloalkoxy, cyano-C 1-3 Alkyl, HO-C 1-3 Alkyl, C 1-3 Alkoxy-C 1-3 Alkyl, C 3-5 Cycloalkyl, amino, C 1-3 Alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 Alkylthio, C 1-3 Alkylsulfinyl, C 1-3 Alkylsulfonyl, carbamoyl, C 1-3 Alkylcarbamoyl, di(C 1-3 alkyl)carbamoyl, carboxyl, C 1-3 Alkylcarbonyl, C 1-4 Alkoxycarbonyl, C 1-3 Alkylcarbonylamino, C 1-3 Alkoxycarbonylamino, C 1-3 Alkylcarbonyloxy, aminocarbonyloxy, C 1-3 Alkylaminocarbonyloxy, di(C 1-3 alkyl)aminocarbonyloxy, C 1-3 Alkylsulfonylamino, aminosulfonyl, C 1-3 Alkylaminosulfonyl, di(C 1-3 alkyl)aminosulfonyl, aminosulfonylamino, C 1-3 Alkylaminosulfonylamino, di(C 1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-3 Alkylaminocarbonylamino and di(C 1-3 alkyl)aminocarbonylamino.
[0121] In some embodiments of Formulas (I) and (II), R 3 Selected from H, D, halogen, OH, CN, NO2, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0122] In some embodiments of Formulas (I) and (II), R 3 It is CN or H.
[0123] In some embodiments of Formulas (I) and (II), R 3 It’s H.
[0124] In some embodiments of Formulas (I) and (II), R 2 Selected from H, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C1-6 Haloalkyl, CN, OR a2 SR a2 、C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and C 6-10 Aryl-C 1-6 Alkyl-, where R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl and C 6-10 Aryl-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0125] In some embodiments of Formulas (I) and (II), R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0126] In some embodiments of formulas (I) and (II), each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NRc21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 .
[0127] In some embodiments of formulas (I) and (II), each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 .
[0128] In some embodiments of formulas (I) and (II), each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C1-6 Alkyl-, where R a21 、R b21 、R c21 and R d21 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R 2B Substituent substitution.
[0129] In some embodiments of formulas (I) and (II), each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl.
[0130] In some embodiments of Formulas (I) and (II), R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituents are substituted; and
[0131] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, ORa21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 .
[0132] In some embodiments of Formulas (I) and (II), R 2 Selected from C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 2A Substituent substitution.
[0133] In some embodiments of formulas (I) and (II), each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NRc21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 .
[0134] In some embodiments of formulas (I) and (II), each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl.
[0135] In some embodiments of Formulas (I) and (II), R 2 Selected from C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0136] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NRc21 R d21 and S(O)R b21 ;and
[0137] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl.
[0138] In some embodiments of Formulas (I) and (II), R 2 is selected from cyclopropyl, pyrazolyl, pyridinyl, pyrimidinyl, dihydropyridin-(2H)-yl and pyridonyl, each of which is optionally substituted by 1 or 2 independently selected R 2A Substituent substitution.
[0139] In some embodiments of formulas (I) and (II), each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 .
[0140] In some embodiments of formulas (I) and (II), each R a21 、R b21 、R c21 and R d21Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0141] In some embodiments of Formulas (I) and (II), R 2 is selected from cyclopropyl, pyrazolyl, pyridinyl, pyrimidinyl, dihydropyridin-(2H)-yl and pyridonyl, each of which is optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0142] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 ;and
[0143] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0144] In some embodiments of Formulas (I) and (II), R 2 Selected from phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R 2 The phenyl group, C 3-7Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution;
[0145] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 , where R 2A The phenyl group, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are optionally substituted by 1, 2 or 3 independently selected R 2B Substituent substitution;
[0146] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl and C 1-6 haloalkyl; and
[0147] Each R 2B independently selected from halogen, OH, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Alkyl, C 1-4 Haloalkyl, amino, C 1-3 Alkylamino and di(C 1-3 alkyl)amino.
[0148] In some embodiments of Formulas (I) and (II), R 2 Selected from C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0149] Each R 2A independently selected from halogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl and C(O)NR c21 R d21 , where R 2A The C 1-4 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2B Substituent substitution;
[0150] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl and C 1-6 haloalkyl; and
[0151] Each R 2B are independently selected from halo and OH.
[0152] In some embodiments of Formulas (I) and (II), R 2 is selected from cyclopropyl, oxazolyl, triazolyl, pyrazolyl, pyridinyl, pyrimidinyl, dihydropyridin-(2H)-yl and pyridonyl, each of which is optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0153] Each R 2A independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 , where R 2A The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2B Substituent substitution;
[0154] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 alkynyl; and
[0155] Each R 2B are independently selected from halo and OH.
[0156] In some embodiments of Formulas (I) and (II), R 2 Selected from 1-(trifluoromethyl)cyclopropyl-1-yl, 1-ethyl-1H-pyrazol-5-yl, 1-propyl-1H-pyrazol-5-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 3,6-dihydropyridin-4-yl-1(2H)-carboxamide, pyridin-4-yl, 4-(1-hydroxyethyl)-2-methyloxazol-5-yl, 2,2-difluoro-1-hydroxyethyl)-2-methyloxazol-5-yl, 1-ethyl-1H-1,2,3-triazol-5-yl and 1-methyl-1H-1,2,3-triazol-5-yl.
[0157] In some embodiments of Formulas (I) and (II), R 2 Selected from 1-(trifluoromethyl)cyclopropyl-1-yl, 1-ethyl-1H-pyrazol-5-yl, 1-propyl-1H-pyrazol-5-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 3,6-dihydropyridin-4-yl-1(2H)-carboxamide, pyridin-4-yl, 4-(1-hydroxyethyl)-2-methyloxazol-5-yl, 2,2-difluoro-1-hydroxyethyl)-2-methyloxazol-5-yl, 1-ethyl-1H-1,2,3-triazol-5-yl and 1-methyl-1H-1,2,3-triazol-5-yl.
[0158] In some embodiments of Formulas (I) and (II), R2 Selected from 1-(trifluoromethyl)cyclopropyl-1-yl, 1-ethyl-1H-pyrazol-5-yl, 1-propyl-1H-pyrazol-5-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 3,6-dihydropyridin-4-yl-1(2H)-carboxamide and pyridin-4-yl.
[0159] In some embodiments of Formulas (I) and (II), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution.
[0160] In some embodiments of formulas (I) and (II), each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 , where R 4A The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 4B Substituent substitution.
[0161] In some embodiments of formulas (I) and (II), each R 4B Independently selected from C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 alkyl-.
[0162] In some embodiments of formulas (I) and (II), each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 .
[0163] In some embodiments of Formulas (I) and (II), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituents are substituted; and
[0164] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 Rd41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 .
[0165] In some embodiments of Formulas (I) and (II), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, 5-6 membered heteroaryl, phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 NR c4 C(O)R b4 NR c4 C(O)OR a4 and NR c4 C(O)NR c4 R d4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, 5-6 membered heteroaryl, phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution.
[0166] In some embodiments of formulas (I) and (II), each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2 and OR a41 .
[0167] In some embodiments of formulas (I) and (II), each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0168] In some embodiments of formulas (I) and (II), each R a41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0169] In some embodiments, any R attached to the same N atom c4 and R d4 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1, 2, 3 or 4 independently selected R 4A Substituent substitution.
[0170] In some embodiments, any R attached to the same N atom c4 and R d4 Together with the N atom to which they are attached, they form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted by 1 or 2 independently selected R 4A Substituent substitution.
[0171] In some embodiments of Formulas (I) and (II), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, 5-6 membered heteroaryl, phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 NR c4 C(O)R b4 NR c4 C(O)OR a4and NR c4 C(O)NR c4 R d4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, 5-6 membered heteroaryl, phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution;
[0172] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2 and OR a41 ;
[0173] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 alkynyl; and
[0174] Each R a41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0175] In some embodiments of Formulas (I) and (II), R 4 Selected from C 1-6 Alkyl, phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NR c4 R d4 and NR c4 C(O)OR a4 , where R 4 The C 1-6 Alkyl, phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R4A Substituent substitution;
[0176] In some embodiments of formulas (I) and (II), each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2 and OR a41 .
[0177] In some embodiments of formulas (I) and (II), each R a4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0178] Alternatively, any R attached to the same N atom c4 and R d4 Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocycloalkyl group.
[0179] In some embodiments of formulas (I) and (II), each R a41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0180] In some embodiments of Formulas (I) and (II), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHORa4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0181] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0182] Each R 4A Independently selected from D, halogen, C1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 , where R 4A The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 4B Substituent substitution;
[0183] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a41 、R b41 、R c41 and R d41 The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 4B Substituents are substituted; and
[0184] Each R 4B independently selected from halogen, OH, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Alkyl, C 1-4 Haloalkyl, amino, C1-3 Alkylamino and di(C 1-3 alkyl)amino.
[0185] In some embodiments of Formulas (I) and (II), R 4 Selected from phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, C(O)R b4 、C(O)NR c4 R d4 and NR c4 R d4 , where R 4 The phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-3 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution;
[0186] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, phenyl and 4-7 membered heterocycloalkyl, where R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, phenyl and 4-7 membered heterocycloalkyl are optionally substituted by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0187] Each R 4A are independently selected from halo, 4-7 membered heterocycloalkyl and OH, wherein R 4A The 4-7 membered heterocycloalkyl group is optionally replaced by 1 or 2 independently selected R 4B Substituents are substituted; and
[0188] Each R 4B independently selected from halogen, OH and C 1-4 alkyl.
[0189] In some embodiments of Formulas (I) and (II), R 4 Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NRc4 R d4 and NR c4 C(O)OR a4 , where R 4 The C 1-6 Alkyl, phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution;
[0190] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2 and OR a41 ;
[0191] Each R a4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0192] Alternatively, any R attached to the same N atom c4 and R d4 Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocycloalkyl group; and
[0193] Each R a41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0194] In some embodiments of Formulas (I) and (II), R 4 Selected from C(O)NHC 1-6 alkyl, C(O)-azetidinyl, C(O)-pyrrolidinyl, C(O)-piperidinyl, C(O)N(C 1-6 alkyl)2, NHC(O)OC 1-6 Alkyl, (azetidinyl)-C 1-6 Alkyl, (pyridyl)-C 1-6 Alkyl, (phenyl)-C 1-6 Alkyl, (fluorophenyl)-C 1-6alkyl, 3,6-dihydro-2H-pyranyl, NH-(phenyl), and pyridinyl.
[0195] In some embodiments of Formulas (I) and (II), R 4 Selected from C(O)NHC 1-6 alkyl, C(O)-azetidinyl, C(O)-pyrrolidinyl, C(O)-piperidinyl, C(O)N(C 1-6 alkyl)2, NHC(O)OC 1-6 Alkyl, (azetidinyl)-C 1-6 Alkyl, (pyridyl)-C 1-6 Alkyl, (phenyl)-C 1-6 Alkyl, (fluorophenyl)-C 1-6 alkyl, 3,6-dihydro-2H-pyranyl, NH-(phenyl), pyridinyl, and (pyrrolo[3,2-b]pyridinyl)-C 1-6 alkyl,
[0196] Each of the C 1-6 The alkyl and azetidinyl groups are optionally substituted with 1 or 2 OH groups; and each pyridinyl group is optionally substituted with methylpiperazinyl.
[0197] In some embodiments of Formulas (I) and (II), R 4 Selected from C(O)NHC 1-6 alkyl, C(O)-azetidinyl, C(O)-pyrrolidinyl, C(O)-piperidinyl, C(O)N(C 1-6 alkyl)2, NHC(O)OC 1-6 Alkyl, (azetidinyl)-C 1-6 Alkyl, (pyridyl)-C 1-6 Alkyl, (phenyl)-C 1-6 Alkyl, (fluorophenyl)-C 1-6 alkyl, 3,6-dihydro-2H-pyranyl, NH-(phenyl) and pyridyl,
[0198] Each of the C 1-6 The alkyl and azetidinyl groups are optionally substituted with 1 or 2 OH groups; and each pyridinyl group is optionally substituted with methylpiperazinyl.
[0199] In some embodiments of Formulas (I) and (II), R 4Selected from C(O)NHCH2CH3, C(O)N(CH3)(CH2CH3), C(O)N(CH2CH3)2, NHC(O)OCH2CH3, C(O)-azetidinyl, C(O)-hydroxyazetidinyl, C(O)-pyrrolidinyl, C(O)-piperidinyl, CH2-azetidinyl, CH2-pyridinyl, CH2-fluorophenyl, CH(OH)-fluorophenyl, NH-phenyl, 3,6-dihydro-2H-pyranyl, (methylpiperazinyl)pyridinyl and (1H-pyrrolo[3,2-b]pyridin-3-yl)methyl.
[0200] In some embodiments of Formulas (I) and (II), R 4 Selected from C(O)NHCH2CH3, C(O)N(CH3)(CH2CH3), C(O)N(CH2CH3)2, NHC(O)OCH2CH3, C(O)-azetidinyl, C(O)-hydroxyazetidinyl, C(O)-pyrrolidinyl, C(O)-piperidinyl, CH2-azetidinyl, CH2-pyridinyl, CH2-fluorophenyl, CH(OH)-fluorophenyl, NH-phenyl, 3,6-dihydro-2H-pyranyl and (methylpiperazinyl)pyridinyl.
[0201] In some embodiments of Formulas (I) and (II), R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a2 SR a2 、C(O)R b2 、C(O)NR c2 R d2 、C(O)OR a2 、OC(O)R b2 、OC(O)NR c2 R d2 NR c2 R d2 NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 、S(O)R b2 and S(O)2R b2 .
[0202] In some embodiments of formulas (I) and (II), each R a2 、Rb2 、R c2 and R d2 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0203] In some embodiments of Formulas (I) and (II), R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a2 SR a2 、C(O)R b2 、C(O)NR c2 R d2 、C(O)OR a2 、OC(O)R b2 、OC(O)NR c2 R d2 NR c2 R d2 NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 、S(O)R b2 and S(O)2R b2 ;and
[0204] Each R a2 、R b2 、R c2 and R d2 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0205] In some embodiments of Formulas (I) and (II), R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and CN.
[0206] In some embodiments of Formulas (I) and (II), R 2 is selected from H, difluoroethyl, bromine and CN.
[0207] In some embodiments of Formulas (I) and (II), R 4 Selected from C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution.
[0208] In some embodiments of formulas (I) and (II), each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0209] In some embodiments of formulas (I) and (II), each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 .
[0210] In some embodiments of Formulas (I) and (II), R 4 Selected from C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0211] Each R a4 、R b4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl; and
[0212] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 .
[0213] In some embodiments of Formulas (I) and (II), R 4 Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NR c4 R d4 and NR c4 C(O)OR a4 , where each C 1-6 The alkyl group is optionally substituted with 1 or 2 OH groups; and the phenyl-C 1-6 Alkyl-optionally substituted with 1 or 2 independently selected halo.
[0214] In some embodiments of formulas (I) and (II), each R a4 、R b4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0215] In some embodiments of formulas (I) and (II), each R 4 Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl- and C(O)NR c4 R d4 , where R 4 The phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 alkyl- are each optionally substituted with 1 or 2 substituents independently selected from OH and halo; and
[0216] Each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0217] In some embodiments of Formulas (I) and (II), R 4 Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NR c4 R d4 NR c4 C(O)OR a4 , where each C 1-6 The alkyl group is optionally substituted with 1 or 2 OH groups; and the phenyl-C 1-6 Alkyl-optionally substituted with 1 or 2 independently selected halo; and
[0218] Each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0219] In some embodiments of Formulas (I) and (II), R 4 Selected from C(O)NHCH2CH3, -CH2-pyridyl, CH2-fluorophenyl and CH(OH)-fluorophenyl.
[0220] In some embodiments of Formula (II), R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a2 SR a2 NHOR a2 、C(O)R b2 、C(O)NR c2 R d2 、C(O)NR c2 (OR a2 )、C(O)OR a2 、OC(O)R b2 、OC(O)NR c2 R d2 NR c2 R d2 NR c2 NR c2 R d2 NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 、C(=NR e2 )R b2 、C(=NOH)R b2 、C(=NCN)R b2 、C(=NR e2 )NR c2 R d2 NR c2 C(=NR e2 )NR c2 R d2 NR c2 C(=NOH)NR c2 R d2 NR c2 C(=NCN)NR c2 R d2 NR c2 C(=NR e2 )R b2 NR c2 S(O)NRc2 R d2 NR c2 S(O)R b2 NR c2 S(O)2R b2 NR c2 S(O)(=NR e2 )R b2 NR c2 S(O)2NR c2 R d2 、S(O)R b2 、S(O)NR c2 R d2 、S(O)2R b2 、S(O)2NR c2 R d2 、OS(O)(=NR e2 )R b2 、OS(O)2R b2 、SF5、P(O)R f2 R g2 、OP(O)(OR h2 )(OR i2 )、P(O)(OR h2 )(OR i2 ) and BR j2 R k2 , where R 2 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 2A Substituents are substituted; and
[0221] R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)NR c4 (OR a4 )、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、C(=NR e4 )R b4 、C(=NOH)R b4 、C(=NCN)R b4 、C(=NR e4 )NR c4 R d4 NR c4 C(=NR e4 )NR c4 R d4 NR c4 C(=NOH)NR c4 R d4 NR c4 C(=NCN)NR c4 R d4 NR c4 C(=NR e4 )R b4 NR c4 S(O)NR c4 R d4 NR c4 S(O)R b4 NR c4 S(O)2R b4 NR c4S(O)(=NR e4 )R b4 NR c4 S(O)2NR c4 R d4 、S(O)R b4 、S(O)NR c4 R d4 、S(O)2R b4 、S(O)2NR c4 R d4 、OS(O)(=NR e4 )R b4 、OS(O)2R b4 、SF5、P(O)R f4 R g4 、OP(O)(OR h4 )(OR i4 )、P(O)(OR h4 )(OR i4 ) and BR j4 R k4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3, 4, 5 or 6 independently selected R 4A Substituent substitution.
[0222] In some embodiments of Formulas (I) and (II), Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituent substitution.
[0223] In some embodiments of Formulas (I) and (II), Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituent substitution.
[0224] In some embodiments of formulas (I) and (II), each R 7 independently selected from halogen, C 1-6 Alkyl, C1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0225] In some embodiments of Formulas (I) and (II), Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituents are substituted; and
[0226] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0227] In some embodiments of Formulas (I) and (II), Cy 1 is selected by 1 or 2 independent R 7 a phenyl group substituted with a substituent; and
[0228] Each R 7 are independently selected from halo and CN.
[0229] In some embodiments of Formulas (I) and (II), Cy 1 It is an unsubstituted phenyl group.
[0230] In some embodiments of Formulas (I) and (II), Cy 1 It is cyanophenyl.
[0231] In some embodiments of Formulas (I) and (II), Cy 1 It is 3-cyanophenyl.
[0232] In some embodiments of Formulas (I) and (II), Cy 1 It is 3-cyanophenyl or 3-cyano-2-fluorophenyl.
[0233] In some embodiments of Formulas (I) and (II), Cy 1 is C(O)NR c7 R d7 Substituted phenyl, wherein R c7 and R d7 Each independently selected from H and C 1-6 alkyl.
[0234] In some embodiments of Formulas (I) and (II), Cy 1 It is a phenyl group substituted by C(O)NH2.
[0235] In some embodiments of Formulas (I) and (II), Cy1 It is 3-formylphenyl.
[0236] In some embodiments of formula (I) and (II):
[0237] R 1 It is H;
[0238] Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituents are substituted; and
[0239] R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0240] In some embodiments of formula (I) and (II):
[0241] R 1 It is H;
[0242] Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituents are substituted; and
[0243] R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0244] In some embodiments of compounds of formula (I) and (II):
[0245] R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 alkyl halide;
[0246] R 2 Selected from C6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution;
[0247] R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0248] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 ;
[0249] Each R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl;
[0250] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 ;
[0251] Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituent substitution;
[0252] Each R a4 、R b4 、R c4 and R 4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0253] Alternatively, any R attached to the same N atom c4 and R d4 Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocycloalkyl group;
[0254] Each R a41 、R b41 、R c41 and Rd41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 alkynyl; and
[0255] Each R 7 independently selected from halogen, C 1-6 Alkyl, C1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0256] In some embodiments of compounds of formula (I) and (II):
[0257] R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 alkyl halide;
[0258] R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a2 SR a2 、C(O)R b2 、C(O)NR c2 R d2 、C(O)OR a2 、OC(O)R b2 、OC(O)NR c2 R d2 NR c2 R d2 NR c2 C(O)R b2 NR c2 C(O)OR a2 NR c2 C(O)NR c2 R d2 、S(O)R b2 and S(O)2R b2 ;
[0259] R 4 Selected from C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NRc4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0260] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 ;
[0261] Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R7 Substituent substitution;
[0262] Each R a4 、R b4 、R c4 and R 4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0263] Alternatively, any R attached to the same N atom c4 and R d4 Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocycloalkyl group;
[0264] Each R a41 、R b41 、R c41 and Rd41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 alkynyl; and
[0265] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0266] In some embodiments of compounds of formula (I) and (II):
[0267] R 1 It is H;
[0268] R 2 Selected from C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0269] R 4 Selected from C 1-6 Alkyl, phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NR c4 R d4 and NR c4 C(O)OR a4, where R 4 The C 1-6 Alkyl, phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution;
[0270] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 ;
[0271] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0272] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2 and ORa41 ;
[0273] Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituent substitution;
[0274] Each R a4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0275] Alternatively, any R attached to the same N atom c4 and R d4 Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocycloalkyl group;
[0276] Each R a41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 alkynyl; and
[0277] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0278] In some embodiments of compounds of formula (I) and (II):
[0279] R 1 It is H;
[0280] R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and CN;
[0281] R 4 Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NR c4 R d4 NR c4 C(O)OR a4 , where each C 1-6 The alkyl group is optionally substituted with 1 or 2 OH groups; and the phenyl-C 1-6 Alkyl-optionally substituted with 1 or 2 independently selected halo;
[0282] Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituent substitution;
[0283] Each R a4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0284] Alternatively, any R attached to the same N atom c4 and R d4 Together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocycloalkyl group; and
[0285] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0286] In some embodiments of compounds of formula (I) and (II):
[0287] R 1 It is H;
[0288] R 2 is selected from cyclopropyl, pyrazolyl, pyridinyl, pyrimidinyl, dihydropyridin-(2H)-yl and pyridonyl, each of which is optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0289] R 4 Selected from C(O)NHC 1-6 alkyl, C(O)-azetidinyl, C(O)-pyrrolidinyl, C(O)-piperidinyl, C(O)N(C 1-6 alkyl)2, NHC(O)OC 1-6 Alkyl, (azetidinyl)-C 1-6 Alkyl, (pyridyl)-C 1-6 Alkyl, (phenyl)-C 1-6 Alkyl, (fluorophenyl)-C 1-6 alkyl, 3,6-dihydro-2H-pyranyl, NH-(phenyl), and pyridyl, wherein each C 1-6 The alkyl and azetidinyl groups are optionally substituted with 1 or 2 OH groups; and each pyridinyl group is optionally substituted with methylpiperazinyl;
[0290] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 ;
[0291] Cy 1 is cyanophenyl; and
[0292] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0293] In some embodiments of compounds of formula (I) and (II):
[0294] R 1 It is H;
[0295] R 2 Selected from H, difluoroethyl, bromine and CN;
[0296] R 4 Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl-, C(O)NR c4 R d4 NR c4 C(O)OR a4 , where each C 1-6The alkyl group is optionally substituted with 1 or 2 OH groups; and the phenyl-C 1-6 Alkyl-optionally substituted with 1 or 2 independently selected halo;
[0297] Cy 1 is cyanophenyl; and
[0298] Each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0299] In some embodiments of formula (I) and (II), the compound is a compound of formula (IIa):
[0300]
[0301] or a pharmaceutically acceptable salt thereof, wherein the variable R 2 、R 3 、R 4 and Cy 1 are defined according to the definitions provided herein for the compounds of formula (I) and (II).
[0302] In some embodiments of Formula (IIa),
[0303] R 3 is H or CN;
[0304] Cy 1 is selected by 1 or 2 independent R 7 a phenyl group substituted with a substituent;
[0305] Each R 7 independently selected from halo and CN;
[0306] R 2 Selected from phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R 2 The phenyl group, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution;
[0307] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, ORa21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 , where R 2A The phenyl group, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are optionally substituted by 1, 2 or 3 independently selected R 2B Substituent substitution;
[0308] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl and C 1-6 alkyl halide;
[0309] Each R 2B independently selected from halogen, OH, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Alkyl, C 1-4 Haloalkyl, amino, C 1-3 Alkylamino and di(C 1-3 alkyl)amino;
[0310] R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, NO2, OR a4 SR a4 NHOR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 , where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0311] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, phenyl, C 3-7Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0312] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 , where R 4A The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, phenyl, C 3-7 Cycloalkyl, 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 4B Substituent substitution;
[0313] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a41 、R b41 、R c41 and R d41 The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 4B Substituents are substituted; and
[0314] Each R 4B independently selected from halogen, OH, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Alkyl, C 1-4 Haloalkyl, amino, C 1-3 Alkylamino and di(C 1-3 alkyl)amino.
[0315] In some embodiments of Formula (IIa),
[0316] R 3 is H or CN;
[0317] Cy 1 is 3-cyanophenyl or 3-cyano-2-fluorophenyl;
[0318] R 2 Selected from C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 2A Substituent substitution;
[0319] Each R 2A independently selected from halogen, C 1-4 Alkyl, C 1-4 Halogenated alkyl and C(O)NR c21 R d21 , where R 2A The C 1-4 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2B Substituent substitution;
[0320] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl and C 1-6 haloalkyl; and
[0321] Each R 2B are independently selected from halo and OH.
[0322] R 4 Selected from phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, C(O)R b4、C(O)NR c4 R d4 and NR c4 R d4 , where R 4 The phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl- and (4-7 membered heterocycloalkyl)-C 1-3 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution;
[0323] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, phenyl and 4-7 membered heterocycloalkyl, where R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, phenyl and 4-7 membered heterocycloalkyl are optionally substituted by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0324] Each R 4A are independently selected from halo, 4-7 membered heterocycloalkyl and OH, wherein R 4A The 4-7 membered heterocycloalkyl group is optionally replaced by 1 or 2 independently selected R 4B Substituents are substituted; and
[0325] Each R 4B independently selected from halogen, OH and C 1-4 alkyl.
[0326] In some embodiments of Formula (IIa),
[0327] R 3 is H or CN;
[0328] Cy 1 is selected by 1 or 2 independent R 7 a phenyl group substituted with a substituent;
[0329] Each R 7 independently selected from halo and CN;
[0330] R 2 Selected from H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and CN;
[0331] R 4Selected from phenyl-C 1-6 Alkyl-, (5-6 membered heteroaryl)-C 1-6 Alkyl- and C(O)NR c4 R d4 , where R 4 The phenyl-C 1-6 Alkyl- and (5-6 membered heteroaryl)-C 1-6 alkyl- are each optionally substituted with 1 or 2 substituents independently selected from OH and halo; and
[0332] Each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0333] In some embodiments of formula (I) and (II), the compound is a compound of formula (IIb):
[0334]
[0335] or a pharmaceutically acceptable salt thereof, wherein n is an integer from 0 to 4, and wherein the variable R 2 、R 4 and R 7 are defined according to the definitions provided herein for the compounds of formula (I) and (II).
[0336] In some embodiments of formula (I) and (II), the compound is a compound of formula (IIc):
[0337]
[0338] or a pharmaceutically acceptable salt thereof, wherein the variable R 2 、R 4 and R 7 are defined according to the definitions provided herein for the compounds of formula (I) and (II).
[0339] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof provided herein is a compound of formula (III):
[0340]
[0341] or a pharmaceutically acceptable salt thereof.
[0342] In some embodiments of Formulas (I) and (III), R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Haloalkyl, where R1 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Each haloalkyl group is optionally replaced by 1, 2, 3 or 4 independently selected R 1A Substituent substitution.
[0343] In some embodiments of Formulas (I) and (III), R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Halogenated alkyl.
[0344] In some embodiments of Formulas (I) and (III), R 1 Is H or C 1-6 alkyl.
[0345] In some embodiments of Formulas (I) and (III), R 1 It’s H.
[0346] In some embodiments of Formulas (I) and (III), R 2 Selected from H, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0347] In some embodiments of Formulas (I) and (III), R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0348] In some embodiments of Formulas (I) and (III), each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 .
[0349] In some embodiments of Formulas (I) and (III), R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution;
[0350] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 Rd21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 , where R 2A The C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2B Substituent substitution;
[0351] Each R a21 、R 241 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a21 、R 241 、R c21 and R d21 The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2A Substituents are substituted; and
[0352] Each R 2B Independently selected from D, halo, OH, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Alkyl, C 1-4 Haloalkyl, amino, C 1-3 Alkylamino and di(C 1-3 alkyl)amino.
[0353] In some embodiments of Formulas (I) and (III), R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituents are substituted; and
[0354] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 .
[0355] In some embodiments of Formulas (I) and (III), R 2 is selected from 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R 2 The 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution;
[0356] Each R 2A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and OH, where R 2A The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2B Substituents are substituted; and
[0357] Each R 2B are independently selected from D, halo and OH.
[0358] In some embodiments of Formulas (I) and (III), R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally replaced by 1 or 2 independently selected R 2A Substituent substitution.
[0359] In some embodiments of Formulas (I) and (III), each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 .
[0360] In some embodiments of Formulas (I) and (III), each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0361] In some embodiments of Formulas (I) and (III), R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally replaced by 1 or 2 independently selected R 2A Substituent substitution;
[0362] Each R 2AIndependently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 ;and
[0363] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0364] In some embodiments of Formulas (I) and (III), R 2 is a 5-6 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution.
[0365] In some embodiments of Formulas (I) and (III), R 2 It is a 5-6 membered heteroaryl group.
[0366] In some embodiments of Formulas (I) and (III), R 2 It is a 5-6 membered heterocycloalkyl group.
[0367] In some embodiments of Formulas (I) and (III), R 2Selected from 6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl, 4-methyloxazol-5-yl, 4-ethyloxazol-5-yl, 3-methylpyridin-4-yl, 4-(2,2-difluoro-1-hydroxyethyl)-2-methyloxazol-5-yl, 2-methyl-4-(2,2,2-trifluoro- 1-(methyl-d3)-6-oxo-1,6-dihydropyridazin-3-yl.
[0368] In some embodiments of Formulas (I) and (III), R 2 Selected from 6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl, 4-methyloxazol-5-yl, 4-ethyloxazol-5-yl and 3-methylpyridin-4-yl.
[0369] In some embodiments of Formulas (I) and (III), R 2 It is a pyridone group.
[0370] In some embodiments of Formulas (I) and (III), R 2 It is 6-oxo-1,6-dihydropyridin-3-yl.
[0371] In some embodiments of Formulas (I) and (III), R 2 It is pyrimidin-4-yl.
[0372] In some embodiments of Formulas (I) and (III), R 2 Selected from the group consisting of 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl, pyrimidin-4-yl and 2,6-dimethylpyridin-4-yl.
[0373] In some embodiments of Formulas (I) and (III), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R 4 The C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1 or 2 independently selected R 4A Substituent substitution.
[0374] In some embodiments of Formulas (I) and (III), each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a41 SR a41 NHOR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 、OC(O)R b41 、OC(O)NR c41 R d41 NR c41 R d41 NR c41 C(O)R b41 NR c41 C(O)OR a41 NR c41 C(O)NR c41 R d41 、S(O)R b41 and S(O)2R b41 , where R 4AThe C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4B Substituent substitution.
[0375] In some embodiments of Formulas (I) and (III), R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0376] In some embodiments of Formulas (I) and (III), R 4 It’s H.
[0377] In some embodiments of Formulas (I) and (III), R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0378] In some embodiments of Formulas (I) and (III), R 2 It’s H.
[0379] In some embodiments of Formulas (I) and (III), R 2 is 6-oxo-1,6-dihydropyridin-3-yl or imidazo[1,2-a]pyridin-6-yl; and R 4 It’s H.
[0380] In some embodiments of Formulas (I) and (III), R 2 is H; and R 4 Yes-NHC(O)OC 1-6 alkyl.
[0381] In some embodiments of Formulas (I) and (III), R 4 Selected from C(O)R b4 、C(O)NR c4R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 .
[0382] In some embodiments of Formulas (I) and (III), each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl.
[0383] In some embodiments of Formulas (I) and (III), R 4 Selected from C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 ;and
[0384] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6Alkynyl.
[0385] In some embodiments of Formulas (I) and (III), R 4 Selected from C(O)NR c4 R d4 and NR c4 C(O)OR a4 .
[0386] In some embodiments of Formulas (I) and (III), R 4 It is NR c4 C(O)OR a4 .
[0387] In some embodiments of Formulas (I) and (III), each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0388] In some embodiments of Formulas (I) and (III), R 4 Selected from C(O)NR c4 R d4 and NR c4 C(O)OR a4 ;and
[0389] Each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl.
[0390] In some embodiments of Formulas (I) and (III), R 4 Yes-NHC(O)OC 1-6 alkyl.
[0391] In some embodiments of Formulas (I) and (III), R 4 It is -NHC(O)OCH2CH3.
[0392] In some embodiments of Formulas (I) and (III), R 4 Selected from C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, OR a4 、C(O)R b4 、C(O)NR c4 R d4、C(O)OR a4 NR c4 R d4 、S(O)2NR c4 R d4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0393] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0394] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, OR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 NR c41 R d41 、S(O)2NR c41 R d41 and S(O)2R b41 , where R 4A The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0395] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl, wherein R a41 、R b41 、R c41 and R d41 The C 1-6 Alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0396] Each R 4B independently selected from halogen, C 1-6Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-3 Alkyl-, (C 3-6 Cycloalkyl)-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-6 membered heteroaryl)-C 1-3 Alkyl-, CN, OR a42 、C(O)R b42 、C(O)NR c42 R d42 、C(O)OR a42 NR c42 R d42 、S(O)2NR c42 R d42 and S(O)2R b42 , where R 4B The C 1-6 Alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-3 Alkyl-, (C 3-6 Cycloalkyl)-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0397] Each R a42 、R b42 、R c42 and R d42 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl, wherein R a42 、R b42 、R c42 and R d42 The C 1-6 Alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0398] Each R 4C Independently selected from C 1-6 Alkyl, C 1-6 Haloalkyl, CN, OR a43、C(O)R b43 、C(O)NR c43 R d43 、C(O)OR a43 NR c43 R d43 、S(O)2NR c43 R d43 and S(O)2R b43 , where R 4C The C 1-6 The alkyl group is optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0399] Each R a43 、R b43 、R c43 and R d43 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a43 、R b43 、R c43 and R d43 The C 1-6 Each alkyl group is optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0400] Alternatively, any R attached to the same N atom c43 and R d43 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, or 6-membered heterocycloalkyl group, wherein said 4-, 5-, or 6-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4D Substituents are substituted; and
[0401] Each R 4D Independently selected from C 1-3 Alkyl and OH.
[0402] In some embodiments of Formulas (I) and (III), R 4 Selected from phenyl-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, OR a4 、C(O)R b4 and S(O)2R b4 , where R 4 The phenyl-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R4A Substituent substitution;
[0403] Each R a4 、R b4 、R c4 and R d4 independently selected from phenyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl-, where R a4 、R b4 、R c4 and R d4 The phenyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0404] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, 5-6 membered heteroaryl, (4-10 membered heterocycloalkyl)-C 1-3 Alkyl-, OR a41 、S(O)2R b41 and NR c41 R d41 , where R 4A The C 1-6 alkyl, 5-6 membered heteroaryl and (4-10 membered heterocycloalkyl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0405] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl and 5-6 membered heteroaryl, wherein R a41 、R b41 、R c41 and R d41 The C 1-6 Alkyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0406] Each R 4B independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, (5-6 membered heteroaryl)-C 1-3 Alkyl-, CN, ORa42 、C(O)R b42 、C(O)OR a42 and NR c42 R d42 , where R 4B The C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0407] Each R a42 、R b42 、R c42 and R d42 Independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 5-7 membered heterocycloalkyl, wherein R a42 、R b42 、R c42 and R d42 The C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 5-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0408] Each R 4C Independently selected from C 1-6 Alkyl, CN, C(O)NR c43 R d43 、C(O)OR a43 NR c43 R d43 and S(O)2R b43 , where R 4C The C 1-6 The alkyl group is optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0409] Each R a43 、R b43 、R c43 and R d43 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a43 、R b43 、R c43 and R d43 The C 1-6 Each alkyl group is optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0410] Alternatively, any R attached to the same N atom c43 and R d43 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, or 6-membered heterocycloalkyl group, wherein said 4-, 5-, or 6-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4D Substituent substitution;
[0411] Each R 4D Independently selected from C 1-3 Alkyl and OH.
[0412] In some embodiments of Formulas (I) and (III), R 4 Selected from C 6-10 Aryl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, OR a4 、C(O)R b4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl- and (5-10 membered heteroaryl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituents are substituted; and
[0413] Each R 4A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, OR a41 SR a41 and NR c41 R d41 , where R 4A The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4B Substituent substitution.
[0414] In some embodiments of Formulas (I) and (III), R 4 Selected from C 6-10 Aryl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, OR a4 、C(O)R b4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0415] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-3 Alkyl-, C 3-10 Cycloalkyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-3 Alkyl-, CN, OR a41 SR a41 and NR c41 R d41 , where R 4A The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-3 Alkyl-, C 3-10 Cycloalkyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4BSubstituent substitution;
[0416] Each R 4B independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OR a42 、COOR a42 and NR c42 R d42 ;
[0417] Each R a4 and R b4 Independently selected from H, C 1-6 Alkyl, C 1-6 haloalkyl, phenyl and azetidinyl, wherein the phenyl group is optionally substituted by 1 or 2 groups selected from halo, C 1-6 Alkyl and C 1-6 haloalkyl radical substitution;
[0418] Each R a41 、R c41 and R d41 Independently selected from H and C 1-6 alkyl; and
[0419] Each R a42 、R c42 and R d42 Independently selected from H and C 1-6 alkyl.
[0420] In some embodiments of Formulas (I) and (III), R 4 Selected from C 6-10 Aryl-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl-, where R 4 The C 6-10 Aryl-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0421] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and OR a41 ;and
[0422] Each R a41 Independently selected from H and C 1-3 alkyl.
[0423] In some embodiments of Formulas (I) and (III), R 4It is a C6 aryl-C 1-3 Alkyl-, optionally substituted with 1, 2 or 3 substituents independently selected from OH and halo.
[0424] In some embodiments of Formulas (I) and (III), R 4pyridin-2-ylmethyl, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H-pyrrolo[2,3-b]pyridin-7-yl, 2-fluorophenoxy, hydroxy(pyridin-2-yl)methyl, 2-(1-methyl-1H-pyrazol-4-yl)benzyl, (imidazo[1,2-a]pyridin-8-yl)methyl, (pyrazolo[1,5-a]pyridin-7-yl)methyl, (2H-indazol-2-yl)methyl, (1H-indazol-1-yl)methyl, (2,6-dimethoxy)methyl fluorophenyl)(hydroxy)methyl, (2,5-difluorophenyl)(hydroxy)methyl, (2,3-difluorophenyl)(hydroxy)methyl, (2-fluorophenyl)(hydroxy)methyl, (2-chlorophenyl)(hydroxy)methyl, hydroxy(phenyl)methyl, phenylsulfonyl, azetidine-1-carbonyl, benzo[d]oxazol-4-ylmethyl, 2-fluoro-6-(1-methyl-1H-pyrazol-5-yl)benzyl, 2-fluoro-6-((6-methyl-5-oxo-2,6-diazaspiro[3.4]oct-2-yl)methyl)benzyl, 2-fluoro-6-((6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)benzyl, 2-fluoro-6-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl, 2-fluoro-6-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl, 2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)benzyl, 2-fluoro-6-(((2-methyl-2H-1,2,3-triazol-4-yl)amino)methyl)benzyl, 2-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl, amino(2,6-difluorophenyl)methyl, (2,6-difluorophenyl)methyl 1-(1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrrolidin-2-yl)methyl, 2-((1-acetylpiperidin-4-yl)methyl)-6-fluorobenzyl, (2-(difluoromethoxy)-6-fluorophenyl)(hydroxy)methyl, 2-fluoro-6-(1-((1-methyl-1H-pyrazol-4-yl)methyl)-1H-pyrazol-4-yl) benzyl, (2-((dimethylamino)methyl)-6-fluorophenyl)(hydroxy)methyl, 2-fluoro-6-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)benzyl, (2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl)(hydroxy)methyl, 2-fluoro-6-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-4-yl)benzyl, 2-fluoro-6-((6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)phenyl)(hydroxy)methyl, 2-fluoro-6-(1-((trans)-3-(methylamino)cyclobutyl)-1H-pyrazol-4-yl)benzyl, 2-(1-(2-cyanoethyl)-1H -pyrazol-4-yl)-6-fluorobenzyl, 2-fluoro-6-(1-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)benzyl, (3-methylpyridin-2-yl)methoxy, (3-((1-(pyridin-4-ylmethyl)-1H-pyrazol-4-yl)amino)pyridin-2-yl)methyl, (3-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyridin-2-yl)methyl, (3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)methyl, 2-((3-hydroxypyrrolidin-1-yl)methyl)benzyl and (6-methoxypyridin-2-yl)methyl.
[0425] In some embodiments of Formulas (I) and (III), R 4Selected from pyridin-2-ylmethyl, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H-pyrrolo[2,3-b]pyridin-7-yl, 2-fluorophenoxy, hydroxy(pyridin-2-yl)methyl, 2-(1-methyl-1H-pyrazol-4-yl)benzyl, imidazo[1,2-a]pyridin-8-ylmethyl, pyrazolo[1,5-a]pyridin-7-ylmethyl, (2H-indazol-2-yl)methyl, 1H-indazol-1-yl)methyl, (2,6-difluorophenyl)(hydroxy)methyl, (2,5-difluorophenyl)(hydroxy)methyl, (2,3-difluorophenyl)(hydroxy)methyl, (2-fluorophenyl)(hydroxy)methyl, (2-chlorophenyl)(hydroxy)methyl, hydroxy(phenyl)methyl, phenylsulfonyl and azetidine-1-carbonyl.
[0426] In some embodiments of Formulas (I) and (III), Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituent substitution.
[0427] In some embodiments of Formulas (I) and (III), Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituent substitution.
[0428] In some embodiments of Formulas (I) and (III), each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0429] In some embodiments of Formulas (I) and (III), Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituents are substituted; and
[0430] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0431] In some embodiments of Formulas (I) and (III), Cy 1 is selected by 1 or 2 independent R 7 a phenyl group substituted with a substituent; and
[0432] Each R 7are independently selected from halo and CN.
[0433] In some embodiments of Formulas (I) and (III), Cy 1 is phenyl, which is optionally substituted by 1 or 2 independently selected from C 1-6 Alkyl, halo and CN substituents are substituted.
[0434] In some embodiments of Formulas (I) and (III), Cy 1 is phenyl, which is optionally substituted by 1 or 2 independently selected from C 1-6 Alkyl and CN substituents are substituted.
[0435] In some embodiments of Formulas (I) and (III), Cy 1 It is an unsubstituted phenyl group.
[0436] In some embodiments of Formulas (I) and (III), Cy 1 It is cyanophenyl or cyanofluorophenyl.
[0437] In some embodiments of Formulas (I) and (III), Cy 1 It is cyanophenyl.
[0438] In some embodiments of Formulas (I) and (III), Cy 1 It is 3-cyanophenyl or 3-cyano-2-fluorophenyl.
[0439] In some embodiments of formula (I) and (III):
[0440] R 1 It is H;
[0441] Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituents are substituted; and
[0442] R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0443] In some embodiments of formula (I) and (III):
[0444] R 1 It is H;
[0445] Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituents are substituted; and
[0446] R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution.
[0447] In some embodiments of formula (I) and (III):
[0448] R 1 Is H or C 1-6 alkyl;
[0449] R 2 is a 5-6 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution;
[0450] R 4 Selected from C 6-10 Aryl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, OR a4 、C(O)R b4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0451] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-3 Alkyl-, C 3-10 Cycloalkyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3Alkyl-, (4-10 membered heterocycloalkyl)-C 1-3 Alkyl-, CN, OR a41 SR a41 and NR c41 R d41 , where R 4A The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-3 Alkyl-, C 3-10 Cycloalkyl-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0452] Each R 4B independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, OR a42 、COOR a42 and NR c42 R d42 .
[0453] Cy 1 is phenyl, optionally substituted with 1, 2 or 3 independently selected R 7 Substituent substitution;
[0454] Each R a4 and R b4 Independently selected from H, C 1-6 Alkyl, C 1-6 haloalkyl, phenyl and azetidinyl, wherein the phenyl group is optionally substituted by 1 or 2 groups selected from halo, C 1-6 Alkyl and C 1-6 haloalkyl radical substitution;
[0455] Each R a41 、R c41 and R d41 Independently selected from H and C 1-6 alkyl;
[0456] Each R a42 、R c42 and R d42 Independently selected from H and C 1-6 alkyl; and
[0457] Each R 7 independently selected from halogen, C1-6 Alkyl, C 1-6 Haloalkyl and CN.
[0458] In some embodiments of formula (I) and (III):
[0459] R 1 Is H or C 1-6 alkyl;
[0460] R 2 is a 5-6 membered heteroaryl group, which is optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution;
[0461] R 4 Selected from C 6-10 Aryl-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl-, where R 4 The C 6-10 Aryl-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2, 3 or 4 independently selected R 4A Substituent substitution;
[0462] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and OR a41 ;
[0463] Cy 1 is phenyl, which is optionally substituted by 1 or 2 independently selected from C 1-6 Alkyl and CN substituents are substituted; and
[0464] Each R a41 Independently selected from H and C 1-3 alkyl.
[0465] In some embodiments of formula (I) and (III):
[0466] R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 alkyl halide;
[0467] R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0468] R 4 Selected from C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 、OC(O)R b4 、OC(O)NR c4 R d4 NR c4 R d4 NR c4 C(O)R b4 NR c4 C(O)OR a4 NR c4 C(O)NR c4 R d4 、S(O)R b4 and S(O)2R b4 ;
[0469] Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituent substitution;
[0470] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 alkynyl; and
[0471] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0472] In some embodiments of formula (I) and (III):
[0473] R 1 Selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 alkyl halide;
[0474] R 2 Selected from C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R2 The C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution;
[0475] R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0476] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 ;
[0477] Cy 1 It is C 6-10 Aryl, optionally substituted with 1, 2, 3 or 4 independently selected R 7 Substituent substitution;
[0478] Each R a21 、R b21 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C2-6 Alkenyl and C 2-6 alkynyl; and
[0479] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0480] In some embodiments of formula (I) and (III):
[0481] R 1 It is H;
[0482] R 2 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0483] R 4 Selected from C(O)NR c4 R d4 and NR c4 C(O)OR a4 ;
[0484] Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituent substitution;
[0485] Each R a4 、R c4 and R d4 Independently selected from H and C 1-6 alkyl; and
[0486] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0487] In some embodiments of formula (I) and (III):
[0488] R 1 It is H;
[0489] R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein R 2 The 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally replaced by 1 or 2 independently selected R 2A Substituent substitution;
[0490] R 4 Selected from H, D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl and C 2-6 Alkynyl;
[0491] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 and S(O)R b21 ;
[0492] Cy 1 is phenyl, optionally substituted with 1 or 2 independently selected R 7 Substituent substitution;
[0493] Each R a21 、R b21 、R c21 and R d21 Independently selected from H and C 1-6 alkyl; and
[0494] Each R 7 independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, CN and NO2.
[0495] In some embodiments of formula (I) and (III):
[0496] R 1 It is H;
[0497] R 2 It is H;
[0498] R 4 It is NR c4 C(O)OR a4 ;
[0499] Cy 1 is cyanophenyl; and
[0500] R a4 and R c4 Each independently selected from H and C 1-6 alkyl.
[0501] In some embodiments of formula (I) and (III):
[0502] R 1 It is H;
[0503] R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl;
[0504] R 4 is H; and
[0505] Cy 1 It is cyanophenyl.
[0506] In some embodiments of formula (I) and (III):
[0507] R 1 It is H;
[0508] R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 C 1-3 Alkyl substitution;
[0509] R 4 It is phenyl-C 1-3 Alkyl- or pyridyl-C 1-3 Alkyl-, wherein the phenyl-C 1-3 Alkyl- and pyridyl-C 1-3 alkyl- are each optionally substituted with 1, 2 or 3 substituents independently selected from OH and halo; and
[0510] Cy 1 It is cyanophenyl.
[0511] In some embodiments of formula (I) and (III):
[0512] R 1 It is H;
[0513] R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl;
[0514] R 4 It is phenyl-C 1-3 alkyl-, which is optionally substituted with 1, 2 or 3 substituents independently selected from OH and halo; and
[0515] Cy 1 It is cyanophenyl.
[0516] In some embodiments of formula (I) and (III):
[0517] R 1 It is H;
[0518] R 2 is pyrimidin-4-yl;
[0519] R 4 It is phenyl-C 1-3 alkyl-, which is optionally substituted with 1, 2 or 3 substituents independently selected from OH and halo; and
[0520] Cy 1 It is cyanophenyl.
[0521] In some embodiments of formula (I) and (III), the compound is a compound of formula (IIIa):
[0522]
[0523] or a pharmaceutically acceptable salt thereof, wherein the variable R 2 、R 4 and Cy 1 are defined according to the definitions provided herein for compounds of formula (I) and (III).
[0524] In some embodiments of Formula (IIIa),
[0525] Cy 1 is selected by 1 or 2 independent R 7 a phenyl group substituted with a substituent;
[0526] Each R 7 independently selected from halo and CN;
[0527] R 2 Selected from H, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, wherein R 2 The C 6-10 Aryl, C 3-10Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2, 3 or 4 independently selected R 2A Substituent substitution;
[0528] Each R 2A Independently selected from D, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, CN, NO2, OR a21 SR a21 NHOR a21 、C(O)R b21 、C(O)NR c21 R d21 、C(O)OR a21 、OC(O)R b21 、OC(O)NR c21 R d21 NR c21 R d21 NR c21 C(O)R b21 NR c21 C(O)OR a21 NR c21 C(O)NR c21 R d21 、S(O)R b21 and S(O)2R b21 , where R 2A The C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2B Substituent substitution;
[0529] Each R a21 、R 241 、R c21 and R d21 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a21 、R 241 、R c21 and R d21 The C 1-6The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2A Substituents are substituted; and
[0530] Each R 2B Independently selected from D, halo, OH, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy, C 1-4 Alkyl, C 1-4 Haloalkyl, amino, C 1-3 Alkylamino and di(C 1-3 alkyl)amino.
[0531] R 4 Selected from C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, OR a4 、C(O)R b4 、C(O)NR c4 R d4 、C(O)OR a4 NR c4 R d4 、S(O)2NR c4 R d4 and S(O)2R b4 , where R 4 The C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0532] Each R a4 、R b4 、R c4 and R d4 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, where R a4 、R b4 、R c4 and R d4 The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0533] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-6 Alkyl-, CN, OR a41 、C(O)R b41 、C(O)NR c41 R d41 、C(O)OR a41 NR c41 R d41 、S(O)2NR c41 R d41 and S(O)2R b41 , where R 4A The C 1-6 Alkyl, C 6-10 Aryl, C 3-10 Cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 Aryl-C 1-6 Alkyl-, C 3-10 Cycloalkyl-C 1-6 Alkyl-, (5-10 membered heteroaryl)-C 1-6Alkyl- and (4-10 membered heterocycloalkyl)-C 1-6 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0534] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl, wherein R a41 、R b41 、R c41 and R d41 The C 1-6 Alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0535] Each R 4B independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-3 Alkyl-, (C 3-6 Cycloalkyl)-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-6 membered heteroaryl)-C 1-3 Alkyl-, CN, OR a42 、C(O)R b42 、C(O)NR c42 R d42 、C(O)OR a42 NR c42 R d42 、S(O)2NR c42 R d42 and S(O)2R b42 , where R 4B The C 1-6 Alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl-C 1-3 Alkyl-, (C 3-6 Cycloalkyl)-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-6 membered heteroaryl)-C 1-3Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0536] Each R a42 、R b42 、R c42 and R d42 Independently selected from H, C 1-6 Alkyl, C 1-6 Halogenated alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl, wherein R a42 、R b42 、R c42 and R d42 The C 1-6 Alkyl, phenyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0537] Each R 4C Independently selected from C 1-6 Alkyl, C 1-6 Haloalkyl, CN, OR a43 、C(O)R b43 、C(O)NR c43 R d43 、C(O)OR a43 NR c43 R d43 、S(O)2NR c43 R d43 and S(O)2R b43 , where R 4C The C 1-6 alkyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0538] Each R a43 、R b43 、R c43 and R d43 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a43 、R b43 、R c43 and R d43 The C 1-6 Each alkyl group is optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0539] Alternatively, any R attached to the same N atom c43 and R d43 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, or 6-membered heterocycloalkyl group, wherein said 4-, 5-, or 6-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4D Substituents are substituted; and
[0540] Each R 4D Independently selected from C 1-3 Alkyl and OH.
[0541] In some embodiments of Formula (IIIa),
[0542] Cy 1 is 3-cyanophenyl or 3-cyano-2-fluorophenyl;
[0543] R 2 is selected from H, 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R 2 The 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution;
[0544] Each R 2A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and OH, where R 2A The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2B Substituent substitution;
[0545] Each R 2B independently selected from D, halo and OH;
[0546] R 4 Selected from phenyl-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, OR a4 、C(O)R b4 and S(O)2R b4 , where R 4 The phenyl-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0547] Each R a4 、Rb4 、R c4 and R d4 independently selected from phenyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl-, where R a4 、R b4 、R c4 and R d4 The phenyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4A Substituent substitution;
[0548] Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, 5-6 membered heteroaryl, (4-10 membered heterocycloalkyl)-C 1-3 Alkyl-, OR a41 、S(O)2R b41 and NR c41 R d41 , where R 4A The C 1-6 alkyl, 5-6 membered heteroaryl and (4-10 membered heterocycloalkyl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0549] Each R a41 、R b41 、R c41 and R d41 Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl and 5-6 membered heteroaryl, wherein R a41 、R b41 、R c41 and R d41 The C 1-6 Alkyl and 5-6 membered heteroaryl are each optionally substituted by 1, 2 or 3 independently selected R 4B Substituent substitution;
[0550] Each R 4B independently selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, (5-6 membered heteroaryl)-C 1-3 Alkyl-, CN, OR a42 、C(O)R b42 、C(O)OR a42 and NR c42R d42 , where R 4B The C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0551] Each R a42 、R b42 、R c42 and R d42 Independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 5-7 membered heterocycloalkyl, wherein R a42 、R b42 、R c42 and R d42 The C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 5-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 4C Substituent substitution;
[0552] Each R 4C Independently selected from C 1-6 Alkyl, CN, C(O)NR c43 R d43 、C(O)OR a43 NR c43 R d43 and S(O)2R b43 , where R 4C The C 1-6 alkyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0553] Each R a43 、R b43 、R c43 and R d43 Independently selected from H, C 1-6 Alkyl and C 1-6 Haloalkyl, where R a43 、R b43 、R c43 and R d43 The C 1-6 Each alkyl group is optionally replaced by 1 or 2 independently selected R 4D Substituent substitution;
[0554] Alternatively, any R attached to the same N atom c43 and R d43 Together with the nitrogen atom to which they are attached, they form a 4-, 5-, or 6-membered heterocycloalkyl group, wherein said 4-, 5-, or 6-membered heterocycloalkyl group is optionally substituted by 1, 2, 3, or 4 independently selected R 4D Substituents are substituted; and
[0555] Each R 4D Independently selected from C 1-3 Alkyl and OH.
[0556] In some embodiments of Formula (IIIa),
[0557] R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 C 1-3 Alkyl substitution;
[0558] R 4 It is phenyl-C 1-3 Alkyl- or pyridyl-C 1-3 Alkyl-, wherein the phenyl-C 1-3 Alkyl- and pyridyl-C 1-3 alkyl- are each optionally substituted with 1, 2 or 3 substituents independently selected from OH and halo; and
[0559] Cy 1 It is 3-cyanophenyl.
[0560] In some embodiments of formula (I) and (III), the compound is a compound of formula (IIIb):
[0561]
[0562] or a pharmaceutically acceptable salt thereof, wherein n is an integer from 0 to 4, and wherein the variable R 2 、R 4 and R 7 are defined according to the definitions provided herein for compounds of formula (I) and (III).
[0563] In some embodiments of formula (I) and (III), the compound is a compound of formula (IIIc):
[0564]
[0565] or a pharmaceutically acceptable salt thereof, wherein the variable R 2 、R 4 and R 7 are defined according to the definitions provided herein for compounds of formula (I) and (III).
[0566] In some embodiments, the compound is the (S)-enantiomer of one of the aforementioned compounds, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is the (R)-enantiomer of one of the aforementioned compounds, or a pharmaceutically acceptable salt thereof.
[0567] It will be further appreciated that certain features of the invention that are described for clarity in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, various features of the invention that are described for brevity in the context of a single embodiment may also be provided individually or in any suitable subcombination.
[0568] At various locations in this specification, a divalent linking substituent is described. Each divalent linking substituent is expressly intended to include both the forward and reverse forms of the linking substituent. For example, -NR(CR'R") n -Include-NR(CR'R") n -and-(CR'R") n NR - Both. If the structure clearly requires a linking group, the Markush variable listed for that group is to be understood as being the linking group.
[0569] The term "n-membered" (where n is an integer) generally describes the number of ring-forming atoms in a moiety, where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridinyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl ring.
[0570] As used herein, the phrase "optionally substituted" means unsubstituted or substituted. Substituents are independently selected, and substitution can be at any chemically accessible position. As used herein, the term "substituted" means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent (e.g., oxo) can replace two hydrogen atoms. It should be understood that substitution at a given atom is limited by valence.
[0571] As used herein, the phrase "each 'variable' is independently selected from" has substantially the same meaning as "at each occurrence the 'variable' is selected from."
[0572] Throughout this definition, the term “C n-m " indicates a range including endpoints, where n and m are integers and indicate the number of carbons. Examples include C 1-3 、C 1-4 、C 1-6 and so on.
[0573] As used herein, the term "Cn-m "Alkyl" refers to a saturated hydrocarbon radical having n to m carbons which may be straight or branched. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (iPr), n-butyl, tert-butyl, isobutyl, sec-butyl; higher carbon number homologues such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group contains 1 to 6 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
[0574] As used herein, “C n-m "Alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds and having n to m carbons. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
[0575] As used herein, “C n-m "Alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds and having n to m carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
[0576] As used herein, the term "C n-m "Alkoxy" refers to a radical of the formula -O-alkyl, where the alkyl radical has n to m carbon atoms. Example alkoxy radicals include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tert-butoxy), and the like. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0577] As used herein, the term "amino" refers to a group of formula -NH2.
[0578] As used herein, the term "aryl," employed alone or in combination with other terms, refers to an aromatic hydrocarbon group which may be monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings). n-m "Aryl" refers to an aromatic radical having n to m ring carbon atoms. Aryl groups include, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, an aryl group has 5 to 10 carbon atoms. In some embodiments, an aryl group is phenyl or naphthyl. In some embodiments, an aryl group is phenyl.
[0579] As used herein, "halo" refers to F, Cl, Br, or I. In some embodiments, halo is F, Cl, or Br. In some embodiments, halo is F or Cl. In some embodiments, halo is F. In some embodiments, halo is Cl.
[0580] As used herein, “C n-m "Haloalkoxy" refers to a radical of the formula -O-haloalkyl having n to m carbon atoms. Example haloalkoxy radicals include OCF3 and OCHF2. In some embodiments, the haloalkoxy radical is a solely fluorinated alkoxy radical. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0581] As used herein, the term "C n-m "Haloalkyl" refers to an alkyl group having from 1 halogen atom to 2s + 1 halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms. In some embodiments, the haloalkyl group is a fluorinated alkyl group only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CH2F, CCl3, CHCl2, C2Cl5, and the like.
[0582] As used herein, the term "thio" refers to a group of formula -SH.
[0583] As used herein, the term "carbamyl" refers to a group of formula -C(O)NH2.
[0584] As used herein, the term "carbonyl," employed alone or in combination with other terms, refers to a -C(O)- group.
[0585] As used herein, the term "C n-m "Alkylamino" refers to a radical of the formula -NH(alkyl) where the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0586] As used herein, the term "C n-m "Alkoxycarbonyl" refers to a radical of the formula -C(O)O-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0587] As used herein, the term "C n-m "Alkylcarbonyl" refers to a radical of the formula -C(O)-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0588] As used herein, the term "C n-m "Alkylcarbonylamino" refers to a radical of the formula -NHC(O)-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0589] As used herein, the term "C n-m "Alkylsulfonylamino" refers to a radical of the formula -NHS(O)2-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0590] As used herein, the term "aminosulfonyl" refers to a group of formula -S(O)2NH2.
[0591] As used herein, the term "C n-m "Alkylaminosulfonyl" refers to a radical of the formula -S(O)2NH(alkyl) where the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0592] As used herein, the term "di(C n-m "S(O)2N(alkyl)2" refers to a radical of the formula -S(O)2N(alkyl)2 wherein each alkyl independently has n to m carbon atoms. In some embodiments, each alkyl independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0593] As used herein, the term "aminosulfonylamino" refers to a group of formula -NHS(O)2NH2.
[0594] As used herein, the term "C n-m "Alkylaminosulfonylamino" refers to a radical of the formula -NHS(O)2NH(alkyl) where the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0595] As used herein, the term "di(C n-m "(alkyl)aminosulfonylamino" refers to a radical of the formula -NHS(O)2N(alkyl)2 wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0596] As used herein, the term "aminocarbonylamino," employed alone or in combination with other terms, refers to a group of formula -NHC(O)NH2.
[0597] As used herein, the term "C n-m"Alkylaminocarbonylamino" refers to a radical of the formula -NHC(O)NH(alkyl) where the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0598] As used herein, the term "di(C n-m "(alkyl)aminocarbonylamino" refers to a radical of the formula -NHC(O)N(alkyl)2 wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0599] As used herein, the term "C n-m "Alkylcarbamoyl" refers to a radical of the formula -C(O)-NH(alkyl) where the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0600] As used herein, the term "C n-m "Alkylthio" refers to a radical of the formula -S-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0601] As used herein, the term "C n-m "Alkylsulfinyl" refers to a radical of the formula -S(O)-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0602] As used herein, the term "C n-m "Alkylsulfonyl" refers to a radical of the formula -S(O)2-alkyl, wherein the alkyl radical has n to m carbon atoms. In some embodiments, the alkyl radical has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0603] As used herein, the term "cyano-C 1-n "Alkyl" refers to a group of the formula -(C 1-n In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms, for example, -(C 1-3 alkylene)-CN.
[0604] As used herein, the term "HO-C 1-n "Alkyl" refers to a group of the formula -(C 1-n In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms, for example, -(C 1-3 Alkylene)-OH.
[0605] As used herein, the term "C 1-n Alkoxy-C 1-n "Alkyl" refers to a group of the formula -(C 1-n Alkylene)-O(C 1-n In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms, for example, -(C 1-6 Alkylene)-O(C 1-6 alkyl).
[0606] As used herein, the term "carboxy" refers to a group of formula -C(O)OH.
[0607] As used herein, the term "di(C n-m -alkyl)amino" refers to a radical of the formula -N(alkyl)2, wherein the two alkyl radicals each independently have n to m carbon atoms. In some embodiments, each alkyl radical independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0608] As used herein, the term "di(C n-m -alkyl)carbamoyl" refers to a group of the formula -C(O)N(alkyl)2, wherein the two alkyl groups each independently have n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0609] As used herein, the term "C n-m "Alkylcarbonyloxy" is a radical of the formula -OC(O)-alkyl, wherein the alkyl radical has n to m carbon atoms.
[0610] As used herein, "aminocarbonyloxy" is a group of the formula -OC(O)-NH2.
[0611] As used herein, “C n-m "Alkylaminocarbonyloxy" is a radical of the formula -OC(O)-NH-alkyl, wherein the alkyl radical has n to m carbon atoms.
[0612] As used herein, "di(C n-m "(alkyl)aminocarbonyloxy" is a radical of the formula -OC(O)-N(alkyl)2 wherein each alkyl radical independently has n to m carbon atoms.
[0613] As used herein, “C n-m "Alkoxycarbonylamino" refers to a group of the formula -NHC(O)O(C n-m alkyl) wherein the alkyl group has n to m carbon atoms.
[0614] As used herein, "cycloalkyl" refers to non-aromatic cyclic hydrocarbons, including cyclized alkyl and alkenyl groups. Cycloalkyl groups may include monocyclic or polycyclic (e.g., with 2 fused rings) groups, spirocycles, and bridged rings (e.g., bridged bicycloalkyl groups). The ring-forming carbon atoms of the cycloalkyl group may optionally be substituted with oxo groups or sulfide groups (e.g., C(O) or C(S)). The definition of cycloalkyl also includes portions in which one or more aromatic rings are fused to the cycloalkyl ring (i.e., having a common bond), such as cyclopentane, cyclohexane, and benzo or thienyl derivatives of the like. Cycloalkyl groups containing fused aromatic rings may be connected by any ring-forming atom (including the ring-forming atoms of the fused aromatic ring). Cycloalkyl groups may have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbon atoms (i.e., C 3-10 In some embodiments, the cycloalkyl group is C 3-10 In some embodiments, the cycloalkyl group is C 3-7 In some embodiments, the cycloalkyl group is C 4-7 In some embodiments, the cycloalkyl group is C 4-10 Spirocycle or bridged cycloalkyl (e.g., bridged bicycloalkyl). Example cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, spiro[3.3]heptyl, and the like. In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0615] As used herein, "heteroaryl" refers to a monocyclic or polycyclic (e.g., having two fused rings) aromatic heterocycle having at least one heteroatom ring member selected from N, O, S, and B. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, any ring-forming N in the heteroaryl moiety may be an N-oxide. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, and S. In some embodiments, the heteroaryl is a 5-6 membered monocyclic heteroaryl having 1 or 2 heteroatom ring members independently selected from N, O, S, and B. In some embodiments, the heteroaryl group is a 5-6 membered monocyclic heteroaryl group having 1 or 2 heteroatom ring members independently selected from N, O, and S. In some embodiments, the heteroaryl group contains 3 to 10, 4 to 10, 5 to 10, 5 to 7, 3 to 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to 4 ring-forming heteroatoms, 1 to 3 ring-forming heteroatoms, 1 to 2 ring-forming heteroatoms, or 1 ring-forming heteroatom. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. Example heteroaryl groups include, but are not limited to, thienyl (or thiophenyl), furyl (or furanyl), pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl, and 1,2-dihydro-1,2-azaalkylboronyl. , pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, azolyl, triazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzothiophenyl, benzofuranyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, triazinyl, thieno[3,2-b]pyridinyl, imidazo[1,2-a]pyridinyl, 1,5-naphthyridinyl, 1H-pyrazolo[4,3-b]pyridinyl, triazolo[4,3-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, indazolyl and the like.
[0616] As used herein, "heterocycloalkyl" refers to a monocyclic or polycyclic heterocycle having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more ring-forming carbon atoms of the heterocycloalkyl group are replaced by heteroatoms selected from N, O, S, and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group are optionally substituted with one or more oxo groups or sulfide groups (e.g., C(O), S(O), C(S), or S(O)2, etc.). When the ring-forming carbon atoms or heteroatoms of the heterocycloalkyl group are optionally substituted with one or more oxo groups or sulfide groups, the O or S of the group are in addition to the number of ring atoms specified herein (e.g., 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl is a 6-membered heterocycloalkyl group, wherein the ring-forming carbon atoms are substituted with oxo groups, and wherein the 6-membered heterocycloalkyl group is further substituted with methyl groups). Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having two fused rings) systems. Heterocycloalkyl includes monocyclic and polycyclic 3 to 10 yuan, 4 to 10 yuan, 5 to 10 yuan, 4 to 7 yuan, 5 to 7 yuan or 5 to 6 yuan heterocycloalkyl.Heterocycloalkyl may also include spirocycle and bridged ring (for example, one or more ring carbon atoms are independently selected from N, O, S and B heteroatom replacement 5 to 10 yuan bridged diheterocycloalkyl ring).Heterocycloalkyl can be connected by ring carbon atoms or ring heteroatoms.In some embodiments, heterocycloalkyl contains 0 to 3 double bonds.In some embodiments, heterocycloalkyl contains 0 to 2 double bonds.
[0617] The definition of heterocycloalkyl also includes moieties in which one or more aromatic rings are fused (i.e., have a common bond) to a non-aromatic heterocyclic ring, such as benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. Heterocycloalkyl groups containing fused aromatic rings may be attached through any ring atom, including a ring atom of the fused aromatic ring.
[0618] In some embodiments, the heterocycloalkyl group contains 3 to 10 ring atoms, 4 to 10 ring atoms, 3 to 7 ring atoms, or 5 to 6 ring atoms. In some embodiments, the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. In some embodiments, the heterocycloalkyl group is a monocyclic 4-6 membered heterocycloalkyl group having 1 or 2 heteroatoms independently selected from N, O, S, and B and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic 5-10 membered heterocycloalkyl group having 1, 2, 3, or 4 heteroatoms independently selected from N, O, S, and B and having one or more oxidized ring members. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic 5-10 membered heterocycloalkyl group having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and having one or more oxidized ring members. In some embodiments, heterocycloalkyl is a monocyclic 5-6 membered heterocycloalkyl having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and having one or more oxygenated ring members.
[0619] Examples of heterocycloalkyl groups include pyrrolidin-2-one (or 2-oxopyrrolidinyl), 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, 1,2,3,4-tetrahydroisoquinoline, benzyl, benzoyl, benzophenone ... azabicyclo[3.1.0]hexyl, diazabicyclo[3.1.0]hexyl, oxobicyclo[2.1.1]hexyl, azabicyclo[2.2.1]heptyl, diazabicyclo[2.2.1]heptyl, azabicyclo[3.1.1]heptyl, diazabicyclo[3.1.1]heptyl, azabicyclo[3.2.1]octyl, diazabicyclo[3.2.1]octyl, oxobicyclo[2.2.2]octyl, azabicyclo[2.2.2]octyl, azaadamantyl, diazaadamantyl, oxo-adamantyl, azaspiro[3.3]heptyl, diazaspiro[3.3]heptyl, oxo-azaspiro[3.3]heptyl, azaspiro[3.4]octyl, diazaspiro[3.4]octyl, oxo-azaspiro[3.4]octyl, azaspiro[2.5]octyl, diazaspiro[2.5]octyl, azaspiro[4.4]nonyl, diazaspiro [4.4]nonyl, oxo-azaspiro[4.4]nonyl, azaspiro[4.5]decyl, diazaspiro[4.5]decyl, diazaspiro[4.4]nonyl, oxo-diazaspiro[4.4]nonyl, oxo-dihydropyridazinyl, oxo-2,6-diazaspiro[3.4]octyl, oxohexahydropyrrolo[1,2-a]pyrazinyl, 3-oxopiperazinyl, oxo-pyrrolidinyl, oxo-pyridyl, and the like. For example, heterocycloalkyl includes the following groups (with and without N-methyl substitution):
[0620]
[0621] As used herein, “C o-p Cycloalkyl-C n-m "Alkyl-" refers to a radical of the formula cycloalkyl-alkylene- wherein the cycloalkyl radical has o to p carbon atoms and the alkylene linking radical has n to m carbon atoms.
[0622] As used herein, “C o-p Aryl-C n-m "Alkyl-" refers to a radical of the formula aryl-alkylene- wherein the aryl group has o to p carbon atoms and the alkylene linking group has n to m carbon atoms.
[0623] As used herein, "heteroaryl-C n-m"Alkyl-" refers to a radical of the formula heteroaryl-alkylene- wherein the alkylene linking group has n to m carbon atoms.
[0624] As used herein, "heterocycloalkyl-C n-m "Alkyl-" refers to a radical of the formula heterocycloalkyl-alkylene- wherein the alkylene linking group has n to m carbon atoms.
[0625] As used herein, an "alkyl linking group" is a divalent straight or branched chain alkyl linking group ("alkylene"). For example, "C o-p Cycloalkyl-C n-m Alkyl-", "C o-p Aryl-C n-m Alkyl-", "phenyl-C n-m Alkyl-", "heteroaryl-C n-m Alkyl-" and "heterocycloalkyl-C n-m "Alkyl-" contains an alkyl linking group. Examples of "alkyl linking groups" or "alkylene" include methylene, ethane-1,1-diyl, ethane-1,2-diyl, propan-1,3-diyl, propan-1,2-diyl, propan-1,1-diyl, and the like.
[0626] In some places, a definition or embodiment refers to a specific ring (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, the ring may be attached to any ring member, provided that the valence of the atom is not exceeded. For example, the azetidine ring may be attached at any position of the ring, while the pyridin-3-yl ring is attached at the 3-position.
[0627] As used herein, the term "oxo" refers to an oxygen atom (i.e., =O) as a divalent substituent that forms a carbonyl (e.g., C=O or C(O)) when attached to a carbon, or a nitroso, sulfinyl, or sulfonyl group when attached to a nitrogen or sulfur heteroatom.
[0628] As used herein, the term "independently selected" means that a variable or substituent (e.g., R 7 or R 2A ) is independently selected from the applicable list at each occurrence.
[0629] The compounds described herein may be asymmetric (e.g., having one or more stereocenters). Unless otherwise indicated, all stereoisomers (such as enantiomers and diastereomers) are contemplated. Compounds of the present disclosure containing asymmetrically substituted carbon atoms can be separated in optically active or racemic forms. Methods for preparing optically active forms from optically inactive starting materials are known in the art, such as by resolving racemic mixtures or by stereoselective synthesis. Many geometric isomers of alkenes, C=N double bonds, and the like may also be present in the compounds described herein, and all such stable isomers are encompassed by the present invention. Cis and trans geometric isomers of the compounds of the present disclosure are described and can be separated into mixtures of isomers or individual isomeric forms. In some embodiments, the compounds have an (R)-configuration. In some embodiments, the compounds have an (S)-configuration. The formulas provided herein (e.g., formula (I), (II), etc.) include stereoisomers of the compounds.
[0630] The racemic mixture of resolving compound can be implemented by any one of numerous methods known in the art.Example method includes the segmented recrystallization using chiral resolution acid (it is an optically active salified organic acid).Suitable resolving agent for segmented recrystallization method is (for example) optically active acid, such as tartaric acid, diacetyl tartaric acid, dibenzoyl tartaric acid, mandelic acid, malic acid, lactic acid or various optically active camphorsulfonic acids (such as β-camphorsulfonic acid) of D and L forms.Other resolving agents suitable for segmented crystallization method include the stereoisomerically pure form (for example, S and R form or non-mirror image isomerically pure form) of α-methylbenzylamine, 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane and likewise.
[0631] Resolution of the racemic mixture can also be carried out by elution on a column packed with an optically active resolving agent (eg, dinitrobenzoylphenylglycine). Suitable elution solvent compositions can be determined by one skilled in the art.
[0632] The compounds provided herein also include tautomeric forms. Tautomeric forms arise from the exchange of single bonds with adjacent double bonds and the accompanying proton migration. Tautomeric forms include prototropic tautomers with isomeric protonation states of the same empirical formula and total charge. Example prototropic tautomers include keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and cyclic forms, wherein protons can occupy two or more positions of a heterocyclic ring system, such as 1H- and 3H-imidazoles, 1H-, 2H-, and 4H-1,2,4-triazoles, 1H- and 2H-isoindoles, 2-hydroxypyridines and 2-pyridones, and 1H- and 2H-pyrazoles. Tautomeric forms can be in equilibrium or spatially locked into one form by appropriate substitution.
[0633] All compounds and pharmaceutically acceptable salts thereof may exist together with other substances such as water and solvents (eg, hydrates and solvates) or may be isolated.
[0634] In some embodiments, preparation of compounds may involve the addition of an acid or base to effect, for example, catalysis of a desired reaction or the formation of a salt form such as an acid addition salt.
[0635] In some embodiments, the compound or its salt provided herein is substantially separated. "Substantially separated" means that the compound is at least partially or substantially separated from its environment formed or detected therein. Partial separation can include, for example, a composition rich in the compound provided herein. Substantial separation can include a composition containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97% or at least about 99% of the compound or its salt provided herein by weight. The method for separating compounds and their salts is conventional in the art.
[0636] As used herein, the term "compound" is intended to include all stereoisomers, geometric isomers, tautomers, and isotopes of the depicted structure. Unless otherwise specified, compounds identified herein as one particular tautomeric form by name or structure are intended to include the other tautomeric forms.
[0637] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit / risk ratio.
[0638] The present application also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues (such as amines); basic or organic salts of acidic residues (such as carboxylic acids); and the like. Pharmaceutically acceptable salts of the present disclosure include, for example, conventional non-toxic salts of the parent compound formed from non-toxic inorganic or organic acids. Pharmaceutically acceptable salts of the present disclosure can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Typically, such salts can be prepared by reacting the free acid or base form of the compound with a stoichiometric amount of an appropriate base or acid in water or in an organic solvent or in a mixture of the two; typically, non-aqueous media such as ether, ethyl acetate, alcohol (e.g., methanol, ethanol, isopropanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is herein incorporated by reference in its entirety.
[0639] synthesis
[0640] As will be appreciated by those skilled in the art, the compounds provided herein, including salts and stereoisomers thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes.
[0641] Compounds of formula 1-14 and 1-15 can be prepared via the synthetic route outlined in Scheme 1. Commercially available starting material 1-1 is alkylated with carbonyl adduct 1-2 (Hal is a halide such as F, Cl, Br, or I), followed by condensation at elevated temperature using a suitable reagent such as ammonium acetate to produce bicyclic compound 1-3. Compound 1-3 can then be reacted with a reagent such as phosphorus oxychloride (POCl3) to produce intermediate 1-4. Intermediate 1-4 undergoes nucleophilic aromatic substitution (S) with amine adduct 1-5 (PG is a suitable protecting group such as 2,4-dimethoxybenzyl). NAr) followed by reduction of the ester functionality with a suitable reducing agent (e.g., DIBAL-H) to afford alcohol 1-6. Halogenation of 1-6 with a suitable reagent such as phosphorus tribromide (PBr3) affords intermediate 1-7. Compound 1-7 can then be cross-coupled with an adduct of formula 1-8 wherein M is an organoboronic acid, an organoboronic ester, or a suitably substituted metal [e.g., M is B(OR)2, Sn(alkyl)3, or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stille cross-coupling conditions (e.g., in the presence of a palladium catalyst) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to afford a cross-coupled product which undergoes protection group removal to afford intermediate 1-9. In some embodiments, Cy 4 It can be R 4 or R 4 -R 4a Halogenation of 1-9 using an appropriate reagent such as N-bromosuccinimide (NBS) affords two isomers 1-10 and 1-11. The two isomers 1-10 and 1-11 can then be reacted with either adduct 1-12 or 1-13 to prepare the final products 1-14 and 1-15 using reaction conditions similar to those described for the preparation of 1-9 from 1-7.
[0642] Solution 1.
[0643]
[0644] Compounds of formula 2-7 can be prepared via the synthetic route outlined in Scheme 2. Commercially available starting material 2-1 (Hal is a halide such as F, Cl, Br, or I) is alkylated with carbonyl adduct 1-2, followed by condensation at elevated temperature using a suitable reagent such as ammonium acetate to produce bicyclic compound 2-2. Compound 2-2 can then be reacted with a suitable reagent such as phosphorus oxychloride (POCl3) to produce intermediate 2-3. Intermediate 2-3 undergoes nucleophilic aromatic substitution (S) with amine adduct 1-5 (PG is a suitable protecting group such as 2,4-dimethoxybenzyl). NAr) followed by removal of the protecting group to afford compound 2-4. Halogenation of 2-4 using a suitable reagent, such as N-bromosuccinimide (NBS), yields compound 2-5. Intermediate 2-5 can be cross-coupled with an adduct of formula 1-12 (wherein M is an organoboronic acid, organoboronic ester, or a suitably substituted metal) [e.g., M is B(OR) 2, Sn(alkyl) 3, or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to afford compound 2-6. Intermediate 2-6 then undergoes a second cross-coupling reaction with compound 1-8 using a procedure similar to that described for the preparation of 2-6 from 2-5 to afford product 2-7.
[0645] Option 2.
[0646]
[0647] Compounds of formula 3-6 can be prepared via the synthetic route outlined in Scheme 3. Compound 1-4 (prepared using the procedure described in Scheme 1) undergoes nucleophilic aromatic substitution (S) with amine adduct 1-5 (PG is a suitable protecting group such as 2,4-dimethoxybenzyl). N Ar) followed by removal of the protecting group affords intermediate 3-1. Halogenation of 3-1 using an appropriate reagent such as N-bromosuccinimide (NBS) followed by reduction of the ester functionality using a suitable reducing agent (e.g., DIBAL-H) yields alcohol 3-2. Intermediate 3-2 can then be oxidized using an appropriate oxidizing agent (e.g., Dess-Martin periodinane) to afford aldehyde 3-3. 3-3 is then reacted with 3-4 (M 1 is a metal group such as MgBr or Li) to give secondary alcohol 3-5. The final product 3-6 can be prepared by a cross-coupling reaction between intermediate 3-5 and an adduct of formula 1-12 (wherein M is an organoboronic acid, an organoboronic ester or a suitably substituted metal) [e.g., M is B(OR) 2, Sn(alkyl) 3 or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst).
[0648] Option 3.
[0649]
[0650] Compounds of formula 4-5 can be prepared via the synthetic pathway outlined in Scheme 4. Halogenation of compound 3-1 (prepared using the procedure from Scheme 3) with an appropriate reagent, such as N-bromosuccinimide (NBS), affords compound 4-1 (Hal is a halide, such as F, Cl, Br, or I). Compound 4-1 can then be cross-coupled with an adduct of formula 1-12 (wherein M is an organoboronic acid, organoboronic ester, or a suitably substituted metal) [e.g., M is B(OR) 2 , Sn(alkyl) 3 , or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to afford intermediate 4-2. Hydrolysis of 4-2 with an appropriate reagent, such as sodium hydroxide, yields carboxylic acid 4-3. Compound 4-3 can then be reacted with amine 4-4 under standard amide coupling conditions (such as using HATU as the coupling agent and DIPEA as the base) to give product 4-5.
[0651] Solution 4.
[0652]
[0653] Compounds of formula 5-7 can be prepared via the synthetic route outlined in Scheme 5. Commercially available starting material 5-1 (Hal is a halide such as F, Cl, Br or I) is subjected to nucleophilic aromatic substitution (S) with amine 1-5 (PG is a suitable protecting group such as 2,4-dimethoxybenzyl). N Ar) to give compound 5-2. Compound 5-2 can then be cross-coupled with an adduct of formula 5-3 (wherein M is an organoboronic acid, organoboronic ester, or a suitably substituted metal) [e.g., M is B(OR)2, Sn(alkyl)3, or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base), standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst), or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to give intermediate 5-4. The protecting group in 5-4 can be removed to give compound 5-5. Halogenation of 5-5 using an appropriate reagent such as N-bromosuccinimide (NBS) gives intermediate 5-6. Compound 5-6 can then be cross-coupled with an adduct of formula 1-12 using a procedure similar to that described for the preparation of 5-4 from 5-2 to give product 5-7.
[0654] Option 5.
[0655]
[0656] Compounds of formula 6-9 can be prepared via the synthetic route outlined in Scheme 6. Commercially available starting material 6-1 (Hal is a halide such as F, Cl, Br, or I) can be reacted with an appropriate reagent such as tert-butyl O-mesitylenecarbamate (Journal of Heterocyclic Chemistry, 1975, 12, 107) to form pyrazinium salt 6-2. Intermediate 6-2 can then undergo a condensation reaction with an adduct of formula 6-3 to form compound 6-4. 6-4 undergoes nucleophilic aromatic substitution (S) with amine 1-5 (PG is a suitable protecting group such as 2,4-dimethoxybenzyl). N Ar) to give compound 6-5. Compound 6-6 can then be prepared by cross-coupling reaction between intermediate 6-5 and an adduct of formula 5-3 (wherein M is an organoboronic acid, an organoboronic ester, or a suitably substituted metal) [e.g., M is B(OR) 2, Sn(alkyl) 3, or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) . The protecting group in 6-6 can be removed to give compound 6-7, which is subjected to a halogenation reaction using an appropriate reagent such as N-bromosuccinimide (NBS) to form compound 6-8. Final product 6-9 can be synthesized by coupling 6-8 with an adduct of formula 1-12 using a procedure similar to that described for the preparation of compound 6-6 from 6-5.
[0657] Option 6.
[0658]
[0659] Compounds of formula 7-9 can be prepared via the synthetic route outlined in Scheme 7. Commercially available starting material 7-1 (Hal is a halide such as F, Cl, Br, or I) is alkylated with carbonyl adduct 1-2, followed by condensation using a suitable reagent such as ammonium acetate at elevated temperature to produce bicyclic compound 7-2. Compound 7-2 can then be reacted with a reagent such as phosphorus oxychloride (POCl3) to produce intermediate 7-3. Intermediate 7-3 undergoes nucleophilic aromatic substitution (S) with amine adduct 7-4 (PG is a suitable protecting group such as 4-methoxybenzyl). NAr) to give intermediate 7-5. Compound 7-5 can then be cross-coupled with an adduct of formula 7-6 (wherein M is an organoboronic acid, an organoboronic ester, or a suitably substituted metal) [e.g., M is B(OR) 2, Sn(alkyl) 3, or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to give compound 7-7. The protecting group in 7-7 is removed, and the resulting intermediate undergoes a halogenation reaction with an appropriate reagent, such as N-bromosuccinimide (NBS), to give adduct 7-8. The final product 7-9 can then be synthesized by coupling 7-8 with an adduct of formula 1-12 using a procedure similar to that described for the preparation of compound 7-7 from 7-5.
[0660] Option 7
[0661]
[0662] Compounds of formula 8-7, 8-10, and 8-11 can be prepared via the synthetic pathway outlined in Scheme 8. Compound 7-5 (which can be prepared as described in Scheme 7) can first be cross-coupled with a reagent of formula 8-1 (wherein M is an organoboronic acid, organoboronic ester, or a suitably substituted metal) [e.g., M is B(OR) 2 , Sn(alkyl) 3 , or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to generate compound 8-2. Halogenation of 8-2 can then be performed using an appropriate reagent (such as 1-bromopyrrolidine-2,5-dione) to provide intermediate 8-3. Another cross-coupling reaction between 8-3 and reagent 1-12 can then be performed using similar conditions as described for the conversion from 7-5 to 8-2 to deliver compound 8-4. The vinyl group in 8-4 is cleaved under suitable conditions (such as using osmium(VIII) oxide and sodium periodate) and the resulting aldehyde 8-5 is reacted with 3-4 (M 1 The protecting group (PG) in 8-6 can then be removed to give the desired product 8-7.
[0663] Alternatively, aldehyde 8-5 can be subjected to reduction using an appropriate reagent such as NaBH4 to afford alcohol 8-8. 8-8 can then be halogenated using a reagent such as PBr3 to afford intermediate 8-9. Cross-coupling of 8-9 with 1-8 (using the conditions described for the synthesis of 8-2 from 7-5) followed by removal of the protecting group (PG) will yield product 8-10. Alternatively, 8-9 can be substituted with a nucleophilic substitution (S N 2) Reaction with amine 4-4 followed by removal of the protecting group (PG) affords product 8-11. The reaction sequence described in this scheme can be rearranged and adjusted accordingly to suit the needs of each analogous synthesis.
[0664] Option 8
[0665]
[0666] Compounds of formula 9-9 can be prepared using the synthetic route outlined in Scheme 9. Commercially available starting material 9-1 (Hal is a halide such as F, Cl, Br or I) can be subjected to nucleophilic aromatic substitution (S) with amine 7-4 (PG is a suitable protecting group such as 4-methoxybenzyl). N Ar) to give compound 9-2. Intermediate 9-2 can be reacted with an appropriate reagent (such as O-(mesitylsulfonyl)hydroxylamine (Journal of Heterocyclic Chemistry, 1975, 12, 107)) to form pyrazinium salt 9-3. Intermediate 9-3 can then undergo a condensation reaction with an intermediate of formula 9-4 to form compound 9-5. Compound 9-6 can then be prepared by a cross-coupling reaction between intermediate 9-5 and an intermediate of formula 5-3 (wherein M is an organic boronic acid, an organic boronic ester, or a suitably substituted metal) [e.g., M is B(OR) 2, Sn(alkyl) 3, or Zn-Hal] under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst and a suitable base) or standard Stiller cross-coupling conditions (e.g., in the presence of a palladium catalyst) or standard Negishi cross-coupling conditions (e.g., in the presence of a palladium catalyst) to prepare compound 9-6. Compound 9-6 can be halogenated using an appropriate reagent such as N-bromosuccinimide (NBS) to form compound 9-7. Compound 9-8 can be synthesized by coupling 9-7 with an intermediate of formula 1-12 using a procedure similar to that described for the preparation of compound 9-6 from 9-5. The final product 9-9 can be formed after removing the protecting group in intermediate 9-8. Certain synthetic steps described herein can be rearranged and / or omitted to prepare different analogs.
[0667] Plan 9.
[0668]
[0669] How to use
[0670] The compounds of the present disclosure can modulate the activity of adenosine receptors (such as subtypes A2A and A2B receptors). Thus, the compounds, salts, or stereoisomers described herein can be used in methods of inhibiting adenosine receptors (e.g., A2A and / or A2B receptors) by contacting the receptors with any one or more of the compounds, salts, or compositions described herein. In some embodiments, the compounds or salts can be used in methods of inhibiting adenosine receptor activity in individuals / patients in need of such inhibition by administering an effective amount of a compound or salt described herein. In some embodiments, modulation is inhibition. In some embodiments, contacting is in vivo. In some embodiments, contacting is ex vivo or in vitro.
[0671] The compounds or salts described herein may be selective. "Selective" means that the compound binds to or inhibits an adenosine receptor with greater affinity or efficacy, respectively, than at least one other receptor, kinase, etc. The compounds of the present disclosure may also be dual antagonists (i.e., inhibitors) of adenosine receptors (e.g., A2A and A2B adenosine receptors).
[0672] Another aspect of the present disclosure relates to a method for treating an adenosine receptor-related disease or condition in an individual (e.g., a patient) by administering to an individual in need of such treatment a therapeutically effective amount or dose of one or more compounds of the present disclosure or a pharmaceutical composition thereof. Adenosine receptor-related diseases or conditions may include any disease, condition, or disorder directly or indirectly associated with the expression or activity (including overexpression and / or abnormal activity levels) of adenosine receptors.
[0673] The compounds of the present disclosure are useful in treating diseases associated with the activity of adenosine receptors, including, for example, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, immunoregulatory disorders, central nervous system diseases, and diabetes.
[0674] Given the striking role of adenosine (e.g., A2A, A2B) receptors in various immunosuppressive mechanisms, the development of inhibitors could enhance the immune system to inhibit tumor progression. Adenosine receptor inhibitors, alone or in combination with other therapies, can be used to treat bladder cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC), lung metastasis), melanoma (e.g., metastatic melanoma), breast cancer, cervical cancer, ovarian cancer, colorectal cancer, pancreatic cancer, esophageal cancer, prostate cancer, kidney cancer, skin cancer, thyroid cancer, liver cancer, uterine cancer, head and neck cancer, and renal cell carcinoma (Antonioli, L. et al., Nature Reviews Cancer, 2013, 13, 842-857). See also https: / / globenewswire.com / news-release / 2017 / 04 / 04 / 954192 / 0 / en / Corvus-Pharmaceuticals-Announces-Interim-Results-from-Ongoing-Phase-1-1b-Study-Demonstrating-Safety-and-Clinical-Activity-of-Lead-Checkpoint-Inhibitor-CPI-444-in-Patients-with-Adva.html; Cekic C. et al., J. Immunol, 2012, 188:198-205; Iannone, R. et al., Am. J. Cancer Res. 2014, 4: 172-181 (studies showing that blocking both A2A and CD73 enhances the anti-tumor activity of anti-CTLA-4 mAb therapy in the B16F10 murine melanoma model); Iannone, R. et al., Neoplasia, 2013, 15: 1400-1410 and Beavis PA., et al., Proc Natl Acad Sci. USA, 2013, 110: 14711-14716 (studies showing that A2A and CD73 blockade reduces metastasis in the 4T1 breast tumor model with high CD73 expression). In some embodiments, the prostate cancer is metastatic castration-resistant prostate cancer (mCRPC). In some embodiments, the colorectal cancer is colorectal cancer (CRC).
[0675] In some embodiments, the disease or disorder is lung cancer (e.g., non-small cell lung cancer), melanoma, pancreatic cancer, breast cancer, head and neck squamous cell carcinoma, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, uterine cancer, kidney cancer, stomach cancer, or a sarcoma. In some embodiments, the sarcoma is Askin's tumor, botryoid sarcoma, chondrosarcoma, Ewing's sarcoma, malignant hemangioendothelioma, malignant neurilemoma, osteosarcoma, alveolar soft part sarcoma, angiosarcoma, cystosarcoma phyllodes, dermatofibrosarcoma protuberans, desmoid tumor, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, gastrointestinal stromal tumor (GIST), hemangiopericytoma, angiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, lymphosarcoma, malignant peripheral nerve sheath tumor (MPNST), neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma.
[0676] In some embodiments, the disease or condition is mesothelioma or adenocarcinoma. In some embodiments, the disease or condition is mesothelioma. In some embodiments, the disease or condition is adenocarcinoma.
[0677] MDSC (myeloid-derived suppressor cells) are a heterologous immune cell population from the myeloid lineage (a family of cells derived from bone marrow stem cells). Due to changes in hematopoiesis, MDSC expands rapidly in pathological conditions such as chronic infections and cancer. MDSC is distinguished from other bone marrow cell types because it has strong immunosuppressive activity rather than immunostimulatory properties. Similar to other bone marrow cells, MDSC interacts with other immune cell types (including T cells, dendritic cells, macrophages, and natural killer cells) to regulate their function. In some embodiments, the compounds described herein, etc. can be used in methods related to cancerous tissues (e.g., tumors) with high MDSC infiltration, including solid tumors infiltrated with high basal levels of macrophages and / or MDSC.
[0678] In some embodiments, the compounds of the present disclosure are useful for treating pulmonary inflammation, including bleomycin-induced pulmonary fibrosis and damage associated with adenosine deaminase deficiency (Baraldi, et al., Chem. Rev., 2008, 108, 238-263).
[0679] In some embodiments, the compounds of the present disclosure can be used as treatments for inflammatory diseases such as allergic reactions (e.g., A2B adenosine receptor-dependent allergic reactions) and other adenosine receptor-dependent immune responses. Other inflammatory diseases that can be treated with the compounds of the present disclosure include respiratory disorders, sepsis, reperfusion injury, and thrombosis.
[0680] In some embodiments, the compounds of the present disclosure can be used as treatments for cardiovascular diseases such as coronary artery disease (myocardial infarction, angina, heart failure), cerebrovascular disease (stroke, transient ischemic attack), peripheral arterial disease, and aortic atherosclerosis and aneurysms. Atherosclerosis is a potential cause of many types of cardiovascular disease. Atherosclerosis begins in adolescence with fatty streaks, which progress to plaques in adulthood and ultimately lead to thrombotic events that cause vascular occlusion, which leads to clinically significant morbidity and mortality. Antagonists for A2B adenosine receptors and A2A adenosine receptors may be beneficial in preventing atherosclerotic plaque formation (Eisenstein, A. et al., J. Cell Physiol., 2015, 230(12), 2891-2897).
[0681] In some embodiments, the compounds of the present disclosure can be used as treatments for the following diseases: motor activity disorders; defects caused by degeneration of the striatonigral dopamine system; and Parkinson's disease; and some motivational symptoms of depression (Collins, LE et al., Pharmacol. Biochem. Behav., 2012, 100, 498-505.).
[0682] In some embodiments, the compounds of the present disclosure may be used as treatments for diabetes and related conditions such as insulin resistance. Diabetes affects adenosine production and the expression of the A2B adenosine receptor (A2BR) that stimulates IL-6 and CRP production, insulin resistance, and A 2B Association between A2BR single nucleotide polymorphisms (ADORA2B SNPs) and inflammatory markers. Increased A2BR signaling in diabetes may increase insulin resistance, in part, by elevating proinflammatory mediators. Selective A2BR blockers may be used to treat insulin resistance (Figler, RA et al., Diabetes, 2011, 60(2), 669-679).
[0683] It is believed that the compounds provided herein (e.g., compounds of formula (I)) or any embodiment thereof may have a satisfactory pharmacological profile and promising biopharmaceutical properties, such as toxicological profiles, metabolic and pharmacokinetic properties, solubility and permeability. It will be understood that the determination of appropriate biopharmaceutical properties is within the knowledge of those skilled in the art, for example, by measuring cytotoxicity in cells or inhibiting certain targets or pathways to determine potential toxicity.
[0684] The terms "subject" or "patient" are used interchangeably and refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.
[0685] The phrase "therapeutically effective amount" refers to that amount of an active compound or agent that elicits the biological or medical response in a tissue, system, animal, individual or human that is being sought by the researcher, veterinarian, physician or other clinician.
[0686] As used herein, the terms "treating" or "treatment" refer to one or more of the following: (1) inhibiting a disease; e.g., inhibiting the disease, disorder, or condition in a subject experiencing or exhibiting the pathology or symptoms of the disease, disorder, or condition (i.e., preventing the pathology and / or symptoms from developing further); and (2) ameliorating a disease; e.g., ameliorating the disease, disorder, or condition in a subject experiencing or exhibiting the pathology or symptoms of the disease, disorder, or condition (i.e., reversing the pathology and / or symptoms), such as reducing the severity of the disease.
[0687] In some embodiments, the compounds of the invention are useful for preventing or reducing the risk of developing any of the diseases mentioned herein; for example, preventing or reducing the risk of developing a disease, disorder, or condition in an individual who may be susceptible to the disease, disorder, or condition but who does not yet experience or display the pathology or symptoms of the disease.
[0688] Combination therapy
[0689] I. Immune Checkpoint Therapy
[0690] In some embodiments, the dual inhibitors of A2A and A2B provided herein can be used in combination with one or more immune checkpoint inhibitors for the treatment of cancer as described herein. In one embodiment, a combination with one or more immune checkpoint inhibitors as described herein can be used to treat melanoma. The compounds disclosed herein can be used in combination with one or more immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules, such as CD20, CD28, CD40, CD122, CD96, CD73, CD47, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, HPK1, CD137 (also known as 4-1BB), ICOS, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, TIGIT, PD-1, PD-L1, and PD-L2. In some embodiments, immune checkpoint molecules are selected from the stimulatory checkpoint molecules of CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, immune checkpoint molecules are selected from the inhibitory checkpoint molecules of A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT and VISTA. In some embodiments, the compounds of the present disclosure provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRβ inhibitors.
[0691] In some embodiments, the dual A2A and A2B inhibitors provided herein can be used in combination with one or more agonists of immune checkpoint molecules, such as OX40, CD27, OX40, GITR, and CD137 (also known as 4-1BB).
[0692] In some embodiments, the immune checkpoint molecule inhibitor is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0693] In some embodiments, the immune checkpoint molecule inhibitor is a PD-1 inhibitor, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), durvalumab, In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD-1 monoclonal antibody is pembrolizumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD-1 antibody is SHR-1210. Other anticancer agents include antibody therapeutics such as 4-1BB (e.g., urelumab or utomilumab).
[0694] In some embodiments, the immune checkpoint molecule inhibitor is a PD-L1 inhibitor, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.
[0695] In some embodiments, the immune checkpoint molecule inhibitor is an inhibitor of PD-1 and PD-L1, such as an anti-PD-1 / PD-L1 monoclonal antibody. In some embodiments, the anti-PD-1 / PD-L1 is MCLA-136.
[0696] In some embodiments, the inhibitor is INCB086550.
[0697] In some embodiments, the inhibitor is MCLA-145.
[0698] In some embodiments, the immune checkpoint molecule inhibitor is a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884, or CP-675,206.
[0699] In some embodiments, the immune checkpoint molecule inhibitor is a LAG3 inhibitor, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, or INCAGN2385.
[0700] In some embodiments, the immune checkpoint molecule inhibitor is a TIM3 inhibitor, such as an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.
[0701] In some embodiments, the immune checkpoint molecule inhibitor is a GITR inhibitor, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, or MEDI1873.
[0702] In some embodiments, the immune checkpoint molecule inhibitor is an OX40 agonist, such as an OX40 agonist antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, or BMS-986178. In some embodiments, the OX40L fusion protein is MEDI6383.
[0703] In some embodiments, the immune checkpoint molecule inhibitor is a CD20 inhibitor, such as an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.
[0704] The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one domain of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3, tumor-specific antigens (e.g., CD70), or TGFβ receptor.
[0705] In some embodiments, the compounds of the present disclosure may be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO, or arginase. Examples of IDO1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099, and LY338196.
[0706] As provided throughout, other compounds, inhibitors, agents, etc. can be combined with the compounds of the present invention in a single or sequential dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
[0707] II. Cancer Therapy
[0708] Cancer cell growth and survival can be affected by multiple signaling pathways. Therefore, it is useful to combine different enzyme / protein / receptor inhibitors (which exhibit different preferences in the targets of their regulated activities) to treat such diseases. Targeting more than one signaling pathway (or more than one biomolecule involved in a given signaling pathway) can reduce the likelihood of drug resistance developing in a cell population and / or reduce the toxicity of the treatment.
[0709] The compounds of the present disclosure may be used in combination with one or more other enzyme / protein / receptor inhibitors or one or more therapies for treating diseases such as cancer. Examples of diseases and indications that can be treated using combination therapy include those described herein.
[0710] The compounds of the present disclosure can be used in combination with one or more other agents (e.g., chemotherapeutic agents, immuno-oncology agents, metabolic enzyme inhibitors, chemokine receptor inhibitors, and phosphatase inhibitors) and targeted therapies (such as Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET, VEGFR, PDGFR, c-Kit, IGF-1R, RAF, and FAK kinase inhibitors). The one or more other agents can be administered to the patient simultaneously or sequentially.
[0711] For example, the compounds disclosed herein can be combined with one or more inhibitors of the following kinases for the treatment of cancer and other diseases or conditions described herein: Akt1, Akt2, Akt3, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFαR, PDGFβR, CSFIR, KIT, FLK -II, KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR / Fl t2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for the treatment of cancer and other diseases and conditions described herein include FGFR inhibitors (FGFR1, FGFR2, FGFR3, or FGFR4, such as INCB54828, INCB62079, and INCB63904), JAK inhibitors (JAK1 and / or JAK2, such as ruxolitinib, baricitinib, or INCB39110), IDO inhibitors (e.g., epastat, NLG919, or BMS-986205), LSD1 inhibitors (e.g., INCB54828, INCB62079, and INCB63904), B59872 and INCB60003), TDO inhibitors, PI3K-δ inhibitors (e.g., INCB50797 and INCB50465), Pim inhibitors, CSF1R inhibitors, TAM receptor tyrosine kinases (Tyro-3, Axl and Mer), histone deacetylase inhibitors (HDAC) (such as HDAC8 inhibitors), angiogenesis inhibitors, interleukin receptor inhibitors, bromo and extra-terminal family member inhibitors (e.g., bromodomain inhibitors or BET inhibitors, such as INCB54329 and INCB57643) and adenosine receptor antagonists, or a combination thereof.
[0712] Example antibodies for use in combination therapy include, but are not limited to, Trastuzumab (e.g., anti-HER2), Ranibizumab (e.g., anti-VEGF-A), Bevacizumab (trade name Avastin, e.g., anti-VEGF), Panitumumab (e.g., anti-EGFR), Cetuximab (e.g., anti-EGFR), Rituxan (anti-CD20), and antibodies to c-MET.
[0713] One or more of the following agents can be used in combination with the compounds of the present disclosure and are presented as a non-limiting list: cytostatics, cisplatin, doxorubicin, taxotere, paclitaxel, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilone, tamoxifen, 5-fluorouracil, methotrexate, temozolomide, cyclophosphamide, SCH66336, R115777, L778,123, BMS214662, IRESSA TM (gefitinib), TARCEVA TM (erlotinib), antibodies targeting EGFR, introns, cytarabine (ara-C), adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylene melamine, triethylenethiophosphamide, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN TMOxaliplatin, pentostatin, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, teniposide 17.alpha.-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate propionate), testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide e), toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, navelbene, anastrazole, letrazole, capecitabine, reloxafine, droloxafine, hexamethylmelamine, avastin, HERCEPTIN TM (trastuzumab), BEXXAR TM (tositumomab), VELCADE TM(bortezomib), ZEVALIN TM (ibritumomab tiuxetan), TRISENOX TM (arsenic trioxide), XELODA TM (capecitabine), vinorelbine, porfimer, ERBITUX TM (cetuximab), thiotepa, altretamine, melphalan, trastuzumab, letrozole, fulvestrant, exemestane, ifosfamide, rituximab, C225 (cetuximab), Campath (alemtuzumab), clofarabine, cladribine, aphidicolon, rituximab, sunitinib, dasatinib, tezacitabine, Sml1, fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, and MDL-101,731.
[0714] The compounds of the present disclosure can be further used in combination with other methods for treating cancer, such as by chemotherapy, irradiation therapy, tumor-targeted therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine therapy (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, adoptive T cell transfer, Toll receptor agonists, STING agonists, oncolytic virus therapy and immunomodulatory small molecules (including thalidomide (thalidomide) or JAK1 / 2 inhibitors) and the like. The compound can be administered in combination with one or more anticancer drugs (such as chemotherapeutic agents). Example chemotherapeutic agents include any of abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, hexamethylmelamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, intravenous busulfan, oral busulfan, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, sodium), daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, drotosterone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate acetate), ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon α2a, irinotecan, lapatinib ditosylateditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, olaparib, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium disodium), pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, rucaparib, streptozotocin, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, niraparib, veliparib, talazoparib, and zoledronate.
[0715] Other examples of chemotherapeutic agents include proteasome inhibitors (eg, bortezomib), thalidomide, revlimid, and DNA damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
[0716] Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVAC TM ), nilotinib, dasatinib, bosutinib and ponatinib and pharmaceutically acceptable salts thereof. Other suitable examples of Bcr-Abl inhibitors include compounds of the genus and species disclosed in U.S. Patent No. 5,521,184, WO 04 / 005281 and U.S. Application No. 60 / 578,491 and pharmaceutically acceptable salts thereof.
[0717] Suitable examples of Flt-3 inhibitors include midostaurin, lestaurtinib, linifanib, sunitinib, sunitinib maleate, sorafenib, quizartinib, crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215 and pharmaceutically acceptable salts thereof. Other suitable examples of Flt-3 inhibitors include compounds disclosed in WO 03 / 037347, WO 03 / 099771 and WO 04 / 046120 and pharmaceutically acceptable salts thereof.
[0718] Suitable example RAF inhibitors include dabrafenib, sorafenib and vemurafenib and pharmaceutically acceptable salts thereof. Other suitable example RAF inhibitors include compounds disclosed in WO 00 / 09495 and WO 05 / 028444 and pharmaceutically acceptable salts thereof.
[0719] Suitable example FAK inhibitors include VS-4718, VS-5095, VS-6062, VS-6063, BI853520 and GSK2256098 and pharmaceutically acceptable salts thereof. Other suitable example FAK inhibitors include compounds disclosed in WO 04 / 080980, WO 04 / 056786, WO 03 / 024967, WO 01 / 064655, WO 00 / 053595 and WO 01 / 014402 and pharmaceutically acceptable salts thereof.
[0720] In some embodiments, the compounds of the present disclosure can be used in combination with one or more other kinase inhibitors, including imatinib, particularly for treating patients who are resistant to imatinib or other kinase inhibitors.
[0721] In some embodiments, the compounds of the present disclosure can be used in combination with chemotherapeutic agents in cancer treatment, and can improve the response compared to the treatment response to a single chemotherapeutic agent without exacerbating its toxic effects. In some embodiments, the compounds of the present disclosure can be used in combination with chemotherapeutic agents provided herein. For example, the additional agents used in the treatment of multiple myeloma may include, but are not limited to, melphalan, melphalan plus prisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Other additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulator. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulator is lenalidomide (LEN) or pomalidomide (POM).Additive or synergistic effects of combining the PI3K inhibitors of the present disclosure with additional agents are desirable results.
[0722] In some embodiments, compounds of the present disclosure may be used in combination with inhibitors of JAK or PI3Kδ.
[0723] The agents may be combined with the compounds of the invention in a single or sequential dosage form, or the agents may be administered simultaneously or sequentially as separate dosage forms.
[0724] The compounds of the present disclosure can be used in combination with one or more other inhibitors or one or more therapies for the treatment of infections. Examples of infections include viral infections, bacterial infections, fungal infections, or parasitic infections.
[0725] In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with a compound of the present disclosure, wherein the dexamethasone is administered intermittently rather than continuously.
[0726] The compound of formula (I) or any of the formulas described herein, the compound as listed in any of the technical solutions and described herein, or a salt thereof can be combined with another immunogenic agent, such as cancer cells, purified tumor antigens (including recombinant proteins, peptides and carbohydrate molecules), cells, and cells transfected with genes encoding immunostimulatory cytokines. Non-limiting examples of useful tumor vaccines include peptides of melanoma antigens, such as gp100, MAGE antigens, Trp-2, MARTI and / or tyrosinase peptides, or tumor cells transfected to express the cytokine GM-CSF.
[0727] Formula (I) or any of the compounds described herein, as listed in any of the technical solutions and described herein, or salts thereof can be used in combination with vaccination regimens for the treatment of cancer. In some embodiments, tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include proteins from viruses involved in human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, the compounds of the present disclosure can be used in combination with tumor-specific antigens, such as heat shock proteins isolated from tumor tissue itself. In some embodiments, formula (I) or any of the compounds described herein, as listed in any of the technical solutions and described herein, or salts thereof can be combined with dendritic cell immunity to activate a potent anti-tumor response.
[0728] The compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target effector cells expressing Fcα or Fcγ receptors to tumor cells. The compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.
[0729] In some other embodiments, the compounds of the present disclosure in combination with other therapeutic agents may be administered to a patient before, during, and / or after a bone marrow transplant or stem cell transplant. The compounds of the present disclosure may be used in combination with a bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.
[0730] Formula (I) or a compound of any formula as described herein, a compound as listed in any technical solution and described herein or its salt can be used in combination with a vaccine to stimulate an immune response to pathogens, toxins and autoantigens. Examples of pathogens for which this method of treatment may be particularly useful include pathogens for which there is currently no effective vaccine or conventional vaccines are not completely effective. The pathogens include but are not limited to HIV, hepatitis (type A, type B and type C), influenza, herpes, Giardia lamblia (Giardia), malaria, Leishmania (Leishmania), Staphylococcus aureus (Staphylococcus aureus), Pseudomonas aeruginosa (Pseudomonas Aeruginosa).
[0731] Infections caused by viruses that can be treated by the methods of the present disclosure include, but are not limited to, human papillomavirus, influenza, hepatitis A, B, C, or D, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, measles virus, herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus.
[0732] Infections caused by pathogenic bacteria that can be treated by the methods of the present disclosure include, but are not limited to, chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and gonococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
[0733] Infections caused by pathogenic fungi that can be treated by the methods of the present disclosure include, but are not limited to, Candida (Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis, etc.), Cryptococcus neoformans, Aspergillus (Aspergillus fumigatus, Aspergillus niger, etc.), Genus Mucorales (Mucorales mucor, Mucorales absidia, Mucorales rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and the like. immitis and Histoplasma capsulatum. Infections caused by pathogenic parasites that can be treated by the methods of the present disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lamblia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.
[0734] Methods for safely and effectively administering most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in standard literature. For example, the administration of many chemotherapeutic agents is described in "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if fully set forth.
[0735] Drug preparations and dosage forms
[0736] When used as a drug, the compounds of the present disclosure can be administered in the form of a pharmaceutical composition. The composition can be prepared in a manner well known in the pharmaceutical field and can be administered by a variety of routes depending on the desired local or systemic treatment and the area to be treated. Administration can be topical (including transdermal, epidermal, ocular and mucosal administration, including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powder or aerosol, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular or injection or infusion administration; or intracranial administration, such as intrathecal or intraventricular. Parenteral administration can be in the form of a single bolus dose, or can be performed, for example, by continuous infusion pump. Pharmaceutical compositions and preparations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be needed or required.
[0737] The present disclosure also includes pharmaceutical compositions containing a compound of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. When preparing the composition of the present disclosure, the active ingredient is usually mixed with an excipient, diluted by the excipient or encapsulated in such a carrier in the form of, for example, a capsule, a sachet, paper or other container. When an excipient is used as a diluent, it can be a solid, semi-solid or liquid material that acts as a vehicle, carrier or medium for the active ingredient. Therefore, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
[0738] When preparing a formulation, the active compound may be milled to provide an appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it may be milled to a particle size of less than 200 mesh. If the active compound is substantially soluble in water, the particle size may be adjusted by milling to provide a substantially uniform distribution in the formulation, for example, about 40 mesh.
[0739] The compounds of the present disclosure may be milled using known milling procedures, such as wet milling, to obtain particle sizes suitable for tablet formation and other formulation types. Fine (nanoparticulate) formulations of the compounds of the present disclosure may be prepared by processes known in the art, for example, see International Application No. WO 2002 / 000196.
[0740] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, gum tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may additionally include: lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; sweeteners; and flavoring agents. The compositions of the present disclosure can be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to a patient by employing procedures known in the art.
[0741] The compositions can be formulated in unit dosage form, each dose containing from about 5 mg to about 1000 mg (1 g), more usually from about 100 mg to about 500 mg of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
[0742] In some embodiments, the compositions of the present disclosure contain from about 5 mg to about 50 mg of active ingredient. Those skilled in the art will appreciate that this encompasses compositions containing from about 5 mg to about 10 mg, from about 10 mg to about 15 mg, from about 15 mg to about 20 mg, from about 20 mg to about 25 mg, from about 25 mg to about 30 mg, from about 30 mg to about 35 mg, from about 35 mg to about 40 mg, from about 40 mg to about 45 mg, or from about 45 mg to about 50 mg of active ingredient.
[0743] In some embodiments, the compositions of the present disclosure contain from about 50 mg to about 500 mg of active ingredient. Those skilled in the art will appreciate that this encompasses compositions containing from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 350 mg to about 400 mg, or from about 450 mg to about 500 mg of active ingredient.
[0744] In some embodiments, the compositions of the present disclosure contain from about 500 mg to about 1000 mg of active ingredient. Those skilled in the art will appreciate that this encompasses compositions containing from about 500 mg to about 550 mg, from about 550 mg to about 600 mg, from about 600 mg to about 650 mg, from about 650 mg to about 700 mg, from about 700 mg to about 750 mg, from about 750 mg to about 800 mg, from about 800 mg to about 850 mg, from about 850 mg to about 900 mg, from about 900 mg to about 950 mg, or from about 950 mg to about 1000 mg of active ingredient.
[0745] Similar dosages of the compounds described herein can be used in the methods and uses of the present disclosure.
[0746] The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. However, it will be understood that the actual amount of compound administered will generally be determined by a physician based on relevant circumstances including the condition to be treated, the route of administration chosen, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.
[0747] To prepare solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulated composition containing a uniform mixture of the disclosed compounds. When the preformulated composition is referred to as uniform, the active ingredient is generally evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above, containing, for example, about 0.1 mg to about 1000 mg of the active ingredient of the disclosure.
[0748] The tablets or pills of the present disclosure may be coated or otherwise compounded to provide a dosage form with a long-lasting effect advantage. For example, a tablet or pill may comprise an inner dosage component and an outer dosage component, the latter being a film-coated version of the former. The two components may be separated by an enteric layer that resists decomposition in the stomach and allows the inner component to enter the duodenum intact or to be released later. Such enteric layers or coatings may be made of a variety of materials, including a large amount of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.
[0749] Liquid forms in which the compounds and compositions of the present disclosure may be incorporated for oral or injection administration include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and emulsions flavored with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
[0750] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, as well as powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the compositions are administered via the oral or nasal respiratory route to achieve a local or systemic effect. The compositions may be aerosolized using an inert gas. The aerosolized solution may be inhaled directly from the aerosolizing device or the aerosolizing device may be attached to a mask, curtain, or intermittent positive pressure breathing machine. The solution, suspension, or powder composition may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.
[0751] Topical preparations may contain one or more conventional carriers. In some embodiments, ointments may contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, and the like. The carrier composition of a cream may be based on a combination of water with glycerol and one or more other components (e.g., glycerol monostearate, PEG-glycerol monostearate, and cetyl stearyl alcohol). Gels may be formulated using isopropyl alcohol and water, suitably in combination with other components (e.g., glycerol, hydroxyethyl cellulose, and the like). In some embodiments, topical preparations contain at least about 0.1 wt%, at least about 0.25 wt%, at least about 0.5 wt%, at least about 1 wt%, at least about 2 wt%, or at least about 5 wt% of a compound of the present disclosure. Topical preparations may be suitably packaged in, for example, 100 g tubes, optionally with instructions for treating selected indications (e.g., psoriasis or other skin disorders).
[0752] The amount of the compound or composition administered to a patient will vary depending on the drug being administered, the purpose of administration (such as prevention or treatment), the patient's state, the mode of administration, and the like. In therapeutic applications, the composition can be administered to a patient suffering from the disease in an amount sufficient to cure or at least partially prevent the symptoms of the disease and its complications. The effective dose will depend on the condition being treated and the judgment made by the attending clinical physician based on factors such as the severity of the disease, the patient's age, weight, and general condition, and the like.
[0753] The composition administered to the patient may be in the form of a pharmaceutical composition as described above. These compositions may be sterilized by conventional sterilization techniques or may be aseptically filtered. The aqueous solution may be packaged for use as is or lyophilized, and the lyophilized formulation may be combined with a sterile aqueous carrier prior to administration. The pH of the compound formulation will typically be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It will be understood that the use of some of the above-mentioned excipients, carriers, or stabilizers will form pharmaceutical salts.
[0754] The therapeutic dose of the compounds of the present invention may vary according to, for example, the specific use of the treatment being performed, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition may vary depending on a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present invention may be provided for parenteral administration in a physiologically buffered aqueous solution containing about 0.1% w / v to about 10% w / v of the compound. Some typical dosage ranges are about 1 μg / kg to about 1g / kg body weight per day. In some embodiments, the dosage range is about 0.01mg / kg to about 100mg / kg body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or condition, the overall health of the specific patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and its route of administration. The effective dose can be extrapolated from a dose-response curve derived from an in vitro or animal model test system.
[0755] The compositions of the present disclosure may also comprise one or more additional agents, such as chemotherapeutic agents, steroids, anti-inflammatory compounds, or immunosuppressants, examples of which are listed herein.
[0756] Labeled compounds and assays
[0757] Another aspect of the present disclosure relates to labeled compounds of the present disclosure (radioactively labeled, fluorescently labeled, etc.), which will be useful not only in imaging techniques but also in both in vitro and in vivo assays for localizing and quantifying A2A and / or A2B receptors in tissue samples (including humans), and for identifying A2A and / or A2B antagonists by inhibiting the binding of labeled compounds. Substitution of one or more atoms of the disclosed compounds can also be used to produce differential ADME (adsorption, distribution, metabolism, and excretion). Thus, the present disclosure includes adenosine receptor (e.g., A2A and / or A2B) assays containing such labeled or substituted compounds.
[0758] The present disclosure also includes isotopically labeled compounds of the present disclosure. An "isotopically labeled" or "radiolabeled" compound is one in which one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated into the compounds of the present disclosure include, but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 18 F. 35 S. 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I. 124 I. 125 I and 131 I. For example, one or more hydrogen atoms in the compounds of the present disclosure may be replaced by deuterium atoms (e.g., C 1-6 One or more hydrogen atoms of an alkyl group may optionally be replaced with a deuterium atom, such as -CD3 replacing -CH3. In some embodiments, the alkyl group of any disclosed formula (e.g., Formula (I)) may be perdeuterated.
[0759] One or more constituent atoms of the compounds presented herein may be replaced or substituted with an isotope of that atom in natural or unnatural abundance. In some embodiments, the compounds comprise at least one deuterium atom. For example, one or more hydrogen atoms in the compounds presented herein may be replaced or substituted with deuterium (e.g., C 1-6 One or more hydrogen atoms of an alkyl group may be replaced by a deuterium atom, such as -CD3 replacing -CH3. In some embodiments, the compound comprises two or more deuterium atoms. In some embodiments, the compound comprises 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 deuterium atoms. In some embodiments, all hydrogen atoms in the compound may be replaced or substituted by a deuterium atom.
[0760] In some embodiments, the alkyl, ... 1-61, 2, 3, 4, 5, 6, 7 or 8 hydrogen atoms attached to the carbon atom of the alkyl-, "alkylene", "alkenylene" and "alkynylene" linking groups are each optionally replaced with a deuterium atom.
[0761] Synthetic methods for incorporating isotopes into organic compounds are known in the art (Alan F. Thomas, Deuterium Labeling in Organic Chemistry (New York, NY, Appleton-Century-Crofts, 1971); Jens Atzrodt, Volker Derdau, Thorsten Fey, and Jochen Zimmermann, The Renaissance of H / D Exchange, Angew. Chem. Int. Ed. 2007, 7744-7765; James R. Hanson, The Organic Chemistry of Isotopic Labelling, Royal Society of Chemistry, 2011). Isotopically labeled compounds are useful in various studies, such as NMR spectroscopy, metabolic experiments, and / or assays.
[0762] Substitution with heavier isotopes, such as deuterium, can provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and thus may be preferred in some cases. (See, for example, A. Kerekes et al., J. Med. Chem. 2011, 54, 201-210; R. Xu et al., J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolic sites can provide one or more therapeutic advantages.
[0763] The radionuclide incorporated into the radiolabeled compounds of the invention will depend on the specific application of the radiolabeled compound. For example, for in vitro adenosine receptor labeling and competition assays, incorporation of 3 H. 14 C. 82 Br, 125 I. 131 I or 35 Compounds of S may be useful. For radioactive imaging applications, 11 C. 18 F. 125 I. 123 I. 124 I. 131 I. 75 Br,76 Br or 77 Br can be useful.
[0764] It is understood that a "radiolabeled" or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments, the radionuclide is selected from the group consisting of: 3 H. 14 C. 125 I. 35 S and 82 Br.
[0765] The present disclosure may also include synthetic methods for incorporating radioisotopes into the disclosed compounds.Synthetic methods for incorporating radioisotopes into organic compounds are well known in the art, and those skilled in the art will readily recognize methods applicable to the disclosed compounds.
[0766] The labeled compounds of the present disclosure can be used in screening assays to identify / evaluate compounds. For example, the ability to bind to adenosine receptors can be assessed by tracking the change in concentration of a newly synthesized or identified compound (i.e., a test compound) when it is in contact with an adenosine receptor. For example, the ability of a test compound (labeled) to reduce the binding of another compound (i.e., a standard compound) known to bind to adenosine receptors can be assessed. Therefore, the ability of a test compound to compete with a standard compound for binding to adenosine receptors is directly related to its binding affinity. In contrast, in some other screening assays, the standard compound is labeled and the test compound is unlabeled. Therefore, the concentration of the labeled standard compound is monitored to assess the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thereby determined.
[0767] medicine box
[0768] The present disclosure also includes pharmaceutical kits that can be used, for example, to treat or prevent adenosine receptor-related diseases or conditions (such as cancer, inflammatory diseases, cardiovascular diseases, or neurodegenerative diseases), the kits comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present disclosure. As will be readily apparent to those skilled in the art, such kits may also include one or more of the various conventional pharmaceutical kit components (such as a container containing one or more pharmaceutically acceptable carriers, other containers, etc.), if desired. The kits may also include instructions (as inserts or as labels) indicating the amounts of the components to be administered, instructions for administration, and / or instructions for mixing the components.
[0769] The present invention will be described in more detail by way of specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. One skilled in the art will readily recognize a variety of noncritical parameters that can be changed or modified to achieve substantially the same results. The compounds of the examples have been found to inhibit the activity of adenosine receptors (e.g., A2A and / or A2B) according to at least one of the assays described herein.
[0770] Example
[0771] Preparative LC-MS purification of some of the prepared compounds was performed on a Waters mass directed fractionation system. The basic equipment setup, protocols, and control software for operating the system have been described in detail in the literature (e.g., see “Two-Pump At Column Dilution Configuration for Preparative LC-MS”, K. Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification”, K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and “Preparative LC-MS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004)). The isolated compounds were usually subjected to analytical liquid chromatography mass spectrometry (LCMS) under the following conditions for purity analysis: Instrument: Agilent 1100 series, LC / MSD, Column: Waters Sunfire TM C 18 5 μm, 2.1×50 mm, buffer: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% B in 3 minutes, flow rate 2.0 mL / min.
[0772] As indicated in the Examples, some of the prepared compounds were also separated on a preparative scale by reversed-phase high performance liquid chromatography (RP-HPLC) with MS detection or flash chromatography (silica gel). Typical preparative reversed-phase high performance liquid chromatography (RP-HPLC) column conditions were as follows:
[0773] pH = 2 purification: Waters Sunfire TM C 18 5μm, 30×100mm or Waters XBridge TM C 18 A 5 μm, 30×100 mm column was used, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 60 mL / min, and the separation gradient was optimized for each compound using a compound-specific method optimization protocol as described in the literature (e.g., see “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)).
[0774] pH = 10 purification: Waters XBridge TM C 18 A 5 μm, 30×100 mm column was used, eluted with mobile phase A: 0.1% NH 4 OH in water and mobile phase B: acetonitrile; the flow rate was 60 mL / min, and the separation gradient was optimized for each compound using a compound-specific method optimization protocol as described in the literature (e.g., see “Preparative LCMS Purification: Improved Compound Specific Method Optimization”, K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)).
[0775] Example 1. 4-amino-6-(3-cyanophenyl)-N-ethyl-7-(1-ethyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0776]
[0777] Step 1: Diethyl 1-(2-(3-cyanophenyl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate
[0778]
[0779] To a solution of diethyl 1H-pyrazole-3,5-dicarboxylate (12.9 g, 60.8 mmol) and 3-(2-bromoacetyl)benzonitrile (13.62 g, 60.8 mmol) in acetone (253 mL) was added potassium carbonate (9.24 g, 66.9 mmol). The mixture was stirred at room temperature (rt or RT) for 12 hours. The reaction mixture was concentrated, and the residue was dissolved in water and dichloromethane (DCM). The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to produce the desired product (21.6 g, 100%) as a white solid. 18 H 18 LC-MS calculated value of N3O5 (M+H) + : m / z = 356.1; found 356.1.
[0780] Step 2: Ethyl 6-(3-cyanophenyl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate
[0781]
[0782] Diethyl 1-(2-(3-cyanophenyl)-2-oxoethyl)-1H-pyrazole-3,5-dicarboxylate (21.6 g, 60.8 mmol) was dissolved in acetic acid (260 mL) and ammonium acetate (46.9 g, 608 mmol) was added. The mixture was stirred at 110° C. for 36 hours. After cooling to room temperature, the mixture was diluted with water, and the precipitate was collected by filtration, washed with water, and dried to give the product. 16 H 13 LC-MS calculated value of N4O3 (M+H) + : m / z = 309.1; found 309.1.
[0783] Step 3: Ethyl 4-chloro-6-(3-cyanophenyl)pyrazolo[1,5-a]pyrazine-2-carboxylate
[0784]
[0785] A mixture of ethyl 6-(3-cyanophenyl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate (15.8 g, 51.2 mmol) and POCl (96 mL, 1025 mmol) was heated at 110°C for 4 hours. After cooling to room temperature, the mixture was slowly added to a flask containing ice and sodium bicarbonate. The resulting precipitate was collected, washed with water and dried to yield the product (15.8 g, 94%). 16 H 12 LC-MS calculated value of ClN4O2 (M+H)+ : m / z = 327.1; found 327.1.
[0786] Step 4. Ethyl 6-(3-cyanophenyl)-4-((2,4-dimethoxybenzyl)amino)pyrazolo[1,5-a]pyrazine-2-carboxylate
[0787]
[0788] A microwave vial was charged with ethyl 4-chloro-6-(3-cyanophenyl)pyrazolo[1,5-a]pyrazine-2-carboxylate (1.22 g, 3.73 mmol), (2,4-dimethoxyphenyl)methanamine (0.749 g, 4.48 mmol), N,N-diisopropylethylamine (DIEA, 1.304 mL, 7.47 mmol), and butan-1-ol (13.0 mL). The mixture was heated at 180° C. in a microwave reactor for 30 minutes. The mixture was diluted with water, and the resulting precipitate was collected by filtration, washed with water, and dried to yield the product (1.5 g, 88%). 25 H 24 LC-MS calculated for N5O4 (M+H) + : m / z = 458.2; found 458.2.
[0789] Step 5: 6-(3-cyanophenyl)-4-((2,4-dimethoxybenzyl)amino)pyrazolo[1,5-a]pyrazine-2-carboxylic acid
[0790]
[0791] A mixture of ethyl 6-(3-cyanophenyl)-4-((2,4-dimethoxybenzyl)amino)pyrazolo[1,5-a]pyrazine-2-carboxylate (1.35 g, 2.95 mmol), sodium hydroxide (5.90 mL, 5.90 mmol), and acetonitrile (20 mL) was stirred at room temperature for 2 hours. The reaction was diluted with 1N HCl (6 mL). The precipitate was collected by filtration, washed with water, and dried to yield the product (1.0 g, 79%). 23 H 20 LC-MS calculated for N5O4 (M+H) + : m / z = 430.1; found 430.1.
[0792] Step 6. 4-Amino-6-(3-cyanophenyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide
[0793]
[0794] To a vial was added 6-(3-cyanophenyl)-4-((2,4-dimethoxybenzyl)amino)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (0.5 g, 1.164 mmol), PyBOP (0.727 g, 1.397 mmol) and dimethylformamide (DMF, 1.0 mL), followed by 2.0 M ethylamine (THF, 1.164 mL, 2.329 mmol) and N,N-diisopropylethylamine (1.017 mL, 5.82 mmol) in tetrahydrofuran. After stirring at room temperature (rt) for 2 hours, the reaction mixture was diluted with water and DCM. The organic layer was dried over Na2SO4, filtered and concentrated. The crude material was treated with trifluoroacetic acid (TFA, 0.5 mL) and heated at 90 ° C for 30 minutes. After removing the solvent, the resulting precipitate was washed with water and ethyl acetate to give the desired product (0.32 g, 90%) as a white solid. 16 H 15 LC-MS calculated for N6O (M+H) + : m / z = 307.1; found 307.1.
[0795] Step 7. 4-Amino-7-bromo-6-(3-cyanophenyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide
[0796]
[0797] To a solution of 4-amino-6-(3-cyanophenyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide (747 mg, 2.439 mmol) in DCM (5 mL) and DMF (1.250 mL) was added N-bromosuccinimide (NBS, 421 mg, 2.365 mmol). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM and water. The organic layer was dried over Na2SO4, filtered and concentrated. The precipitate was collected and washed with ethyl acetate to give the desired product (0.75 g, 80%) as a white solid. 16 H 14 LC-MS calculated for BrN6O (M+H) + : m / z = 385.0, 387.0; found 385.0, 387.0.
[0798] Step 8. 4-Amino-6-(3-cyanophenyl)-N-ethyl-7-(1-ethyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0799] A mixture of 4-amino-7-bromo-6-(3-cyanophenyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide (14 mg, 0.036 mmol), 1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (9.69 mg, 0.044 mmol), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine-(2'-aminobiphenyl-2-yl)(chloro)palladium (1:1) (2.86 mg, 3.63 μmol) and tripotassium phosphate hydrate (18.41 mg, 0.080 mmol) in 1,4-dioxane (0.6 mL) / water (0.200 mL) was stirred at 80° C. for 1 hour. The residue was dissolved in methanol and 1N HCl and purified by preparative LCMS (pH 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 21 H 21 LC-MS calculated for N8O (M+H) + : m / z = 401.2; found 401.2. 1 H NMR(600MHz,DMSO)δ8.07(t,J=6.0Hz,1H),7.80-7.73(m,3H),7.73-7.70(m,1H),7.56-7.46(m,4H),6.3 2(d,J=1.8Hz,1H),3.87(m,1H),3.75(m,1H),3.27(m,2H),1.16(t,J=7.2Hz,3H),1.08(t,J=7.1Hz,3H).
[0800] Example 2. 4-amino-6-(3-cyanophenyl)-N-ethyl-7-(1-propyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0801]
[0802] The title compound was prepared using a procedure similar to that described for Example 1, substituting 1-propyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole in step 8. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 22 H 23 LC-MS calculated for N8O (M+H) + : m / z = 415.2; found 415.2.
[0803] Example 3. 4-amino-6-(3-cyanophenyl)-N-ethyl-7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0804]
[0805] The title compound was prepared using a procedure similar to that described for Example 1, substituting 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one for 1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole in Step 8. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 22 H 20 LC-MS calculated value of N7O2 (M+H) + : m / z = 414.2; found 414.2.
[0806] Example 4. 4-amino-6-(3-cyanophenyl)-N-ethyl-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0807]
[0808] A mixture of 4-amino-7-bromo-6-(3-cyanophenyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide (Example 1, Step 7; 10 mg, 0.026 mmol), 4-(tributylstannyl)pyrimidine (14.4 mg, 0.039 mmol), copper(I) chloride (3.1 mg, 0.031 mmol), lithium chloride (1.3 mg, 0.031 mmol), and tetrakis(triphenylphosphine)palladium(0) (3.0 mg, 2.60 μmol) in THF (1.0 mL) was first purged with N2 and then heated and stirred at 90°C for 2 hours. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt (4.2 mg, 42%). 20 H 17 LC-MS calculated for N8O (M+H) + : m / z = 385.1; found 385.1.
[0809] Example 5. 4-amino-6-(3-cyanophenyl)-7-(1,1-difluoroethyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide
[0810]
[0811] To a vial was added 4-amino-6-(3-cyanophenyl)-N-ethylpyrazolo[1,5-a]pyrazine-2-carboxamide (Example 1, Step 6; 20.0 mg, 0.065 mmol), sodium 1,1-difluoroethane-1-sulfinate (59.6 mg, 0.392 mmol), diethyl carbonate (2.0 mL), water (1.3 mL) and tert-butyl hydroperoxide (0.090 mL, 0.653 mmol). The resulting mixture was heated at 90 ° C for 3 hours. The reaction mixture was purified by preparative LCMS (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt (5.6 mg, 23%). 18 H 17 LC-MS calculated for F2N6O (M+H) + : m / z = 371.1; found 371.1.
[0812] Example 6. 4-amino-6-(3-cyanophenyl)-N-ethyl-7-(1-(trifluoromethyl)cyclopropyl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0813]
[0814] The title compound was prepared using a procedure similar to that described for Example 5, substituting sodium 1-(trifluoromethyl)cyclopropane-1-sulfinate for sodium 1,1-difluoroethane-1-sulfinate. The reaction mixture was purified by preparative LCMS (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 20 H 18 LC-MS calculated for F3N6O (M+H) + : m / z = 415.1; found 415.1.
[0815] Example 7. 3-(4-amino-2-(azetidine-1-carbonyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0816]
[0817] Step 1. Ethyl 4-amino-7-bromo-6-(3-cyanophenyl)pyrazolo[1,5-a]pyrazine-2-carboxylate
[0818]
[0819] A solution of ethyl 6-(3-cyanophenyl)-4-((2,4-dimethoxybenzyl)amino)pyrazolo[1,5-a]pyrazine-2-carboxylate (Example 1, Step 4; 8.35 g, 18.26 mmol) was treated with TFA (20 mL) and heated at 90 ° C for 30 minutes. After removing the solvent, the resulting precipitate was washed with water and ethyl acetate. The crude product was dissolved in DCM (73.0 mL) and DMF (18.26 mL), and NBS (3.15 g, 17.71 mmol) was added to this solution. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM and water. The precipitate was collected by filtration and washed with water to give the desired product (5.6 g, 79%) as a white solid. 16 H 13 LC-MS calculated for BrN5O2 (M+H) + : m / z = 386.0; found 386.0.
[0820] Step 2. Ethyl 4-amino-6-(3-cyanophenyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate
[0821]
[0822] A mixture of ethyl 4-amino-7-bromo-6-(3-cyanophenyl)pyrazolo[1,5-a]pyrazine-2-carboxylate (904 mg, 2.341 mmol), 4-(tributyltinyl)pyrimidine (1.3 g, 3.51 mmol), copper (I) chloride (278 mg, 2.81 mmol), lithium chloride (119 mg, 2.81 mmol) and tetrakis (triphenylphosphine) palladium (0) (270 mg, 0.234 mmol) in THF (15 mL) was first purged with N2 and then heated and stirred at 90°C for 2 hours. The reactant was diluted with ethyl acetate and water, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to produce the desired product (0.34 g, 38%). 20 H 16 LC-MS calculated value of N7O2 (M+H) + : m / z = 386.1; found 386.2.
[0823] Step 3. 4-Amino-6-(3-cyanophenyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid
[0824]
[0825] A mixture of ethyl 4-amino-6-(3-cyanophenyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylate (340 mg, 0.882 mmol), 1.0 M sodium hydroxide (4.41 mL, 4.41 mmol), acetonitrile (10 mL) and THF (5.00 mL) was stirred at room temperature for 2 hours. The reaction was quenched with 1 N HCl to pH 4. After removing most of the organic solvent, the precipitate was collected by filtration, washed with water and dried under vacuum to give the desired product as a white solid (295 mg, 94%). 18 H 12 LC-MS calculated value of N7O2 (M+H) + : m / z = 358.1; found 358.1.
[0826] Step 4. 3-(4-amino-2-(azetidine-1-carbonyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0827] To a solution of 4-amino-6-(3-cyanophenyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxylic acid (8.0 mg, 0.022 mmol) and HATU (8.51 mg, 0.022 mmol) in N,N-dimethylformamide (1.0 mL) was added azetidine (3.02 μl, 0.045 mmol) and DIEA (7.82 μl, 0.045 mmol). After stirring at room temperature for 2 hours, the reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt (2.5 mg, 28%). 21 H 17 LC-MS calculated for N8O (M+H) + : m / z = 397.1; found 397.1. 1 H NMR (500MHz, DMSO) δ9.11 (m, 1H), 8.94 (d, J = 5.2Hz, 1H), 7.96-7.90 (m, 2H), 7.79-7.73 (m, 3H), 7.55(m,2H),7.47(t,J=7.7Hz,1H),4.29(t,J=7.7Hz,2H),4.03(t,J=7.7Hz,2H),2.24(m,2H).
[0828] Example 8. 3-(4-amino-7-(pyrimidin-4-yl)-2-(pyrrolidine-1-carbonyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0829]
[0830] The title compound was prepared using a procedure similar to that described for Example 7, substituting pyrrolidine for azetidine in step 4. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 22 H 19 LC-MS calculated for N8O (M+H) + : m / z = 411.2; found 411.2.
[0831] Example 9. 3-(4-amino-2-(piperidine-1-carbonyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0832]
[0833] The title compound was prepared using a procedure similar to that described for Example 7, substituting piperidine for azetidine in step 4. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 23 H 21 LC-MS calculated for N8O (M+H) + : m / z = 425.2; found 425.3.
[0834] Example 10. 4-Amino-6-(3-cyanophenyl)-N,N-diethyl-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0835]
[0836] The title compound was prepared using a procedure similar to that described for Example 7, substituting diethylamine for azetidine in step 4. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 22 H 21 LC-MS calculated for N8O (M+H) + : m / z = 413.2; found 413.2. 1H NMR(500MHz,DMSO)δ9.16(d,J=1.3Hz,1H),8.93(d,J=5.2Hz,1H),8.02-7.95(m,2H),7.87(m,1H),7.83-7.75(m,2 H),7.58-7.38(m,3H),3.50(q,J=6.8Hz,2H),3.41(q,J=7.0Hz,2H),1.12(t,J=7.0Hz,3H),1.00(t,J=6.9Hz,3H).
[0837] Example 11. 4-Amino-6-(3-cyanophenyl)-N-ethyl-N-methyl-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazine-2-carboxamide
[0838]
[0839] The title compound was prepared using a procedure similar to that described for Example 7, substituting N-methylethylamine for azetidine in step 4. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 21 H 19 LC-MS calculated for N8O (M+H) + : m / z = 399.2; found 399.2.
[0840] Example 12. 3-(4-amino-2-(3-hydroxyazetidine-1-carbonyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0841]
[0842] The title compound was prepared using a procedure similar to that described for Example 7, substituting azetidin-3-ol for azetidine in step 4. The reaction mixture was purified by preparative HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 21 H 17 LC-MS calculated value of N8O2 (M+H) + : m / z = 413.1; found 413.1.
[0843] Example 13. 3-(4-amino-2-(azetidin-1-ylmethyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0844]
[0845] Step 1. 3-(4-amino-7-bromo-2-(hydroxymethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0846]
[0847] To a solution of ethyl 4-amino-7-bromo-6-(3-cyanophenyl)pyrazolo[1,5-a]pyrazine-2-carboxylate (Example 7, Step 1; 0.547 g, 1.416 mmol) in CH2Cl2 (7.08 mL) and THF (7.08 mL) was added 1.0 M DIBAL-H (4.25 mL, 4.25 mmol) in THF at 0°C. The resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction was diluted with DCM and 1 N NaOH solution. The organic layer was separated and dried over Na2SO4, filtered and concentrated. The crude material was used in the next step without purification. 14 H 11 LC-MS calculated for BrN5O (M+H) + : m / z = 344.0; found 344.0.
[0848] Step 2. 3-(4-amino-2-(hydroxymethyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0849]
[0850] A mixture of 3-(4-amino-7-bromo-2-(hydroxymethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (487 mg, 1.415 mmol), 4-(tributyltinyl)pyrimidine (575 mg, 1.556 mmol), copper(I) chloride (168 mg, 1.698 mmol), lithium chloride (72.0 mg, 1.698 mmol) and tetrakis(triphenylphosphine)palladium(0) (164 mg, 0.141 mmol) in THF (12 mL) was first purged with N2 and then heated and stirred at 90°C for 2 hours. The reactant was diluted with ethyl acetate and water, and the aqueous layer was extracted once with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to produce the desired product (0.16 g, 34% in 2 steps). 18 H 14 LC-MS calculated for N7O (M+H) + : m / z = 344.1; found 344.1.
[0851] Step 3. 3-(4-amino-2-formyl-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0852]
[0853] A mixture of 3-(4-amino-2-(hydroxymethyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (160 mg, 0.466 mmol), Dess-Martin periodinane (237 mg, 0.559 mmol), and CHCl (4660 μL) was stirred at room temperature for 2 hours. The reaction was diluted with DCM and saturated NaHCO solution. After stirring for 30 minutes, the organic layer was separated and dried over NaSO, filtered, and concentrated. The crude product was used in the next step without purification. 18 H 12 LC-MS calculated for N7O (M+H) + : m / z = 342.1; found 342.1.
[0854] Step 4. 3-(4-amino-2-(azetidin-1-ylmethyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0855] To a mixture of 3-(4-amino-2-formyl-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (10 mg, 0.029 mmol) and azetidine (3.35 mg, 0.059 mmol) in DCM (1 mL) was added sodium triacetoxyborohydride (12.4 mg, 0.059 mmol). After stirring at room temperature for 2.5 hours, the solvent was removed in vacuo. The resulting residue was dissolved in methanol and 1N HCl (1N) and purified by preparative LCMS (pH = 2, acetonitrile / water + TFA) to give the desired product as a TFA salt. 21 H 19 LC-MS calculated value of N8 (M+H) + : m / z = 383.2; found 383.2.
[0856] Example 14. Ethyl (8-amino-6-(3-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate
[0857]
[0858] Step 1. tert-Butyl ((mesitylsulfonyl)oxy)carbamate
[0859]
[0860] To a solution of 2,4,6-trimethylbenzenesulfonyl chloride (9.10 g, 41.6 mmol) and tert-butyl N-hydroxycarbamate (5.54 g, 41.6 mmol) in methyl tert-butyl ether (MTBE, 90 mL) was added triethylamine (TEA, 6.09 mL, 43.7 mmol) dropwise at 0°C while stirring. The resulting suspension was stirred at 0°C for another 30 minutes and then warmed to ambient temperature. The reaction was then diluted with water (90 mL) and adjusted to pH 4 using 1N HCl. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to produce the desired product. 14 H 22 LC-MS calculated value of NO5S (M+H) + : m / z = 316.1; found 316.1.
[0861] Step 2. O-(mesitylsulfonyl)hydroxylamine
[0862]
[0863] To TFA (37.7 mL, 490 mmol) at 0°C was slowly added tert-butyl ((mesitylenesulfonyl)oxy)carbamate (12.56 g, 39.8 mmol). The reaction mixture was stirred at 0°C for 1.5 hours and then quenched with the sequential addition of crushed ice and water. The resulting white suspension was vigorously stirred for 5 minutes at ambient temperature. Without drying the filter cake, the solid was collected by careful vacuum filtration, followed by subsequent rinsing with water until the filtrate reached pH 6. The wet filtrate was dissolved in DCM, and the resulting biphasic solution was separated. The DCM layer was dried over MgSO4 for 30 minutes and then filtered and rinsed with DCM to provide the compound in solution. C9H 14 LC-MS calculated value of NO3S (M+H) + : m / z = 216.1; found 216.1.
[0864] Step 3. 1,2-Diamino-3,5-dibromopyrazin-1-ium 2,4,6-trimethylbenzenesulfonate
[0865]
[0866] To a solution of O-(mesitylsulfonyl)hydroxylamine (2.468 g, 11.47 mmol) in CH2Cl2 (50 mL) was added 3,5-dibromopyrazin-2-amine (2.90 g, 11.47 mmol) and the resulting solution was stirred at ambient temperature overnight. The precipitate was collected by filtration and dried under vacuum. LC-MS calculated for C4H5Br2N4 (M) +: m / z = 266.9; found 266.9.
[0867] Step 4. Ethyl (6,8-dibromo-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate
[0868]
[0869] To a suspension of 1,2-diamino-3,5-dibromopyrazin-1-ium 2,4,6-trimethylbenzenesulfonate (190 mg, 0.406 mmol) in DCM (1.0 mL) and N,N-dimethylformamide (1 mL) was added O-ethyl isothiocyanate (52.7 μl, 0.446 mmol). The resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with DCM and water. The organic layer was separated and dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography to produce the desired product (10 mg, 8%). LC-MS calculated for C8H8Br2N5O2 (M+H) + : m / z = 365.9; found 365.8.
[0870] Step 5. Ethyl (6-bromo-8-((2,4-dimethoxybenzyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate
[0871]
[0872] To a mixture of ethyl (6,8-dibromo-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate (10 mg, 0.027 mmol) and (2,4-dimethoxyphenyl)methanamine (4.58 mg, 0.027 mmol) in DCM (1 mL) was added DIEA (9.57 μl, 0.055 mmol). After stirring at 40 ° C for 2.5 hours, the solvent was removed in vacuo. The residue was purified by flash chromatography to give the desired product (6.0 mg, 49%). 17 H 20 LC-MS calculated for BrN6O4 (M+H) + : m / z = 451.1, 453.1; found 451.1, 453.1.
[0873] Step 6. Ethyl (6-(3-cyanophenyl)-8-((2,4-dimethoxybenzyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate
[0874]
[0875] A mixture of ethyl (6-bromo-8-((2,4-dimethoxybenzyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate (6.0 mg, 0.013 mmol), (3-cyanophenyl)boronic acid (1.954 mg, 0.013 mmol), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine-(2'-aminobiphenyl-2-yl)(chloro)palladium (1:1) (1.046 mg, 1.330 μmol) and tripotassium phosphate hydrate (6.74 mg, 0.029 mmol) in 1,4-dioxane (0.6 mL) / water (0.200 mL) was stirred at 70° C. for 1 hour. The resulting residue was dissolved in methanol and 1N HCl and purified using preparative LCMS (pH 2) to give the desired product (4.2 mg, 66%) as a white solid. 24 H 24 LC-MS calculated value of N7O4 (M+H) + : m / z = 474.2; found 474.2.
[0876] Step 7. Ethyl (8-amino-6-(3-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate
[0877] A mixture of ethyl (6-(3-cyanophenyl)-8-((2,4-dimethoxybenzyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate (6.3 mg, 0.013 mmol) and trifluoroacetic acid (0.3 mL) was stirred at 90° C. for 30 minutes. The volatiles were removed and the resulting residue was diluted with methanol and purified by preparative LCMS (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt (0.3 mg, 7%). 15 H 14 LC-MS calculated value of N7O2 (M+H) + : m / z = 324.1; found 324.1.
[0878] Example 15. 3-(8-amino-5-(6-oxo-1,6-dihydropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0879]
[0880] Step 1. 6-Bromo-N-(2,4-dimethoxybenzyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine
[0881]
[0882] A vial was charged with 6,8-dibromo-[1,2,4]triazolo[1,5-a]pyrazine (720 mg, 2.59 mmol), (2,4-dimethoxyphenyl)methanamine (433 mg, 2.59 mmol), DIEA (679 μl, 3.89 mmol), 2-propanol (6 mL), and N,N-dimethylformamide (6 mL). The mixture was heated at 90° C. for 2 hours and then diluted with water. The resulting precipitate (0.94 g, 100%) was collected by filtration. 14 H 15 LC-MS calculated for BrN5O2 (M+H) + :m / z=364.0, 366.0;Found 364.0, 366.0
[0883] Step 2. 3-(8-((2,4-dimethoxybenzyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0884]
[0885] A mixture of 6-bromo-N-(2,4-dimethoxybenzyl)-[1,2,4]triazolo[1,5-a]pyrazin-8-amine (0.94 g, 2.58 mmol), (3-cyanophenyl)boronic acid (0.417 g, 2.84 mmol), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine-(2'-aminobiphenyl-2-yl)(chloro)palladium (1:1) (0.203 g, 0.258 mmol) and tripotassium phosphate hydrate (1.486 g, 6.45 mmol) in 1,4-dioxane (9.68 mL) / water (3.23 mL) was stirred at 70 ° C for 1 hour. After cooling to room temperature, the mixture was diluted with water. The resulting precipitate (0.7 g, 70%) was collected by filtration. 21 H 19 LC-MS calculated value of N6O2 (M+H) + : m / z = 387.1; found 387.1.
[0886] Step 3. 3-(8-amino-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0887]
[0888] A mixture of 3-(8-((2,4-dimethoxybenzyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile (0.70 g, 1.812 mmol) and trifluoroacetic acid (4.19 mL, 54.3 mmol) was heated at 90° C. for 30 minutes. The volatiles were removed in vacuo. The resulting solid was washed with water and ethyl acetate and dried in vacuo (0.35 g, 82%). 12 LC-MS calculated value for H9N6 (M+H) + : m / z = 237.1; found 237.1.
[0889] Step 4. 3-(8-amino-5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0890]
[0891] To a solution of 3-(8-amino-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile (129 mg, 0.546 mmol) in DCM (5 mL) and DMF (1.250 mL) was added NBS (94 mg, 0.530 mmol). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM and water. The precipitate was collected by filtration and washed with water and ethyl acetate (135 mg, 78%). 12 LC-MS calculated for H8BrN6 (M+H) + : m / z = 315.0, 317.0; found 315.0, 317.0.
[0892] Step 5. 3-(8-amino-5-(6-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0893]
[0894] A mixture of 3-(8-amino-5-bromo-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile (20 mg, 0.063 mmol), (6-methoxypyridin-3-yl)boronic acid (9.71 mg, 0.063 mmol), dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine-(2'-aminobiphenyl-2-yl)(chloro)palladium (1:1) (5.0 mg, 6.35 μmol) and potassium phosphate trihydrate (32.2 mg, 0.140 mmol) in 1,4-dioxane (0.6 mL) / water (0.200 mL) was stirred at 70° C. for 1 hour. The residue was dissolved in methanol and 1N HCl and purified by preparative LCMS (pH = 2, acetonitrile / water + TFA) to give the desired product (12 mg, 55%) as a white solid. 18 H 14 LC-MS calculated for N7O (M+H) + : m / z = 344.1; found 344.1.
[0895] Step 6. 3-(8-amino-5-(6-oxo-1,6-dihydropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0896] A mixture of 3-(8-amino-5-(6-methoxypyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile (10 mg, 0.029 mmol), potassium iodide (14.50 mg, 0.087 mmol) and acetic acid (1.0 mL) was heated at 90° C. for 1 hour. The mixture was diluted with methanol and purified by preparative LCMS (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt (3.5 mg, 37%). 17 H 12 LC-MS calculated for N7O (M+H) + : m / z = 330.1; found 330.1.
[0897] Example 16. 3-(4-amino-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0898]
[0899] Step 1: 3-(4-(2,4-dimethoxybenzylamino)-2-(hydroxymethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0900]
[0901] To a solution of ethyl 6-(3-cyanophenyl)-4-((2,4-dimethoxybenzyl)amino)pyrazolo[1,5-a]pyrazine-2-carboxylate (Example 1, Step 4; 4.00 g, 8.74 mmol) in THF (200 mL) was added diisobutylaluminum hydride (1.0 M solution in toluene, 35.0 mL, 35.0 mmol) at -78 ° C. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 30 minutes. The reaction mixture was quenched by adding 300 mL of saturated aqueous Rochelle's salt solution. The resulting mixture was stirred at room temperature for 1 hour, then concentrated and the residue was extracted with DCM. The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to give the desired product (2.1 g, 58%) as a white solid. 23 H 22 LC-MS calculated value of N5O3 (M+H) + : m / z = 416.1; found 416.2.
[0902] Step 2: 3-(2-(Bromomethyl)-4-(2,4-dimethoxybenzylamino)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0903]
[0904] 3-(4-(2,4-dimethoxybenzylamino)-2-(hydroxymethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (3.0 g, 7.22 mmol) was dissolved in DCM (200 mL) and PBr (1.4 mL, 14.44 mmol) was added. The mixture was stirred at room temperature for 5 hours. Upon completion, the reaction was quenched by the addition of saturated NaHCO and the mixture was extracted with DCM. The organic phase was washed with brine, dried over NaSO, filtered and concentrated. The residue was purified by flash chromatography to give the desired product (2.4 g, 69%) as a white solid. 23 H 21 LC-MS calculated for BrN5O2 (M+H) + : m / z = 478.1; found 478.1.
[0905] Step 3: 3-(4-(2,4-dimethoxybenzylamino)-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0906]
[0907] A mixture of 3-(2-(bromomethyl)-4-(2,4-dimethoxybenzylamino)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (700 mg, 1.46 mmol), CuI (55.7 mg, 0.293 mmol), CsF (445 mg, 2.93 mmol), tetrakis(triphenylphosphine)palladium(0) (169 mg, 0.146 mmol) and 2-(tributylstannyl)pyridine (646 mg, 1.756 mmol) in 1,4-dioxane (2 mL) was heated at 140 ° C. for 1 hour in a microwave reactor. The reaction was diluted with water and extracted with DCM. The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to give the desired product (428 mg, 62%) as a white solid. 28 H 25 LC-MS calculated value for N6O2 (M+H)+: m / z=477.2; found 477.2.
[0908] Step 4. 3-(4-amino-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0909] A reaction vial was charged with 3-(4-(2,4-dimethoxybenzylamino)-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (428 mg, 0.9 mmol) and TFA (1 mL). The mixture was heated at 70 ° C for 20 minutes. The mixture was diluted with water and quenched with saturated NaHCO 3. The mixture was extracted with DCM. The organic phase was washed with brine, dried over Na 2 SO 4, filtered and concentrated. The residue was purified by flash chromatography to give the desired product (260 mg, 89%) as a light yellow solid. 19 H 15 LC-MS calculated value of N6 (M+H) + : m / z = 327.1; found 327.2.
[0910] Example 17. 3-(4-amino-2-(pyridin-2-ylmethyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0911]
[0912] Step 1: 3-(4-amino-7-bromo-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0913]
[0914] To a solution of 3-(4-amino-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (Example 16, Step 4; 260 mg, 0.8 mmol) in DMF (2 mL) was added dropwise a solution of N-bromosuccinimide (122 mg, 0.68 mmol) in DMF (0.5 mL) at 0 ° C. The resulting mixture was stirred at 0 ° C for 10 minutes. The reaction mixture was diluted with water. The mixture was extracted with DCM. The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography to give the desired product (202 mg, 62%) as a light yellow oil. 19 H 14 LC-MS calculated for BrN6 (M+H) + : m / z = 405.0; found 405.1.
[0915] Step 2. 3-(4-amino-2-(pyridin-2-ylmethyl)-7-(pyrimidin-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile
[0916] A mixture of 3-(4-amino-7-bromo-2-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrazin-6-yl)benzonitrile (15 mg, 0.037 mmol), CuI (1.4 mg, 0.007 mmol), CsF (11 mg, 0.074 mmol), tetrakis(triphenylphosphine)palladium(0) (4.2 mg, 0.004 mmol) and 4-(tributylstannyl)pyrimidine (16.4 mg, 0.044 mmol) in 1,4-dioxane was heated at 140° C. i...
Claims
1. A compound of formula (IIIa): or a pharmaceutically acceptable salt thereof, wherein: Cy 1 is 3-cyanophenyl or 3-cyano-2-fluorophenyl; R 2 is selected from H, 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R 2 The 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl are each unsubstituted or substituted with 1, 2 or 3 independently selected R 2A Substituent substitution; Each R 2A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and OH, where R 2A The C 1-6 Alkyl is unsubstituted or substituted with 1, 2 or 3 independently selected R 2B Substituent substitution; Each R 2B are independently selected from D, halo and OH; R 4 Selected from phenyl-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl-, (5-10 membered heteroaryl)-C 1-3 Alkyl-, OR a4 、C(O)R b4 and S(O)2R b4 , where R 4 The phenyl-C 1-3 Alkyl-, (4-7 membered heterocycloalkyl)-C 1-3 Alkyl- and (5-10 membered heteroaryl)-C 1-3 Alkyl - each unsubstituted or substituted with 1, 2 or 3 independently selected R 4A Substituent substitution; Each R a4 and R b4 independently selected from phenyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl-, where R a4 and R b4 The phenyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each unsubstituted or substituted with 1, 2 or 3 independently selected R 4A Substituent substitution; Each R 4A independently selected from halogen, C 1-6 Alkyl, C 1-6 haloalkyl, 5-6 membered heteroaryl, (4-10 membered heterocycloalkyl)-C 1-3 Alkyl-, OR a41 、S(O)2R b41 and NR c41 R d41 , where R 4A The C 1-6 alkyl, 5-6 membered heteroaryl and (4-10 membered heterocycloalkyl)-C 1-3 Alkyl - each unsubstituted or substituted with 1, 2 or 3 independently selected R 4B Substituent substitution; Each R a41 , R b41 , R c41 and R d41 Independently selected from H, C 1-6 Alkyl, C 1-6 Haloalkyl and 5-6 membered heteroaryl, wherein R a41 , R b41 , R c41 and R d41 The C 1-6 The alkyl and 5-6 membered heteroaryl groups are each unsubstituted or substituted with 1, 2 or 3 independently selected R 4B Substituent substitution; Each R 4B independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl, (5-6 membered heteroaryl)-C 1-3 Alkyl-, CN, OR a42 、C(O)R b42 、C(O)OR a42 and NR c42 R d42 , where R 4B The C 1-6 Alkyl, C 3-6 Cycloalkyl, 4-7 membered heterocycloalkyl and (5-6 membered heteroaryl)-C 1-3 Alkyl - each unsubstituted or substituted with 1, 2 or 3 independently selected R 4C Substituent substitution; Each R a42 , R b42 , R c42 and R d42 Independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 5-7 membered heterocycloalkyl, wherein R a42 , R b42 , R c42 and R d42 The C 1-6 Alkyl, C 3-6 Cycloalkyl, 5-6 membered heteroaryl and 5-7 membered heterocycloalkyl are each unsubstituted or substituted with 1, 2 or 3 independently selected R 4C Substituent substitution; Each R 4C Independently selected from C 1-6 Alkyl, CN, C(O)NR c43 R d43 、C(O)OR a43 NR c43 R d43 and S(O)2R b43 , where R 4C The C 1-6 Alkyl is unsubstituted or substituted with 1 or 2 independently selected R 4D Substituent substitution; Each R a43 , R b43 , R c43 and R d43 Independently selected from H, C 1-6 Alkyl and C 1-6 A haloalkyl group, wherein R a43 , R b43 , R c43 and R d43 The C 1-6 The alkyl groups are each unsubstituted or substituted with 1 or 2 independently selected R 4D Substituent substitution; Alternatively, any R attached to the same N atom c43 and R d43 Together with the N atom to which they are attached, they form a 4, 5 or 6-membered heterocycloalkyl group, wherein the 4, 5 or 6-membered heterocycloalkyl group is unsubstituted or substituted with 1, 2, 3 or 4 independently selected R 4D Substituents are substituted; and Each R 4D Independently selected from C 1-3 Alkyl and OH.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is substituted with any alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl substituent or -C 1-6 1, 2, 3, 4, 5, 6, 7 or 8 hydrogen atoms attached to the carbon atoms of the alkyl-, alkylene, alkenylene and alkynylene linking groups are each optionally replaced with a deuterium atom.
3. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from 1-ethyl-1H-pyrazol-5-yl, 1-propyl-1H-pyrazol-5-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 3,6-dihydropyridin-4-yl-1(2H)-carboxamide, pyridin-4-yl, 4-(1-hydroxyethyl)-2-methyloxazol-5-yl, (2,2-difluoro-1-hydroxyethyl)-2-methyloxazol-5-yl, 1-ethyl-1H-1,2,3-triazol-5-yl and 1-methyl-1H-1,2,3-triazol-5-yl.
4. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 4 Selected from phenyl-C 1-3 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Alkyl-, where R 4 The phenyl-C 1-3 Alkyl- and (5-6 membered heteroaryl)-C 1-6 Each alkyl- is optionally substituted with 1 or 2 substituents independently selected from OH and halo.
5. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl, wherein R 2 The 5-10 membered heteroaryl and 4-7 membered heterocycloalkyl are each optionally substituted by 1, 2 or 3 independently selected R 2A Substituent substitution; Each R 2A independently selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl and OH, where R 2A The C 1-6 The alkyl group is optionally substituted with 1, 2 or 3 independently selected R 2B Substituents are substituted; and Each R 2B Independently selected from D, halo and OH.
6. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 2 6-oxo-1,6-dihydropyridin-3-yl, pyrimidin-4-yl, 1-methyl-6-oxo-1,6-dihydropyridin-3-yl, 1-methyl-6-oxo-1,6-dihydropyridazin-3-yl, 4-methyloxazol-5-yl, 4-ethyloxazol-5-yl, 3-methylpyridin-4-yl, 4-(2,2-difluoro-1-hydroxyethyl)-2-methyloxazol-5-yl, 2-methyl-4-(2,2,2-trifluoro- 1-(methyl-1H-pyrazol-5-yl), 1-ethyl-1H-pyrazol-5-yl, 6-hydroxypyridin-3-yl, 2,6-dimethylpyridin-4-yl, 3-methyl-1H-pyrazol-4-yl, [1,2,4]triazolo[4,3-a]pyridin-6-yl, oxazol-5-yl, imidazo[1,2-a]pyridin-6-yl, 3-fluoropyridin-4-yl and 1-(methyl-d3)-6-oxo-1,6-dihydropyridazin-3-yl.
7. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 2 It's H.
8. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein R 4 pyridin-2-ylmethyl, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H-pyrrolo[2,3-b]pyridin-7-yl, 2-fluorophenoxy, hydroxy(pyridin-2-yl)methyl, 2-(1-methyl-1H-pyrazol-4-yl)benzyl, (imidazo[1,2-a]pyridin-8-yl)methyl, (pyrazolo[1,5-a]pyridin-7-yl)methyl, (2H-indazol-2-yl)methyl, (1H-indazol-1-yl)methyl, (2,6-difluorophenyl)(hydroxy)methyl, (2,5-difluorophenyl)(hydroxy)methyl, (2,3-difluorophenyl)(hydroxy)methyl, (2-fluorophenyl)(hydroxy)methyl, (2-chlorophenyl)(hydroxy)methyl, hydroxy(phenyl)methyl, phenylsulfonyl, benzo[d]oxazol-4-ylmethyl, 2-fluoro-6-(1-methyl-1H-pyrazol-5-yl)benzyl, 2-fluoro-6-((6-methyl-5-oxo-2,6-diazaspiro[3.4]oct-2-yl)methyl)benzyl, 2-fluoro-6-((6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)benzyl, 2-fluoro-6-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl, 2-fluoro-6-(((3-oxopiperazin-1-yl)methyl)benzyl, 2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)benzyl, 2-fluoro-6-(((2-methyl-2H-1,2,3-triazol-4-yl)amino)methyl)benzyl, 2-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl, amino(2,6-difluorophenyl)methyl, (2,6-difluorophenyl)methyl 1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-2-yl)methyl, 2-((1-acetylpiperidin-4-yl)methyl)-6-fluorobenzyl, (2-(difluoromethoxy)-6-fluorophenyl)(hydroxy)methyl, 2-fluoro-6-(1-((1-methyl-1H-pyrazol-4-yl)methyl)-1H-pyrazol-4-yl) benzyl, (2-((dimethylamino)methyl)-6-fluorophenyl)(hydroxy)methyl, 2-fluoro-6-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)benzyl, (2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl)(hydroxy)methyl, 2-fluoro-6-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-4-yl)benzyl, 2-fluoro-6-((6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)phenyl)(hydroxy)methyl, 2-fluoro-6-(1-((trans)-3-(methylamino)cyclobutyl)-1H-pyrazol-4-yl)benzyl, 2-(1-(2-cyanoethyl)-1H 1H-pyrazol-4-yl)-6-fluorobenzyl, 2-fluoro-6-(1-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)benzyl, (3-methylpyridin-2-yl)methoxy, (3-((1-(pyridin-4-ylmethyl)-1H-pyrazol-4-yl)amino)pyridin-2-yl)methyl, (3-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyridin-2-yl)methyl, (3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)methyl, 2-((3-hydroxypyrrolidin-1-yl)methyl)benzyl and (6-methoxypyridin-2-yl)methyl.
9. The compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl, wherein the 5-6 membered heteroaryl and 4-6 membered heterocycloalkyl are each optionally substituted by 1 or 2 C 1-3 Alkyl substituted; and R 4 It is phenyl-C 1-3 Alkyl- or pyridyl-C 1-3 Alkyl-, wherein the phenyl-C 1-3 Alkyl- and pyridyl-C 1-3 Each alkyl- is optionally substituted with 1, 2 or 3 substituents independently selected from OH and halo.
10. The compound according to claim 1 or 2, wherein the compound is selected from: 3-(8-amino-2-(pyridin-2-ylmethyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (S)-1-(2-((8-amino-6-(3-cyanophenyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorobenzyl)pyrrolidine-3-carboxylic acid; 1-(2-((8-amino-6-(3-cyanophenyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorobenzyl)azetidine-3-carboxylic acid; 3-(2-((1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-8-amino-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(2-((7H-pyrrolo[2,3-b]pyridin-7-yl)methyl)-8-amino-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluorophenoxy)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(hydroxy(pyridin-2-yl)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-(1-methyl-1H-pyrazol-4-yl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(4-methyloxazol-5-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(4-ethyloxazol-5-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(3-methylpyridin-4-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(imidazo[1,2-a]pyridin-8-ylmethyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(pyrazolo[1,5-a]pyridin-7-ylmethyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(2-((2H-indazol-2-yl)methyl)-8-amino-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(2-((1H-indazol-1-yl)methyl)-8-amino-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,5-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,3-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2-fluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2-chlorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(hydroxy(phenyl)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(phenylsulfonyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(6-hydroxypyridin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(benzo[d]oxazol-4-ylmethyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-(1-methyl-1H-pyrazol-5-yl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (R)-1-(2-((8-amino-6-(3-cyanophenyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorobenzyl)-3-methylpyrrolidine-3-carboxylic acid; 3-(8-amino-2-(2-fluoro-6-((6-methyl-5-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-((6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (S)-3-(8-amino-2-(2-fluoro-6-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 2-((2-((8-amino-6-(3-cyanophenyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorobenzyl)amino)acetamide; 3-(8-amino-2-(2-fluoro-6-((3-oxopiperazin-1-yl)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (1S,3S)-3-((2-((8-amino-6-(3-cyanophenyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorobenzyl)amino)cyclobutane-1-carboxylic acid 3-(8-amino-2-(2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-(((2-methyl-2H-1,2,3-triazol-4-yl)amino)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (S)-3-(8-amino-2-(2-(((2-oxopyrrolidin-3-yl)amino)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (R)-1-(2-((8-amino-6-(3-cyanophenyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorobenzyl)-3-methylpyrrolidine-3-carboxylic acid; 3-(8-amino-2-(amino(2,6-difluorophenyl)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(methylamino)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)((2-hydroxyethyl)amino)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(amino(2-fluorophenyl)methyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(amino(2,6-difluorophenyl)methyl)-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((3-(oxazol-5-yl)pyridin-2-yl)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-(1-methyl-1H-pyrazol-4-yl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; (S)-3-(8-amino-2-(2-fluoro-6-(((1-methyl-2-oxopyrrolidin-3-yl)amino)methyl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-(2-fluoro-6-((6-methyl-5-oxo-2,6-diazaspiro[3.4]octan-2-yl)methyl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-5-(4-methyloxazol-5-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-5-(4-(2,2-difluoro-1-hydroxyethyl)-2-methyloxazol-5-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-5-(2-methyl-4-(2,2,2-trifluoro-1-hydroxyethyl)oxazol-5-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((1-((1-methyl-1H-imidazol-4-yl)sulfonyl)pyrrolidin-2-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(2-(2-((1-acetylpiperidin-4-yl)methyl)-6-fluorobenzyl)-8-amino-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(1-ethyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2-(difluoromethoxy)-6-fluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-(1-((1-methyl-1H-pyrazol-4-yl)methyl)-1H-pyrazol-4-yl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((2-((dimethylamino)methyl)-6-fluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(3-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(5-([1,2,4]triazolo[4,3-a]pyridin-6-yl)-8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(oxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(3-methylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2-fluoro-6-(pyrrolidin-1-ylmethyl)phenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(2-fluoro-6-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-4-yl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((2-fluoro-6-((6-oxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methyl)phenyl)(hydroxy)methyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 2-(4-(2-((8-amino-6-(3-cyano-2-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorophenyl)-1H-pyrazol-1-yl)-N,N-dimethylacetamide; 2-(4-(2-((8-amino-6-(3-cyano-2-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl)-3-fluorophenyl)-1H-pyrazol-1-yl)acetamide; 3-(8-amino-2-(2-fluoro-6-(1-((trans)-3-(methylamino)cyclobutyl)-1H-pyrazol-4-yl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-(2-(1-(2-cyanoethyl)-1H-pyrazol-4-yl)-6-fluorobenzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-(2-fluoro-6-(1-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-1H-pyrazol-4-yl)benzyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((3-methylpyridin-2-yl)methoxy)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((3-((1-(pyridin-4-ylmethyl)-1H-pyrazol-4-yl)amino)pyridin-2-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((3-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyridin-2-yl)methyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-2-((3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; (S)-3-(8-amino-2-(2-((3-hydroxypyrrolidin-1-yl)methyl)benzyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)-2-fluorobenzonitrile; 3-(8-amino-5-(1-(methyl-d3)-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; and 3-(8-amino-2-((6-methoxypyridin-2-yl)methyl)-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1, wherein the compound is 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(pyrimidin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1, wherein the compound is 3-(8-amino-2-((2,6-difluorophenyl)(hydroxy)methyl)-5-(2,6-dimethylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1, wherein the compound is 3-(8-amino-5-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-2-(pyridin-2-ylmethyl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
14. A compound selected from: Ethyl (8-amino-6-(3-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)carbamate; 3-(8-amino-5-(6-oxo-1,6-dihydropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-2-(azetidine-1-carbonyl)-5-(4-methyloxazol-5-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; 3-(8-amino-5-(imidazo[1,2-a]pyridin-6-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile; and 3-(8-amino-2-(azetidine-1-carbonyl)-5-(3-fluoropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)benzonitrile, or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
16. Use of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease or condition, wherein the disease or condition is bladder cancer, lung cancer, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, prostate cancer or head and neck cancer.
17. The use according to claim 16, wherein the disease or condition is head and neck cancer.
18. The use according to claim 17, wherein the head and neck cancer is head and neck squamous cell carcinoma.
19. The use of claim 16, wherein the disease or condition is lung cancer.
20. The use according to claim 19, wherein the lung cancer is non-small cell lung cancer (NSCLC).
21. The use of claim 16, wherein the disease or condition is ovarian cancer.
22. The use of claim 16, wherein the disease or condition is prostate cancer.
23. The use of claim 22, wherein the prostate cancer is metastatic castration-resistant prostate cancer.
24. The use of claim 16, wherein the disease or condition is breast cancer.
25. The use of claim 16, wherein the disease or condition is bladder cancer.
26. The use of claim 16, wherein the disease or condition is colorectal cancer.
27. The use of claim 16, wherein the disease or condition is pancreatic cancer.
Citation Information
Cited By
Fused pyrazine derivatives as A2A / A2B inhibitors
CN117304191A
